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ABSTRACT
Design and Synthesis of Ceragenins–Cationic Steroid Antimicrobial Compounds,
Structural Improvement and Synthesis of Cyclopentenone Prostaglandins
and Modification and Synthesis of Derivatives of Ribityllumazines:
Potential Antigens for Activation of MAIT Cells
Yubo Li
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Antimicrobial peptides (AMPs) are ubiquitous and display broad-spectrum antimicrobial
activity that can control bacterial colonization of surfaces. Ceragenins are small-molecule
mimics of AMPs and have several advantages over AMPs, including cost of manufacture and
stability. A ceragenin, CSA-120, modified with an acrylamide group was directly incorporated
into fluoropolymer coatings as a means of inhibiting bacterial biofilm formation. The ceragenincontaining coatings displayed improved performance. By conjugating a copper chelating group
to the ceragenin, chelation of 64Cu by the conjugate was effective and provided a stable complex
that allowed in vivo imaging. This conjugate may provide a means of identifying infection sites
in patients presenting general signs of infection without localized symptoms. A combination
nanoparticle comprised of a maghemite core for enhanced T2 MRI contrast diagnostics, a
colloidal silver shell acting as an antimicrobial and therapeutic vehicle, and a ceragenin (CSA124) surfactant providing microbial adhesion was synthesized and characterized by multiple
methods. Silver nanoparticles conjugated with ceragenin, CSA-124, as a potential Grampositiveselective antimicrobial were synthesized and termed as CSA-SNPs. Herein, CSA-SNPs
are characterized using multiple methods and the antimicrobial properties are determined
through minimum inhibitory concentration/minimum bactericidal concentration (MIC/MBC) and
time-kill studies.
Prostanoids are a natural subclass of eicosanoids generated mainly from metabolic
oxidation of arachidonic acid. Cyclopentenone prostaglandins (cyPGs) contain a highly reactive
α,β-unsaturated carbonyl group in their cyclopentenone ring and possess three main potentially
therapeutic properties: anti-inflammatory, antiproliferative and antiviral. We designed and
synthesized EC and its derivatives in reducing secretion of pro-inflammatory cytokines IL-6 and
IL-12. Mucosal-Associated Invariant T (MAIT) Cells are unique innate-like T cells and play a
key role in host defense against bacterial and fungal infection as well as in human autoimmune
diseases. The MAIT cells are activated through T-cell receptor αβ chain (TCR-αβ) binding with
the MR1-ligand, which is vitamin B metabolites presented on MR1. Rribityllumazines, one of
important MR1-ligand was synthesized in my study.

Keywords: antimicrobial peptides, ceragenin, cationic steroid antimicrobial, nanoparticle,
cyclopentenone prostaglandins, ribityllumazines.
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Chapter 1
Design and Synthesis of Ceragenins--Cationic Steroid Antimicrobial Compounds
1.1 Introduction
1.1.1 Origin of Ceragenins
Infectious diseases are a continuous challenge to higher organisms. Antimicrobial peptides
(AMPs), small peptides isolated from organisms ranging from insects to plants to mammals, are
one of the primary means of protecting their hosts from multiple kinds of microorganisms.
AMPs inhibit biofilm formation, display a wide antimicrobial spectrum, and play an important
position in the innate immune system of multicellular organisms.1-5 Human antimicrobial
cathelicidin LL37 and magainins, from amphibians are the best-studied endogenous
antimicrobial peptides.
AMPs share common features: small size and either linear or cyclic structure. A linear
structure includes amphipathic α-helices while a cyclic structure contains β-sheet secondary
structure with one or more disulfide bridges.6 They demonstrate the same structural properties,
with cationic and facially amphiphilic morphology, as shown in Figure 1.1. One face presents
cationic residues and the other face hydrophobic groups.7
Researchers have studied the mechanisms of action of AMPs. Two basic types of mechanisms
have been proposed. One is a disruptive mechanism, embodied in membrane lysis, and the other
one is undisruptive mechanism, associated with intracellular targets.8,9 In the disruptive
mechanism, one basic important role of AMPs is their interaction with cytoplasmic membranes
via electrostatic interactions.10 Several permeabilization mechanisms have been proposed to
explain their disruption activities, including the toroidal model, the carpet model, the aggregate
model, the barrel model and so on.11 A description of the “carpet model” as an example to
1

demonstrate how cathelicidins or magainins traverse the membranes of Gram-negative bacteria.
There are 3 layers in Gram-negative bacterial membranes: an outer membrane (OM) with a lipid
bilayer, made up mostly of lipopolysaccharide (LPS) interlocked with teichoic acid; a
peptidoglycan cell wall; an inner membrane (cytoplasmic membrane), made up of phospholipid
bilayer. The first important activity is disruption of the OM. Lipopolysaccharide (LPS), the
primary component of the OM (which has a major role in protection against the environment), is
composed of three main regions: O-antigen, core polysaccharide and lipid A. As shown in Figure
1.2, the cationic face of AMPs binds to the negative membrane surface by electrostatic
interactions. When the concentration of the AMPs is increased to the critical point, the peptides
cause membrane reorienting and depolarize the membrane, which is sufficient to cause cell death.
However, AMPs also have some serious drawbacks that limit their applications in therapeutic
areas. The complex structure and large size of AMPs make them difficult to isolate and prepare
and result in a high manufacturing cost. They are salt-sensitive and susceptible to degradation in
a short time when met with proteases.12,13 Because of AMPs’ limitations, researchers designed
and synthesized novel compounds to mimic the activities of antibacterial peptides. Ceragenins
are one kind of these non-peptide mimics.

2

Figure 1.1 Helix-wheel representations of antimicrobial peptides cathelicidin LL-37 and magainin I showing facial
amphiphilicity (Adapted from ref [23]).

Figure 1.2 One typical structure of LPS (lipid A) and “Carpet model” of bactericidal activity of AMPs.

1.1.2 Design of Ceragenins
Early in the research with ceragenins, Li et al. designed a series of new sensitizers of Gramnegative bacteria based on the consideration of bactericidal behavior of polymyxin B and its
3

derivatives. They synthesized several series of cholic acid derivatives, such as amine- and
guanidine-functionalized derivatives, and found these compounds had good antibacterial activity
against Gram-negative and Gram-positive bacteria, and also had the ability to inhibit bacterial
growth.14-19 Later, these series of cholic acid derivatives were termed cationic steroid
antimicrobials (CSAs) or ceragenins.20-23
Shown in Figure 1.3, ceragenins, cationic steroid antimicrobials (CSAs), are derived from cholic
acid, which is inherently facially amphiphilic with three hydroxyl groups on one face of the
steroid. To mimic the bactericidal behavior of AMPs, amine groups are covalently attached
through the hydroxyl groups on the cholic acid. As a result, the ceragenins have a net cationic
charge and can electrostatically attract negatively charged bacterial membranes. They also have a
hydrophobic face, giving them their facially amphiphilic character. Position C-24 is also very
important and the groups attached at this point substantially influence CSAs’ bactericidal activity
against Gram-negative bacteria. Ceragenins are not peptide based, so they are not substrates of
proteases and are therefore very stable under physiological conditions. Furthermore, their
structures are simple and easily prepared at a large scale.
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Figure 1.3 Structures of cholic acid and CSA-13 showing facial amphiphilicity character of CSAs.

1.1.3 Development and Applications of Ceragenins
More than one hundred CSAs have been prepared so far. CSAs have demonstrated broadspectrum activity against viruses, multidrug-resistant bacteria, fungi and parasites, and have the
potential ability to kill both Gram-negative and Gram-positive organisms. CSAs can also
permeabilize the outer membrane of Gram-negative bacteria. The antibacterial activities of these
agents are typically characterized via measurement of minimum inhibition concentrations (MICs)
and minimum bactericidal concentrations (MBCs). Membrane selectivity is determined by MIC
5

and minimum hemolytic concentration (MHC). Many studies have been carried out to
investigate the antibacterial activities of these ceragenins. For example, Ding et al. studied CSAs’
cell selectivity and their association with lipid A by appending a fluorophore on these antibiotics.
The experimental results showed that CSAs have higher selectivity for Escherichia coli (Gramnegative) over both Staphylococcus aureus (Gram-positive bacteria) and Chinese hamster ovary
(eukaryotic cell) membranes. The results also suggested that CSAs with higher affinity for lipid
A display greater antibacterial activity and greater cell selectivity.24
Paying attention to the issue of increasing multidrug resistance in microbes, Chin et al.
compared the antibacterial activities of CSA-8 and CSA-13 to those of daptomycin, linezolid,
and vancomycin against clinical isolates of VISA (vancomycin-intermediate S. aureus), hVISA
(heterogeneous VISA), and VRSA (vancomycin-resistant S. aureus). Their results demonstrated
that ceragenins have therapeutic implications for infections caused by strains of VISA and
hVISA.25 Leszczyńska et al. demonstrated the anti-Helicobacter pylori potential of ceragenin
CSA-13, as it yielded much lower MBC values than those of cathelicidin LL-37 and WLBU2
(synthetic analog of LL-37). Furthermore, at low pH, only CSA-13 kept its antibacterial
activity.26
To evaluate the potential of ceragenins as antiviral agents and antimicrobial agents, Howell et
al. demonstrated the CSA-13 had antiviral activity against vaccinia virus (VV) under in vitro or
in vivo models and protected the KC cells against VV-mediated cell death. Therefore, ceragenins
may be a potential intervention for disseminated VV skin infection.27 Isogai et al. confirmed that
CSA-13 has antimicrobial activities against oral pathogens, including cariogenic and
periodontopathic bacteria.28 Leszczynska et al. also demonstrated the ceragenins CSA-13, CSA90 and CSA-92 have antibacterial activity against oral and upper respiratory tract bacteria
6

comparable to that of LL-37 and exhibit less resistance.29 Durnaś et al. demonstrated that when
compared with LL-37, ceragenins, including CSA-13, CSA-131 and CSA-192, have better
fungicidal activity against four fluconazole–resistant Candida strains and showed an increased
ability to kill DNA-induced Candida biofilm.30
To confirm the utility of ceragenins on medical devices, due to their ability to prevent biofilm
formation, Williams et al. investigated the in vivo efficacy of a silicon-ceragenin coating to
prevent biofilm implant-related infections and the results indicated that CSA-13 had the ability to
prevent biofilm implant-related osteomyelitis, which may indicate promise for clinical
application of ceragenins.31 Zahoor et al. illustrated that when another ceragenin, CSA-107, was
labeled with 99mTc via transchelating agent Na–K tartrate, it showed good human serum stability
and binding activity with S. aureus bacteria. This result makes CSAs promising in
radiopharmaceuticals for infection imaging.32 Hoppens et al. successfully synthesized novel
nanoparticles with an iron oxide core, reduced silver shell and CSA-124 as surfactant. Their
characterization results suggest this nanoparticle could be a good potential candidate for
diagnostic use.33 Niemirowicz et al. prepared CSA-13-coated magnetic nanoparticles (MNPCSA-13) and characterized their physicochemical properties. They further demonstrated MNPCSA-13 could increase antimicrobial properties and decrease hemolytic activity. These results
implied a promising future of ceragenins’ applications in a drug delivery system.34 To further
explore MNP-ceragenins’ applications, they illustrated the combination of core-shell MNPs with
membrane-active compounds, including ceragenins and other classical antibiotics, to show a
novel method to treat and overcome infections caused by multidrug resistant (MDR)
pathogens.35
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To evaluate the safety of ceragenins, Leszczynska et al. illustrated that although CSA-13
would cause lysis of erythrocytes at high concentration, when CSA-13 was mixed with pluronic
F-127, the hemolytic activity of CSA-13 decreased in the presence of pluronic F-127. This
finding suggests there is a useful way to reduce ceragenins’ toxicity.36 They further demonstrated
the mixture was also a good solution for the toxicity of CSA-13 to eukaryotic cells.37
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1.2 Ceragenin-Containing Coatings for Use in Inhibiting Marine Biofouling
1.2.1 Introduction
The economic impacts of marine biofouling are well established (Yebra et al. 2004; Callow
and Callow 2011) and with increasing efforts to harness marine hydrokinetic (MHK) energy
through wave motion and tidal flows, these impacts are likely to grow. Marine biofouling occurs
in stages, with formation of bacterial biofilms on surfaces believed to be a key initial step leading
to biofouling with higher organisms (Dang and Lovell 2016). Controlled release of cytotoxic
metals proved to be successful in controlling biofouling; however, use of these metals has been
discontinued due to concerns over effects on the marine environment (Callow and Callow 2011).
MHK energy deployment projects must also adhere to these environmental policies, thus there is
a need to investigate metal free antifouling coatings for these renewable energy technologies.
More recent efforts have turned to naturally-occurring biocides as a means of controlling
biofouling initiated by bacterial biofilm formation (Trepos et al. 2015 and references cited
therein). In general, efforts have been placed on incorporation of these biocides into coatings
from which the biocides leach over time.
The activities of antimicrobial peptides (AMPs) are one of the most common means by which
bacterial growth is controlled by higher organisms, and AMPs are found in organisms ranging
from mammals to plants (Lai and Gallo 2009). The diversity of their primary sequences argues
that they have evolved independently at least dozens of times. Due to their bactericidal activity
and their suggested unlikelihood of engendering bacterial resistance (Mangoni et al. 2016),
substantial efforts have been made to develop AMPs for clinical use. They have also been
applied in antimicrobial coatings, demonstrating that AMPs retain antibacterial activities after
covalent attachment to surfaces (Gao et al. 2011). It has also been suggested that AMPs could
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find use in preventing marine biofouling (Trepos et al. 2015). However, there are impediments
to the use of AMPs for many applications, including their relatively high cost of manufacturing
relative to small molecules and their susceptibility to hydrolysis by ubiquitous proteases (Afacan
et al. 2012).
We have developed small molecules that mimic the antibacterial activities of AMPs, termed
ceragenins (Lai et al. 2008). These molecules are based on a bile acid scaffolding, and due to
their simplicity, they can be produced at large scale. Also because they are not peptide based,
ceragenins are not substrates for proteases. Nevertheless, ceragenins retain the broad-spectrum
antibacterial activities of AMPs and are active against Gram-negative and positive bacteria. They
selectively target bacterial membranes, causing depolarization and cell death (Epand et al. 2010
and Ding et al. 2004).

Figure 1.2.1 Structure of Ceragenin CSA-120

Recently, we demonstrated that ceragenins, even when covalently attached to a polymer, are
capable of preventing bacterial colonization of surfaces (Gu et al. 2013).

Immobilization

required appending the ceragenin with an acrylamide group to allow radical polymerization (e.g.,
CSA-120, Figure 1.2.1).

A short tether was used between the acrylamide group and the

ceragenin to allow flexibility with how the ceragenin interacts with microbial membranes.
Because many coating materials polymerize via radical-based reactions, CSA-120 is well
suited for incorporation into multiple different types of coatings, including those designed to
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inhibit biofouling in marine environments. The fluoropolymer-based coating IS970 (International
InterSleek 970) is well recognized as a fouling-release coating (Watson et al. 2015), and we
reasoned that the combination of fouling-release by IS970 with the antibiofilm activities of CSA120 would provide a novel and effective coating for prevention of biofouling. A key aspect of
this combination is that the ceragenin is covalently (i.e., permanently) attached to the coating, so
material is not leaching into the environment.
To test this combination, we incorporated CSA-120 at two concentrations into commercially
available Intersleek formulation IS970 and coated primed aluminum coupons. Coated coupons
were tested for biofilm formation and compared to the parent coating in open water testing at
Pacific Northwest National Laboratory’s (PNNL) Marine Sciences Laboratory under low and
high velocity flows. Coating of the coupons with the combination coating (IS970 and CSA-120)
resulted in a decrease in biofouling relative to controls, and we attribute this to inhibition of
initial bacterial biofilm formation on the coating.

1.2.2 Materials and Methods

Chemical reagents and materials
Intergard®264, Intersleek® 900 (IS 900) and IS730 coating systems were purchased from
International Paint, Houston, TX, USA. Aluminum test coupons, painted on all sides with an
epoxy-based primer (Intergard 264), were used as substrates for the coatings. Coupons were 1”
x 1”, 3” x 3” and 8” x 8” squares. Coupons had holes drilled in each corner for use in mounting
the coupons during testing.
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1.2.3 Synthesis of CSA-120
Synthesis of Tris-Boc CSA-8
After a few decade studies for CSAs in our group, we developed a general effective and
efficient synthetic pathway to prepare all CSAs. Among these intermediates, Tris-Boc CSA.8
played key role in whole synthetic pattern of various CSAs including CSA-120. The scheme
1.2.1 presents synthetic route for Tris-Boc CSA.8.
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Scheme 1.2.1 Synthesis of Tris-Boc CSA-8
Reagents: a) LAH, THF, reflux, 93%; b) Triphenylmethyl chloride, pyridine, Acetonitrile, 70%; c) allyl bromide,
KHMDS, THF, 81%; d) 9-BBN, THF, r.t, NaOH, H2O2, 50%; e) i) MsCl, TEA, DCM; ii) NaN3, DMSO, 80 oC,
92%; f) p-TSA, MeOH/DCM(1:1), 82%; g) Triphenyl phosphine, THF,H2O, 78%; h) (Boc)2O, TEA, DCM, 95%.

Cholic acid 1.1 was reduced by LAH to obtain compound 1.2. The primary hydroxyl group of
1.2 was then protected by trityl group giving compound 1.3. Treatment of compound 1.3 with
allyl bromide and strong base KHMDS provided compound 1.4. Hydroboration-oxidation of
compound 1.4 yielded alcohol compound 1.5. The compound 1.5 was converted to azide 1.6,
followed by removal of trityl group of compound 1.6 giving compound 1.7. Amine 1.8 was
obtained by reduction of azide compound 1.7. Protection of the primary amine groups of 1.8
afforded compound 1.9 (Tris-Boc CSA-8).
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Synthesis of PEG tether side chain (Compound 1.13)
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Scheme 1.2.2 Synthesis of compound 1.13
Reagents: a) i) MsCl, TEA, DCM; ii) NaN3, DMSO, 80 oC, 82%; b) H3PO4, PPh3, Et2O, EtOAc, 72%; c) phenyl
chloroformate, TEA, DCM, 0 oC, 94%.

Compound 1.13 is an important synthetic block as a short tether which was used between the
functional group such as acrylamide group and the ceragenin to allow flexibility with how the
ceragenin interacts with microbial membranes. Pentaethylene glycol 1.10 was converted to the
corresponding di-azide 1.11 by reacting with MsCl and TEA first and then NaN3 in DMSO.
Reduction of compound 1.11 by triphenyl phosphine in the presence of phosphorus acid afforded
compound 1.12. The primary amine of compound 1.12 was coupling with phenyl chloroformate
in presence of basic condition to give the compound 1.13.
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Synthesis of CSA.120 HCl salt
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Scheme 1.2.3 Synthesis of CSA-120
Reagents: a) MsCl, TEA, DCM; b) Octyl amine, 85%; c) 1.13, K2CO3, acetonitrile, 80 oC, 12 hrs, 64%; d)
Triphenyl phosphine, THF/H2O (3:1), 73%; e) EDC, HOBt, acrylic acid, DCM, 100%; f) HCl/Dioxane, 91%.

With the important intermediate Tris-Boc CSA.8 in hand, compound 1.14 was converted with
MsCl and TEA at 0 oC, followed treatment of octyl amine without any solvent at 80 oC for 1
hour afforded compound 1.15. Then the amine 1.15 was reacted with compound 1.13 in presence
of base at 80 oC for 12 hours to obtain the coupling product compound 1.19. Reduction of azide
group afforded the corresponding amine 1.20, which was coupled with acrylic acid providing
compound 1.21 in reasonable yield. Deprotection of the remaining amines gave the target
compound 1.22 as CSA.120 HCl salt form.
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1.2.4 Application of Coatings
All coupons were primed with IS730 prior to final coating according to manufacturer
instructions. For the ceragenin/fluoropolymer coating, CSA-120 was added as either 1 or 2.5%
of the total solids in the coating.

Application of the IS970 coating requires use of three

components: A, B and C. CSA-120 was added to component B before mixing by first dissolving
CSA-120 in isopropanol (10% solution (w/v)).

The three components were then mixed

according to manufacturer instructions and applied on lateral sides using a nylon roller designed
for smooth surfaces. Solvents in the coating solution were allowed to evaporate at room
temperature for 15 min, and then coupons were exposed to direct sunlight for a minimum of 1 h,
per side. Coupons were soaked in water for 1 h and washed with flowing water for 5 min to
remove any non-covalently linked material. Coupons were dried and subjected to biofouling
testing.
To determine the effectiveness of incorporation of CSA-120 into the coatings, primed 3” x 3”
coupons were coated on one side with IS970 alone and with IS970 (120 mg cured weight)
containing 2.5% CSA-120 (3.0 mg). The coatings were cured as described above, and the
coupons were immersed in deionized water (120 mL) for 24 h. The water was removed by
lyophilization. From the IS970 alone, 0.59 mg µg of a white solid was recovered; from the IS970
coating containing CSA-120, 0.97 mg of a white solid was recovered. If the difference between
the IS970 alone and the CSA-120-containing coating (0.38 mg) were CSA-120 or a derivative
thereof (CSA-120 is clear oil), covalent attachment is greater than 85%. Material recovered
from the CSA-containing coating was subjected to mass spectrometry, and CSA-120 was not
detected (detection limit of ca. 10 µg). This result suggests that >99% of the CSA-120 was
covalently immobilized in the coating.
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1.2.5 Biofouling Testing
Tests were conducted using two different flow
velocity systems in tanks filled with unfiltered
seawater to simulate the marine environment
where currents are dynamic ranging from 0 to 5
knots (0.0 ~ 2.5 m/s). The low-flow velocity
environment used circular 500 gal tanks (Figure
1.2.2) with rotational currents < 0.5 knots. The
high flow environment used a raceway tank with a
flow velocity of 2.5-4 knots (Figure 1.2.2). The
low velocity tanks were located indoors and used
ambient temperatures and a diurnal light cycle.
The raceway flume was located outdoors and also Figure 1.2.2 Top: One of the 500 gal tanks used
for the low-velocity studies. Bottom left: Raceway

used ambient conditions.
For the indoor, low-flow rate tank tests, water
exchange rates were maintained at 30% volume

flume used for the high-velocity studies. Bottom
right: Frames (empty) used to hold coupons in the
raceway.

per hour or greater. Salinity and temperature were monitored and recorded. For the outdoor,
high-flow rate tests in the flume shown in Figure 1.2.2; the flow velocity was set at a single (nonvarying) rate and measured at the location of each coupon. The coupons were held vertically and
at a 45-degree angle relative to the direction of flow such that one coupon surface faced the flow
and the backside of the coupon was exposed to turbulence and back eddies. The coupons were
arranged in a staggered pattern through the tank.
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For each antifouling coating, PNNL tested a total of six 1” x 1” coupons, two 3” x 3” coupons,
and two 8” x 8” coupons per time period. The 1” x 1” coupons were used for total organic carbon
(TOC) measurements. The 3” x 3” coupons were used to assess changes in weight during the
exposure period. The 8” x 8” coupons were used for visual analysis, staining, and for molecular
characterization. Coupons were submerged in the tanks and recovered after 30 (short-term), 60
(mid-term), and 90 (long-term) days. Primer control, SN1, IS970 coatings were used as reference
standards.

1.2.6 Methods of Analysis
Total Organic Carbon (TOC)
Each 1” x 1” coupon was transferred to a sterile 50 mL polypropylene centrifuge tube and
hydrogen peroxide (3%, 30 mL) was added. Tubes incubated in 55 °C (water bath) for an hour.
Tubes were vortexed vigorously and then attached to a Vial Tweeter sonication unit and oriented
such that one face of the coupon faced the Vial Tweeter horn. Following one-minute sonication,
the tube was rotated 180° so the other side of coupon faced the horn for one-minute sonication.
The resulting suspension was transferred and analyzed for TOC.
Weight Analysis
Each 3” x 3” coupon was weighed prior to testing. After exposure to seawater, coupons were
removed and passed through a Dyson Airblade hand dryer unit to remove bulk water and then
weighed. Wet biomass weights were determined by subtraction of initial weights from final
weights.
Visual Analysis
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Each 8” x 8” coupon was photographed and assessed to determine percent coverage by slime
and macrobiota species. One edge of the coupon was wiped clean (approximately ½ inch wide)
and the coupon was then stained with mixture of three different dyes. Erythrosine B is a general
red dye for biomass, rhodamine stains nucleic acids and coomassie brilliant blue is used to detect
proteins. The coupon was photographed and analyzed (Matlab) to quantify biofilm growth
intensities.
1.2.7 Results and Discussion
Fluoropolymer coatings (e.g., IS970) are effective fouling-release coatings; however, these
coatings perform best in flowing systems in which shear forces cause loss of adhered organisms.
We reasoned that anti-biofouling performance of these coatings under conditions with lower
shear forces could be improved by incorporation of a means to inhibit the first stages in
biofouling. Based on operation, not all MHK Wave and Tidal energy devices will reach or
experience the required velocity and shear rates necessary for foul release coatings. AMPs are
one of Nature’s primary means of controlling microbial growth (Lai and Gallo 2009). And
AMPs maintain antimicrobial activity even when covalently attached to a surface (Gao et al.
2011). Use of AMPs to inhibit biofouling has been reported with good results (Trepos et al.
2015). However, due to the cost of AMPs and their susceptibility to degradation by proteases, it
is unlikely that they will find wide-spread use in coatings. As mimics of AMPs, ceragenins offer
the same antimicrobial mechanism without the cost and stability issues.
AMPs and ceragenins are membrane active; consequently, it is not surprising that they retain
antimicrobial activity when immobilized on a solid surface. However, design of a means of
incorporating this type of molecule in a polymer must take into account the need for the
molecules to attack microbial membranes at optimal angles. This need can be met by using a
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sufficiently flexible tether between the immobilized ceragenin and the polymer, and CSA-120 a
short span of polyethyleneglycol (PEG) is used as a tether. The acrylamide group at the end of
the PEG tether is for incorporation into the polymer. Acrylamides, like related acrylates found in
acrylic paints (Bao et al. 2015), readily engage in radical polymerizations that can be initiated via
UV light and/or atmospheric oxygen. To ensure complete radical polymerization, CSA-120,
added to the components of IS970 was exposed to both atmospheric oxygen and UV light. And
to approximate conditions likely to be used in practical applications, sunlight was used as the UV
source.
Once polymerization occurred, little or no unpolymerized starting material remained. No
CSA-120 was observed after soaking coatings in water. CSA-120 is highly soluble in water (> 5%
w/v), so unreacted CSA-120 would have been readily removed upon exposure to water.
Furthermore, anti-biofouling testing was performed over extended periods, so any unreacted
ceragenin would be washed from the coupons well before it had any impact on adhesion of
microorganisms.
Two different amounts of CSA-120 were incorporated into IS970 to determine the impact of
local concentration of the ceragenin. Previously, we observed antibacterial activity of CSA-120
immobilized in a hydrogel at a concentration of 1% (Gu et al. 2013), so one of the concentrations
used was 1% and a high concentration of 2.5% was included in the study. Both concentrations
were obtained by dissolving CSA-120 in isopropanol and then mixing it with component B of
IS970, which employs ethylbenzene as a solvent. The resulting stable solution was then mixed
with the remaining components of IS970 and immediately applied to the coupons.
To quantify biofouling, coupons were placed in either the static tank (S) or raceway flume (F)
shown in Figure 1.2.2. Comparators were primer control and IS970-coated coupons. By each
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measure (total carbon, added weight, and biofilm growth intensity) a small amount of biofouling
was observed in the static tank relative to the raceway flume, and larger amounts of biofouling
allowed more meaningful distinction among the coated coupons.
For determination of total carbon adhered to the coatings, 1” x 1” coupons were used, and the
measurement (parts per million) reflects adherence of both bacteria and other, higher organisms
(Figure 1.2.3).

Substantially greater amounts of carbon were found on the primer control

coupons in the flume as compared to coupons with coatings containing differing amounts of
CSA-120 (BYU1 with 1.0% CSA-120, and BYU2 with 2.5% CSA-120) (Figure 1.2.3A).
Notably, lower amounts of carbon accumulated on BYU1 and BYU2 coupons as compared to
the IS970-coated coupons; with one exception (long-term, static tank with BYU1), all of the
amounts of adhered carbon with BYU1 and BYU 2 were below those with the IS970 coupons
(Figure 1.2.3B).
In measurement of total attached carbon there were not substantial differences between BYU1
and BYU2 coupons. As mimics of AMPs, ceragenins are membrane active and require a
threshold concentration for activity. It is likely that this threshold is met with 1% CSA-120. The
idea that if some is good then more is better may not hold with molecules of this type. It is likely
that if CSA-120 is too densely packed on a surface that the compounds may be unable to obtain
the necessary orientation for antibacterial activities. This idea may explain why there is not a
significant difference between coatings containing different amounts of CSA-120 by this
measure of biofouling.
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Total Organic Carbon (ppm)

A

Total Organic Carbon (ppm)

B

Figure 1.2.3 Total organic carbon measurements for coated coupons. (S) indicates coupons tested in the static tank;
(F) indicates coupons tested in the raceway flume (2.5-4 knots). Short-term-30 days; Mid-term-60 days; Long-term90 days; 3A: Primer control, IS970 containing 1% CSA-120 (BYU1) and IS970 containing 2.5% CSA-120 (BYU2).
3B: IS970 (Intersleek), BYU1 and BYU2.

The intermediate-sized coupons (3” x 3”) were used for determination of wet biomass weight
accumulation (Figure 1.2.4). As expected, substantial amounts of biomass accumulated on the
primer coupons in the static tank and in the raceway flume (Figure 4A). BYU1 and BYU2
coupons accumulated less biomass in all measurements. As seen with measurement of total
organic carbon (Figure 1.2.3A), the BYU1 coupons accumulated less biofouling as compared to
BYU2.
As compared to the IS970-coated coupons, BYU1 and BYU2 were comparable in the static
tank. In the flume, these coupons accumulated more biomass than the IS970-coupons at short
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and intermediate time points. However at the long time point (90 days), there was a substantial
difference; BYU1 and BYU2 lost most of the accumulated biomass. There are multiple possible
explanations for this difference, and a possibility is that the immobilized CSA-120 interfered
with formation of the initial bacterial biofilm layer, which in turn interfered with the strength of
adherence of higher organisms; with a longer exposure to higher velocity flows accumulated
biofouling was lost.
A
Wet Biomass Increase (g)

B
Wet Biomass Increase (g)

Figure 1.2.4 Wet biomass accumulated on coated coupons. (S) indicates coupons tested in the static tank; (F)
indicates coupons tested in the raceway flume (2.5-4 knots). Short-term- 30 days; Mid-term- 60 days; Long-term90 days; 1.3.4A: Primer control, IS970 containing 1% CSA-120 (BYU1) and IS970 containing 2.5% CSA-120
(BYU2). 1.3.3B: IS970 (Intersleek), BYU1 and BYU2.
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The 8” x 8” coupons were used to determine biofilm growth intensities (Figure 1.2.5). As
compared to primer-coated coupons, less biofouling was observed on BYU1 and BYU2 (Figure
1.2.3A) at both mid and long-term exposure in the raceway flume. A small difference was
observed between the BYU1 and BYU2, and as with other measures of inhibition of biofouling,
BYU1 proved to be better than BYU2.
A comparable amount of biofilm formation was observed on the BYU1 and BYU2 coupons in
the static tank; however, at 90 days, both supported less biofilm growth than the IS970-coated
coupons (Figure 1.2.5B). In contrast, in the raceway flume, a substantially greater amount of
biofouling was observed on both BYU1 and BYU2 relative to the IS970-coated coupons at the
short- and mid-term time points. At 90 days, BYU1 and Intersleek coupons had comparable
amounts of biofilm.
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A
Biofilm Growth Intensity

B
Biofilm Growth Intensity

Figure 1.2.5 Biofilm growth intensity on coated coupons. (S) indicates coupons tested in the static tank; (F)
indicates coupons tested in the raceway flume (2.5-4 knots). Short-term- 30 days; Mid-term- 60 days; Long-term90 days; 1.3.4A: Primer control, IS970 containing 1% CSA-120 (BYU1) and IS970 containing 2.5% CSA-120
(BYU2). 3B: IS970 (Intersleek), BYU1 and BYU2.

1.2.8 Conclusions
Inhibition of biofouling in marine environments is a daunting challenge given the number of
types of organisms that can adhere to surfaces and the variety of conditions under which surfaces
can be colonized (e.g., variations in temperature, shear forces, exposure to light, etc.).
Consequently, optimization of ant biofouling coatings may require combinations of strategies to
inhibit colonization.

Fluoropolymer coatings have proven useful in inhibiting biofouling,

especially under conditions in which shear forces aid in removing adhered organisms from the
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coating. Under conditions lacking shear forces, fluoropolymer coatings are left vulnerable to
biofouling (Watson et al. 2015). Since biofouling follows a progression of colonization by
bacteria to adherence of higher organisms, adding a method of preventing bacterial biofilm
formation on coatings was expected to provide added antifouling protection to fluoropolymer
coatings.
The prevalence of AMPs in organisms ranging from mammals to amphibians to insects to
plants argues that AMPs are one of the primary ways in which these organisms control and
prevent bacterial growth. This prevalence also argues that bacteria are unlikely to generate high
resistance to AMPs.

These observations have led to efforts to use AMPs in coatings for

prevention of bacterial colonization of surfaces, include efforts to inhibit marine biofouling
(Trepos et al. 2015). These efforts are complicated by the high costs of AMP synthesis and
sensitivity of AMPs to degradation. Ceragenins offer the same broad-spectrum antimicrobial
activities as AMPs with substantially lower production costs and no sensitivity to proteases.
Ceragenin CSA-120 can be copolymerized in a fluoropolymer coating at varied concentrations,
and the resulting coatings differ from the parent coating. By measures total adhered organic
carbon and wet biomass, CSA-120 containing coatings displayed some improvements over the
parent fluoropolymer coating. Only in long-term exposure to flowing sea water was one of the
ceragenin coatings comparable to the parent coating. Results from these studies suggest that
combination of strategies, in this case use of a fluoropolymer and an AMP mimic, may improve
inhibition of biofouling. Further optimization of relative concentrations of ceragenin and use of
alternative tethering groups may lead to incremental improvements in the antibiofouling
properties of this type of coating.
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1.2.9 Experimental Section
General: Reagents were purchased from Aldrich Chemical Co. unless otherwise noted.
Methylene chloride, THF, DMF, pyridine, and DMSO were dried by passage through a Glass
Contour solvent drying system containing a cylinder of activated alumina. Silica gel was used for
chromatography unless otherwise noted.
Instrumentation: 1H and 13C NMR spectra were recorded on a Varian Gemini 500 (500 MHz)
spectrometer. Proton chemical shift were referenced to tetramethylsilane (TMS). Carbon
chemical shifts were referenced to carbon resonance of solvents (CDCl3, CD3OD). High
resolution electron impact mass spectra (HR-MS) were obtained on a JOEL SX 102A
spectrometer.

Experiment:
OH

HO

OH

OH
1.2

Compound 1.2 To a suspension of LiAlH4 (9 g, 236.8 mmol) in 1 L of THF, cholic acid (50
g, 122.5 mmol) was added at 0 oC. The mixture was refluxed 24 hrs. 120 mL of saturated
Na2SO4 was added to quench the reaction at 0 oC. The filter cake was washed with 100 mL of
cold MeOH. 42 g of 1.2 was obtained as a white powder, after the trace amount of water was
removed under120 oC. The yield was 95%. 1H NMR (CDCl3 / 30% CD3OD, 200 MHz) δ 3.98
(br, 1 H), 3.83 (br, 1 H), 3.60-3.46 (m, 2 H), 3.38 (br, 5 H), 2.30-2.10 (m, 2 H), 2.05-1.05 (m,
22 H), 1.03 (br, 2H), 0.92 (s, 3 H), 0.71 (s, 3 H);
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13

C NMR (CDCl3, 50 MHz) δ 73.89, 72.44,

68.99, 63.51, 48.05,47.12, 42.49, 40.37, 39.99, 36.62, 36.12, 35.58, 35.40, 32.77, 30.69, 30.04,
29.02, 28.43, 27.27, 23.96, 23.08, 18.00, 13.02; HRMS (ESI) calcd for C24H42O4 [M+H]+:
566.4889, found:566.4898.
OH

HO

OTr

OH
1.3

Compound 1.3 To a suspension of 1.2 (42 g, 106.5 mmol) in 400 mL of MeCN, TrCl (41.5 g,
149 mmol) and dry pyridine (12.6 g, 159.75 mmol) was added. The suspension was heated at
65 oC for 16 hrs. After the temperature was cooled down to room temperature, 240 mL of
MeCN was added. The mixture was stirred for 2 hrs. The solid was washed with 100 mL of
MeCN. 61 g of 1.3 was obtained as a white powder, after the trace amount of the solvent
1
was removed under 120 oC. The yield was 92%. H NMR (CDCl3, 200 MHz) δ 7.46-7.42 (m,

6 H), 7.32-7.17 (m, 9H), 3.97 (br, 1 H), 3.83 (br, 1 H), 3.50-3.38 (m, 1 H), 3.01 (br, 1 H), 2.94
(dd, J = 14.2, 12.2 Hz, 2H), 2.64 (br, 1 H), 2.51 (br, 1 H), 2.36-2.10 (m, 2 H), 2.00-1.05 (m, 22
H), 0.96 (d, J = 5.8 Hz, 3H), 0.87 (s, 3 H), 0.64 (s, 3 H);

13

C NMR (CDCl3, 50 MHz) δ 144.77,

128.93, 127.91, 127.01,86.43, 73.35, 72.06, 68.66, 64.28, 47.47, 46.53, 41.74, 41.62, 39.64,
35.57, 35.46, 34.91, 34.82,32.40, 30.55, 28.21, 27.69, 26.80, 26.45, 23.36, 22.59, 17.83,
12.61; HRMS (ESI) calcd for C43H56O4 [M+H]+: 637.4179, found: 637.4183.
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O

O

OTr

O
1.4

Compound 1.4 To a solution of 1.3 (41.5 g, 65.2 mmol) in 400 mL of dry THF, NaH (8 g,
326 mmol), tetrabutylammonium iodide (802.4 mg, 2.17 mmol), and allyl bromide (39.4 g, 326
mmol) were added. The mixture was refluxed overnight. 20 mL of MeOH was added to
quench the reaction at 0 oC.

After the solvent was removed, 100 mL of water was added.

Hexanes were used to extract the mixture. The combined organic layer was dried over Na2SO4.
After the solvent was removed, 44.4 g of the crude product was obtained and used in the next
step directly.

1

H NMR (CDCl3, 200 MHz) δ 7.48-7.30 (m, 6 H), 7.32-7.14 (m, 9H), 6.04-5.80

(m, 3 H), 5.36-5.04 (m, 6H), 4.14-3.94 (m 4 H), 3.74 (dt, J = 13.8, 5.8 Hz, 2 H), 3.53 (br, 1 H),
3.20-2.94 (m 3 H), 3.31 (br, 1 H), 2.38-1.90 (m, 4 H), 1.90-0.96 (m, 20 H), 0.90 (d, J = 5.4 Hz,
3 H), 0.89 (s, 3 H), 0.64 (s, 3 H); 13C NMR (CDCl3, 50 MHz) δ 144.83, 136.27, 136.08, 128.94,
127.90, 126.98, 116.46,115.40, 86.42, 80.94, 79.29, 74.98, 69.52, 69.39, 68.86, 64.39, 46.51,
46.42, 42.67, 42.14, 39.92,35.63, 35.51, 35.13, 32.45, 28.98, 28.09, 27.66, 27.57, 26.72, 23.32,
23.11, 17.92, 12.69; HRMS (ESI) calcd for C52H68O4 [M+H]+: 757.5118, found: 757.5123.
HO

HO

O

OTr

O

O
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OH

Compound 1.5 To a 100 mL of 1 M BH3 in THF, cyclohexene (16 g, 200 mmol) in 50 mL
of THF was added 0 oC. The mixture was stirred 30 mins. 1.4 (22 g, 30 mmol) in 200 mL of
THF was added, and the solution was refluxed for 6 hrs. After the temperature was cooled
down to 0 oC, 70 mL of 20% NaOH and 70 mL of H2O2 was added dropwise carefully. The
reaction mixture was refluxed overnight. Before the THF was removed, KI / starch test paper
was used to make sure that no peroxide remained. EtOAc was used to extract the mixture and
after dried over Na2SO4, the solvent and the cyclohexanol were removed under vacuum. The
resulting sticky oil was used in the next step without purification. The crude yield was 90%. 1H
NMR (CDCl3, 200MHz) δ 7.50-7.42 (m, 6 H), 7.32-7.14 (m, 9H), 3.90-3.65 (m, 8 H), 3.50 (br,
6 H), 3.40-2.96 (m6 H), 2.30-0.94 (m, 30 H), 0.90 (s, 3 H), 0.88 (d, J = 5.4 Hz, 3 H), 0.64 (s, 3
H); 13C NMR (CDCl3, 50 MHz) δ 144.73, 128.88, 127.85, 126.94, 86.36, 80.52, 78.90, 76.36,
66.82, 66.18,65.77, 64.22, 61.53, 61.41, 61.34, 46.89, 46.04, 42.60, 41.59, 39.60, 35.37, 35.27,
34.88, 32.75,32.44, 32.31, 28.82, 27.65, 27.48, 27.13 26.77, 23.35, 22.74, 22.38, 18.08, 12.48;
HRMS (ESI) calcd for C52H74O7 [M+H]+: 811.5435, found: 811.5440.
N3

N3

O

O

OTr

O

N3

1.6

Compound 1.6 To a solution of crude 1.5 in 100 mL of THF, MsCl (3.8 g, 33 mmol) and
Et3N (3.4 g, 33.5 mmol) were added at 0 oC. The solution was stirred for 30 mins.

After

removing the solvent, 50 mL of water was added. The mixture was extracted with EtOAc.
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The combined organic phase was dried over Na2SO4. After the solvent was removed, 100 mL
of DMSO was used to dissolve the residue. Sodium Azide (6.6 g, 100 mmol) was added, and
the mixture was stirred at 80 oC for 12 hrs.

The reaction was allowed to cool down to RT.

150 mL cold DI water was used to quench reaction. Then t h e m i x t u r e w a s e x a c t e d w i t h
E t O A c ( 1 0 0 m L × 4 ) . The combined organic layer was dried over Na2SO4. After the solvent
was removed, 7.3 g of the product was isolated through a column chromatography (SiO2).
The yield was 75%. 1H NMR (CDCl3, 200 MHz) δ 7.50-7.42 (m, 6 H) 7.32-7.14 (m, 9H),
3.90-3.65 (m, 5H), 3.50 (br, 6 H), 2.30-0.94 (m, 30 H), 1.49-1.6 (m, 6H), 0.90 (s, 3 H), 0.88 (d,
J = 5.4 Hz, 3H), 0.64 (s, 3 H);

13

C NMR (CDCl3, 50 MHz) δ 144.73, 128.88, 127.85, 126.94,

86.36, 80.52,78.90, 76.36, 66.82, 66.18, 65.77, 64.22, 46.89, 46.53, 46.41, 46.34, , 46.04, 42.60,
41.59, 39.60,35.37, 35.27, 34.88, 32.75, 32.44, 32.31, 28.82, 27.65, 27.48, 27.13, 26.77, 23.35,
22.74, 22.38, 18.08, 12.48; HRMS (ESI) calcd for C52H71N9O4 [M+H]+: 886.56290,
found:886.56410.
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N3

O

O

OH

O

N3

1.7

Compound 1.7 To a solution of 1.6 (23 g, 26 mmol) in 240 mL of DCM and MeOH (1:1),
p-toluenesulfonic acid (1.3g, 6.5mmol) was added. The mixture was stirred at RT for 2hrs. A
solution of saturated NaHCO3 was used to quench reaction. Then the mixture was exacted with
EtOAc. The combined organic layer was dried over Na2SO4. After the solution was removed,
37

15g of the product was isolated through a column chromatography (SiO2). The yield was 90%.
1

H NMR (CDCl3, 200 MHz) δ 3.90-3.65 (m, 6H), 3.50 (br, 6 H), 2.30-0.94 (m, 30 H), 1.49-

1.6 (m,6 H), 0.90 (s, 3 H), 0.88 (d, J = 5.4 Hz, 3H), 0.64 (s, 3 H); 13C NMR (CDCl3, 50 MHz)
δ 80.52,78.90, 76.36, 66.82, 66.18, 65.77, 64.22, 46.89, 46.53, 46.41, 46.34, 46.04, 42.60,
41.59, 39.60,35.37, 35.27, 34.88, 32.75, 32.44, 32.31, 28.82, 27.65, 27.48, 27.13, 26.77, 23.35,
22.74, 22.38,18.08, 12.48; HRMS (ESI) calcd for C33H57N9O4 [M+H]+: 644.45335 , found:
644.46143.
H2N

H2N

O

O

OH

O

NH2

1.8

Compound 1.8 To a solution of 1.7 (16.73g, 26mmol) in 400 mL of THF and H2O (3:1),
Triphenyl phosphine (68.2g, 260mmol) was added. The reaction was stirred at RT overnight.
Then the mixture was exacted with EtOAc, the combined organic layer was dried over Na2SO4.
After the solvent was removed, 11.5g of the product was isolated through a column
chromatography (SiO2). The yield was 78%. 1H NMR (CDCl3 / 30% CD3OD, 300 MHz) δ 4.43
(bs, 7 H), 3.74-3.68 (m, 1 H), 3.66-3.60 (m, 1 H), 3.50-3.57 (m, 5 H),3.25-3.34 (m, 2 H), 3.063.17 (m, 2 H), 2.74-2.84 (m, 6 H), 2.01-2.19 (m, 3 H), 0.96-1.97 (m, 27H), 0.94 (d, J = 7.2 Hz,
3 H), 0.92 (s, 3 H), 0.69 (s, 3 H);

13

C NMR (CDCl3, 75 MHz) δ 80.44,79.27, 75.77, 66.59,

66.53, 65.86, 62.51, 46.21, 45.84, 42.55, 41.53, 40.09, 39.43, 39.31, 39.02,35.16, 34.93, 34.86,
34.57, 32.93, 32.71, 31.57, 28.66, 28.33, 27.64, 27.22, 23.04, 22.40, 22.29,17.06, 11.98;
HRMS (ESI) calcd for C33H63N3O4 [M+H]+: 566.4889, found: 566.4898.
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Tris-Boc CSA-8 To a solution of 1.8 (11.5g, 20mmol) in 300 ml of DCM, (Boc)2O (19.7g,
86mmol) was added. The reaction was stirred at RT overnight. 50 ml of MeOH was used to
quench reaction. After the solvent was removed, 16.4g of the product was isolated through a
column chromatography (SiO2). The yield was 95%. 1H NMR (CDCl3, 500 MHz) δ 4.82-5.34
(m, 3 H), 3.41-3.56 (m, 4 H), 3.25-3.40 (m, 3 H), 2.81-3.20 (m, 8 H), 2.40-2.58 (m, 2 H), 1.842.20 (m, 2 H), 1.41-1.82 (m, 17 H), 1.18- 1.40 (m, 36 H), 0.81-0.89 (m, 2 H), 0.79 (d, J= 6.4 Hz,
3 H), 0.72 (s, 3 H), 0.51 (s, 3 H).

13

C NMR (CDCl3, 125 MHz) δ 155.9, 155.75, 80.23, 78.88,

78.24, 75.37, 66.11, 65.40, 63.48, 46.28, 45.78, 42.34, 41.49, 39.39, 39.16, 38.25, 38.02, 35.20,
34.90, 34.53, 32.77, 30.25, 29.82, 28.47, 28.19, 28.16, 27.31, 27.16, 23.02, 22.55, 22.17, 17.67,
12.11; HRMS (ESI) calcd for C48H87N3O10 [M+H]+: 866.6391, found: 866.7021.
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Compound 1.15 To a solution of Boc-CSA-8 (20.5 g, 23.7 mmol) in 200 mL of THF, MsCl
(2.98 g, 26.1 mmol) and Et3N (2.64 g, 26.1 mmol) were added at 0 oC. The temperature was
allowed to rise up to room temperature. The solution was stirred for 30 mins. Then, 100 mL of
water was used to wash the solution. The aqueous layer was extracted with DCM three times.
The combined organic layer was dried over Na2SO4. After the solvent was removed, 50 mL of
octylamine was added to dissolve the residue. The mixture was stirred at 80 oC overnight. The
temperature was cooled to room temperature then, 200 mL of water and 200 mL of DCM
were added.

The aqueous layer was extract with DCM three times and the combined organic

phase was dried over Na2SO4. After removing the solvent, 19.32g of the product was isolated
through a column chromatography (SiO2). The yield was 85%. 1H NMR (CDCl3, 500 MHz) δ
4.82-5.34 (m, 3 H), 3.41-3.56 (m, 2 H), 3.25-3.40 (m, 3 H), 2.81-3.20 (m, 8 H), 2.40-2.58 (m, 6
H), 1.84-2.20 (m, 2 H), 1.41-1.82 (m, 29 H), 1.18- 1.40 (m, 36 H), 0.81-0.89 (m, 2 H), 0.88 (t,
3H), 0.79 (d, J= 6.4 Hz, 3 H), 0.72 (s, 3 H), 0.51 (s, 3 H). 13C NMR (CDCl3, 125 MHz) δ 155.9,
155.75, 80.23, 78.88, 78.24, 75.37, 66.11, 65.40, 48.71, 47.86, 46.28, 45.78, 42.34, 41.49, 39.39,
39.16, 38.25, 38.02, 35.20, 34.90, 34.53, 32.77, 32.23, 30.25, 29.82, 29.31, 29.12, 28.47, 28.19,
28.16, 27.31, 27.16, 27.10, 23.17, 23.02, 22.55, 22.17, 17.67, 14.63, 12.11; HRMS (ESI) calcd
for C56H104N4O9 [M+H]+: 977.7803, found: 977.8023.
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40
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Compound 1.11.To a solution of pentaethylene glycol (50g, 210 mmol) in 300 ml of DCM,
MsCl (49 ml, 630 mmol) and Et3N (102 ml, 740mmol) were added sequentially at oC. The
reaction was allowed to stir at RT for 1 hour. Then 150 ml of cold DI water was used to quench.
The mixture was exacted with DCM and washed with Brine (150 ml), the combined organic
layer was dried over Na2SO4. After removing the solvent, the crude compound was dissolved in
150 ml of DMSO (dry). 48g of NaN3 was added and the mixture was stirred at 80 oC overnight.
Then the cold DI water (200ml) was used to quench. The mixture was exacted with EtOAc
(100ml ×4). The combined organic layer was dried over Na2SO4. After removing the solvent,
49g of the product was isolated through a column chromatography (SiO2). The yield was 82%.
1

H NMR (200 MHz, CDCl3): d 3.62–3.60 (m, 16H), 3.34 (t, 4H, J = 5.1 Hz).

13

C NMR (50 MHz,

CDCl3): d 70.5, 69.9, 50.5 (10· CH2). ; HRMS (ESI) calcd for C10H20N6O4 [M+H]+: 289.1546,
found: 289.1632.
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O

O

O

N3

1.12

Compound 1.12 To a solution of 1.11 (49g, 172mmol) in 240 ml of Et2O and EtOAc (1:1),
210 ml of H3PO4 (2M) and 52 g of triphenyl phosphine were added sequentially. The reaction
was stirred at RT overnight. After washing the aqueous layer with DCM, the combined organic
layer was dried over Na2SO4. 32g of the product was isolated through a column chromatography
(SiO2). The yield was 72%. 1H NMR (CDCl3, 400 MHz) δ 3.6-3.7 (m, 16 H), 3.40 (t, 2 H), 3.36
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(t, 2 H); 13C NMR (CDCl3, 125 MHz) δ 70.70, 70.67, 70.62, 70.61, 70.57, 70.31, 70.02, 69.85,
50.63, 40.84; HRMS (ESI) calcd for C10H22N4O4 [M+H]+:263.1641, found: 263.1657.
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Compound 1.13.To a solution of 1.12 (23g, 88mmol) in 150 ml of DCM, Et3N (17ml, 125
mmol) and phenyl chloroformate (12ml, 96.5 mmol) were added at 0 oC. The reaction was stirred
for 1 hour. Then 100 ml of cold DI water was used to quench the reaction. The aqueous layer
was exacted with DCM (3×50 ml) and the combined organic layer was dried over Na2SO4. After
removing the solvent, 32g of the product was isolated through a column chromatography (SiO2).
The yield was 94%.1H NMR (CDCl3, 400 MHz) δ 7.35 (t, 2 H), 7.19 (t, 1 H), 7.12 (d, 2 H), 3.63.7 (m, 16 H), 3.47 (t, 2 H), 3.36 (t, 2 H).13C NMR (CDCl3, 125 MHz) δ 154.88, 151.10, 129.24,
125.21, 121.63, 70.70, 70.67, 70.62, 70.61, 70.57, 70.31, 70.02, 69.85, 50.63, 41.04. HRMS (ESI)
calcd for C17H26N4O6 [M+H]+:383.1852, found: 383.2053.
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Compound 1.19 To a solution of compound 1.15 (5.25g, 5.4 mmol) in 100 ml of MeCN (dry),
K2CO3 (2.1g, 5.4 mmol) and compound 1.13 (0.75g, 5.4 mmol) were added sequentially. The
reaction was allowed to reflux overnight. After cooled down to RT, 50 ml of DI water was used
to quench. The mixture was exacted with EtOAc, and the combined organic layer was dried over
Na2SO4. After removing the solvent, 4.4g of the product was isolated through a column
chromatography (SiO2). The yield was 64%. 1H NMR (CDCl3, 500 MHz): δ 4.79 (br, 1 H), 3.63.7 (m, 18 H), 3.03-3.58 (m, 24 H), 1.55-2.11 (m, 17 H), 1.43 (s, 27 H), 1.20-1.31 (m, 21 H),
0.98-1.03 (m, 2 H), 0.88-0.94 (m, 11 H), 0.69 (s, 3 H).

13

C NMR (CDCl3, 125 MHz): δ 158.02,

156.23,156.07, 80.56, 79.26, 78.89, 78.63, 70.70, 70.67, 70.63, 70.61, 70.57,70.52, 70.15, 70.02,
66.40, 65.76, 50.61, 47.78, 47.37, 47.05, 46.15, 42.60, 41.88, 41.84, 39.68, 39.43,38.64, 38.35,
35.66, 35.21, 34.91, 34.86, 33.16, 31.83, 30.57, 30.11, 29.69, 29.47, 29.27, 28.72, 28.61, 28.54,
28.48, 27.61, 27.04, 25.63, 23.31, 22.95, 22.87, 22.48, 17.89, 14.11, 12.49. HRMS (ESI) calcd
for C67H124N8O14 [M+H]+: 1264.9237, found:1264.9648.
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Compound 1.20 To a solution of 1.19 (18.3g, 14.5 mmol) in 200 ml of THF and H2O (3:1),
triphenyl phosphine (7.6g, 29 mmol) was added. The reaction was stirred at RT overnight. Then
THF was removed, the aqueous layer was exacted with DCM (3×100 ml). The mixture was dried
over Na2SO4 following to dry off the solvent. 13g of the target compound was isolated through a
column chromatography. The yield was 73%.
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Compound 1.21 To a solution of 1.20 (6.5 g, 5.2 mmol) in dichloromethane (100 mL), triethyl
amine (1.4ml, 10mmol) was cooled to 0 °C. Acryloyl chloride (0.6 mL, 7.5mmol) was added
dropwise over 10 minutes, and the mixture was stirred at room temperature for 15 min. Water
(50 mL) was added, and the aqueous layer was extracted dichloromethane (3 x 50mL). The
combined organic extracts were dried over sodium sulfate. The solvent was removed under
vacuum, and 1.18 was recovered as clear oil (6.8 g, 100% yield). 1H NMR (CDCl3, 500 MHz): δ
6.51 (br, 1 H), 6.32 (d, 1 H), 6.16 (dd, 1 H), 5.63 (d, 1 H), 5.12 (br, 1 H), 4.8 (br, 1 H), 3.6-3.7
(m, 18 H), 3.03-3.58 (m, 24 H), 1.55-2.11 (m, 17 H), 1.43 (s, 27 H), 1.20-1.31 (m, 21 H), 0.981.03 (m, 2 H), 0.88-0.94 (m, 11 H), 0.69 (s, 3 H). 13C NMR (CDCl3, 125 MHz): δ 165.37, 158.02,
156.23,156.07,130.82, 126.51, 80.56, 79.26, 78.89, 78.63, 70.70, 70.67, 70.63, 70.61,
70.57,70.52, 70.15, 70.02, 66.40, 65.76, 47.78, 47.37, 47.05, 46.15, 42.60, 41.88, 41.84, 39.68,
39.43, 39.41, 38.64, 38.35, 35.66, 35.21, 34.91, 34.86, 33.16, 31.83, 30.57, 30.11, 29.69, 29.47,
29.27, 28.72, 28.61, 28.54, 28.48, 27.61, 27.04, 25.63, 23.31, 22.95, 22.87, 22.48, 17.89, 14.11,
12.49. HRMS (ESI) calcd for C70H128N6O15 [M+H]+: 1292.9438, found:1292.9715.

44

ClH3N

O
N
O

ClH3N

O

O

NH

NH3Cl

O
O

O

1.22
CSA 120

O

NH
O

CSA 120.4.6g of 1.21 was dissolved into 40 mL of 4 M HCl/Dioxane solution. The solution
was stirred overnight at RT. After removing the solvent, 200 mL of toluene was poured into the
residue. 4.2g of CSA-120 was obtained by azeotropic removing the solvent in 91% yield. 1H
NMR (CDCl3, 500 MHz): δ 8.26 (br, 4 H), 8.12 (br, 2 H), 6.32 (d, 1 H), 6.16 (dd, 1 H), 5.63 (d, 1
H), 4.79 (br, 1 H), 3.6-3.7 (m, 18 H), 3.03-3.58 (m, 24 H), 1.55-2.11 (m, 17 H), 1.20-1.31 (m, 21
H), 0.98-1.03 (m, 2 H), 0.88-0.94 (m, 11 H), 0.69 (s, 3 H);

13

C NMR (CDCl3, 100 MHz): δ

165.37, 158.02,130.82, 126.51, 80.56, 79.26, 78.89, 78.63, 70.70, 70.67, 70.63, 70.61,
70.57,70.52, 70.15, 70.02, 66.40, 65.76, 47.78, 47.37, 47.05, 46.15, 42.60, 41.88, 41.84, 39.68,
39.43, 39.41,39.22, 39.21, 38.35, 35.66, 35.21, 34.91, 34.86, 33.16, 31.83, 30.57, 30.11, 29.69,
29.47, 29.27, 28.72, 28.61, 27.61, 27.04, 25.63, 23.31, 22.95, 22.87, 22.48, 17.89, 14.11, 12.49.
HRMS (ESI) calcd for C55H104N6O9 [M+H]+: 992.7865, found: 992.8021.
1.2.10 References
1. Afacan, N. J.; Yeung, A. T. Y.; Pena, OM. Hancock REW. Therapeutic potential of host
defense peptides in antibiotic-resistant infections. Curr. Pharm. Design. 2012, 18, 807-819.
2. Bao, Y.; Ma, J.; Zhang, X.; Shi, C. Recent advances in modification of polyacrylate latexes.
J. Mater. Sci. 2015, 50, 6839-6863.
3. Callow, J. A.; Callow, M.E. Trends in the development of environmentally friendly foulingresistant marine coatings. Nat. Commun. 2011, 2, 1-10.
45

4. Dang, H.; Lovell, C. R. Microbial surface colonization and biofilm development in marine
environments. Microb. Mol. Biol. Rev. 2016, 80, 91-138.
5. Ding, B.; Yin, N.; Liu, Y.; Cardenas-Garcia, J.; Evanson, R.; Orsak, R.; Fan, M.; Turin, G.;
Savage, P. B. Origins of cell selectivity of cationic steroid antibiotics. J. Am. Chem. Soc. 2004,
126, 13642-13648.
6. Epand, R. F.; Pollard, J. E.; Wright, J. O.; Savage, P. B.; Epand, R. M. Depolarizaton,
bacterial membrane composition and the antimicrobial action of ceragenins. Antimicrob.Agents.
Chemother. 2010, 54, 3708-3717.
7. Gao, G.; Yu, K.; Kindrachuk, J.; Brooks, D. E.; Hancock REW, Kizhakkedathu, J.N.
Antibacterial surfaces based on polymer brushes: Investigation on the influence of bursh
properties on antimicrobial peptide immobilization and antimicrobial activity. Biomacromol.
2011, 12, 3715-3727.
8. Gu, X.; Jennings, J. D.; Snarr, J.; Chaudhary, V.; Pollard, J. E.; Savage, P. B. Optimization
of ceragenins for prevention of bacterial colonization of hydrogel contact lenses. Invest. Ophthal.
Vis. Sci. 2013, 54, 6217-6223.
9.

Lai, X. Z.; Feng, Y.; Pollard, J.; Chin, J.N.; Rybak, M.J.; Bucki, R.; Epand, R. F.; Epand, R.

M.; Savage, P. B. Ceragenins: Cholic acid-based mimics of antimicrobial peptides. Acc. Chem.
Res. 2008, 4, 1233-1240.
10. Lai, Y.; Gallo, R. AMPed up immunity: how antimicrobial peptides have multiple roles in
immune defense. Trends Immunol. 2009, 30, 131-141.
11. Mangoni, M. L.; DmDermott, A.M.; Zasloff, M. Antimicrobial peptides and wound healing:
biological and therapeutic considerations. Exper. Dermatol. 2016, 25, 167-173.

46

12. Trepos, R.; Cervin, G.; Pile, C.; Pavia, H.; Hellio, C.; Svenson, J. Evaluation of cationic
micropeptides derived from the innate immune system as inhibitors of marine biofouling.
Biofouling. 2015, 31, 393-403.
13. Watson, M. G.; Scardino, A. J.; Zalizniak, L.; Shimetam J. Colonization and succession of
marine biofilm-dwelling ciliate assemblages on biocidal antifouling and fouling-release coatings
in temperate Australia. Biofouling. 2015, 31, 709-720.
14. Yebra, D. M.; Kiil, S.; Dam-Johansen, K. Antifouling technology- past, present and future
steps towards efficient and environmentally friendly antifouling coatings. Prog. Org. Coat. 2004,
50, 75-104.

47

1.3 Translation of Ceragenin Affinity for Bacteria to an Imaging Reagent for Infection
1.3.1 Introduction
Identification of sites of bacterial infection is important for proper clinical care of patients
manifesting general signs of infection (e.g., fever and elevated white blood cell counts). This is
especially true with patients that are immunocompromised because they often have reduced
symptoms of infection and consequently it may be difficult to pinpoint these sites.1,2 Signs of
inflammation can be used to identify sites of infection at superficial sites or in the extremities;
however, infection in internal structures (i.e., abdomen, chest and brain) can be difficult to
localize at early stages.3 Only after infection has progressed to tissue necrosis and/or abscess
formation can it be observed via X-ray computed tomography and ultrasound. Consequently, a
method of imaging infections at their initial stages would be useful for diagnosis and treatment.
A key element for imaging infections is a targeting motif in a molecule that provides for
selective association with bacteria. Multiple small molecules are known to associate with
bacteria; for example, polymyxins bind the lipid A portion of lipopolysaccharides found in the
outer membranes of Gram-negative bacteria4. Similarly, endogenous antimicrobial peptides
(AMPs) associate with Gram-negative5 and Gram-positive bacteria.6 Ceragenins are small
molecule mimics of AMPs, and they also display affinity for Gram-negative and positive
bacteria, specifically bacterial membrane components lipid A6-8 and lipotechoic acid. 6 Due to
the relatively simple structures of ceragenins, they can be readily modified, and one such
modification has allowed them to be attached to silver nanoparticles.9,10 Silver nanoparticles,
coated with a ceragenin, were placed in the presence of bacteria, and confocal imaging showed
the ceragenin-appended nanoparticles associated with bacteria. This association was attributed
to the affinity of the appended ceragenin for the bacterial membrane components. In a related
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study, the association of a fluorophore-appended ceragenin with intact cells showed that the
ceragenin displayed selectivity for bacterial cells over eukaryotic cells.7
Nuclear medicine techniques such as positron emission tomography (PET) and single photon
computed tomography (SPECT) have become a primary means of visualizing tumors and
inflammation due to their high levels of sensitivity, low background interference and the threedimensionality of their images. Some SPECT agents have been developed that allow imaging of
infection. For example, Ga-citrate6, 7 binds to bacteria, but it does not discriminate between
bacterial infections and proteins that accumulate at sites of inflammation11, 12. Similarly, 99mTclabeled compounds have been used to label leukocytes for infection/inflammation imaging;
however, these have been shown to be non-specific for bacterial infections.13,14 The use of
radiolabeled antibiotics such as ciprofloxacin and kanamycin has also suffered from a lack of
specificity to date.15 Radiolabeled AMPs, such as ubiquicidin, human lactoferrin, and human defensin-3, also appear promising.15
As mimics of AMPs and due to their simplicity and insensitivity to proteases, we reasoned that
ceragenins might be well suited for imaging of infections. By conjugating a ceragenin (bacteria
targeting) to an appropriate metal chelating group (positron emission), we generated compounds
with features necessary for selectively imaging infections. In initial studies of infection imaging,
ceragenins were non-specifically labeled with

99m

Tc and successfully imaged an infection

(Staphylococcus aureus) model in rats16. However, the nature of the ceragenin-technetium
complex was not well established. Additionally, ceragenins display higher cell selectivity for
Gram-negative bacteria (e.g., Escherichia coli) over Gram-positive organisms (e.g., S. aureus).
Consequently, we anticipated that Gram-negative infections would be preferentially labeled by
ceragenin conjugates.
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Conjugates of a ceragenin with 1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid (NOTA) were
prepared, along with structural variants, and these were stably labeled with 64Cu and injected into
mice. Distribution of the labeled compounds was determined in un-infected mice and in mice
with a local thigh infection. 64Cu-labeled conjugates derived from a ceragenin accumulated in the
infected muscle in significantly greater amounts than structural variants lacking a ceragenin. The
presence of a C8 lipid chain on a ceragenin-containing conjugate increased the lipophilicity of
the compound but did not significantly alter accumulation of the conjugate in infected muscle.

Figure 1.3.1 Structures of ceragenin-NOTA conjugates 1 and 2 and structural variants 3-5

1.3.2 Synthesis of Ceragenin-NOTA Conjugates and Structural Variants
To generate desired conjugates 1 and 2, amines 5a and 5b (Scheme 1.3.1) were reacted with
phenylcarbamate 6 to give 7a and 7b in reasonable yields. The azide groups in 7a and 7b were
reduced to the corresponding amines, which were reacted with bis-Boc NOTA, using COMU as
a coupling agent. Deprotection of both the carbamates and the t-butyl esters with hydrogen
chloride in dioxane gave 1 and 2.
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Scheme 1.3.1 Preparation of ceragenin-NOTA conjugates 1 and 2

For generation of 3 and 4 the steps outlined in Scheme 1.3.2 were followed. Alcohol in
compound 8 was converted to the mesylate and then to either the corresponding amine 9a or
octylamine 9b. Coupling with the PEG tether 6 gave 10a and 10b, which were reduced and
coupled with NOTA to give 3 and 4.

Scheme 1.3.2 Preparation of tri-ammonium-NOTA conjugates 3 and 4

For generation of 8 the steps outlined in Scheme 1.3.3 were followed. 3-amino-1-propanol was
treated with Boc2O to obtain 10, which was converted to mesylate and then to the corresponding
amine, finally to Boc-protected alcohol 11. The same procedure as last step was followed to
generate 8.
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Scheme 1.3.2 Preparation of 8

1.3.3 Results and Discussion
We have found that lipid chains extending from the nitrogen on C24 of ceragenins impact their
antimicrobial properties.17. Consequently, two different forms of ceragenin were used as
bacterial membrane recognition elements: one without a lipid chain (1) and one with an octyl
chain (2) (Figure 1.3.1). NOTA was used for binding

64

Cu, which is a positron emitter with a

12.7 hour half-life. NOTA has been well characterized as a thermodynamically and kinetically
stable copper binding ligand suitable for radiolabeling a variety of targeting groups.18 An oligoethylene glycol linker was used to separate the ceragenin and NOTA to ensure that the bound
copper ion did not interfere with interactions with bacterial membranes. In efforts to determine
the structural features of conjugates 1 and 2 that impact bacterial labeling and imaging, structural
variants 3 and 4 were prepared. Variants 3 and 4 retain three positive charges and lack the bile
acid backbone found in 1 and 2. The absence (1, 3) or presence (2, 4) of an octyl lipid chain was
used to determine its role in association with bacteria. Conjugates 1-4 were loaded with

64

Cu2+

(CuCl2) to give the corresponding complexes, which were analyzed via reversed-phase HPLC.
Radiochemical purity was determined as 98 ± 1.3%, and specific activity was maintained at ca.
20 µCi/µg for all compounds. As shown in Figure 1.3.2, copper-labeled, ceragenin-NOTA
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conjugates 1 and 2 (64Cu-1 and 64Cu-2) gave retention times of 12.0 and 15.4 min, respectively,
without loss of the copper label (i.e., free copper was not detected). To the extent that retention
times on a C18 silica chromatography column provide information about the lipophilicity of
analytes, labeled structural variants 3 and 4 (64Cu-3 and

64

Cu-4) proved to have lipophilicities

comparable to and less than those of 64Cu-1 and 64Cu-2.

Figure 1.3.2 HPLC chromatograms of

64

Cu radiolabeled compounds. Retention times were 12.02, 15.4, 7.5 and

11.3 min for 64Cu-1, 64Cu-2, 64Cu-3 and 64Cu-4, respectively. If present, free copper would appear at 2.5 min.

To further demonstrate the stability of the complexes, studies were conducted in human serum
to investigate potential degradation of the radiolabeled compounds. The stability of ceragenin
complexes was determined by measuring the radioactive fraction of the parent compound at
incubation intervals in human serum at 37 °C. No unbound metal was observed over the
evaluation time indicating that the complex remained 100% intact up to 4 h.
To determine the relative uptake and retention of the conjugates, biodistribution experiments
were conducted in CD-1 mice with labeled 1-4. The most substantial differences in uptake and
retention among the conjugates were that 64Cu-1 and 64Cu-2 were retained in the liver in higher
relative amounts than

64

Cu-3 and

64

Cu-4, and that

relative amounts than 64Cu-2.
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64

Cu-1 was retained in the kidney in higher

We used a model of thigh muscle infection with Escherichia coli (TG1) in CD-1 mice to
evaluate the impact of infection on distribution of the conjugates. The infection was established
24 h before injection of the conjugates. The primary measure of uptake was percentage of
injected dose per gram in each type of tissue (%ID/g). We previously observed high affinity of
ceragenins for the outer membranes of Gram-negative bacteria, including the lipid A portion of
lipopolysaccharide,6, 7 and it was anticipated that this affinity would result in accumulation of the
conjugates at the site of infection. Similar to the uninfected mice 64Cu-1 and 64Cu-2 accumulated
in the liver and kidney, relative to

64

Cu-3 and

64

Cu-4 (Figure 1.3.3) of infected mice. Uptake

values for labeled conjugates in the left thigh muscle (control, no bacteria) were not significantly
different (Figure 1.3.3B). Uptake in the right thigh muscle, containing the bacterial infection,
was highest with

64

Cu-1 (1.86 ± 0.78 %ID/g) and was lowest with

64

Cu-3 (0.26 ± 0.07 %ID/g)

with a p value of 0.008. The uptake of 64Cu-2 was also significantly increased relative to 64Cu-3
and 64Cu-4.

Figure 1.3.3 Overall biodistribution results (%ID/g) of 64Cu-1, 64Cu-2, 64Cu-3 and 64Cu-4 in CD-1 mice with
intramuscular infection in right thigh muscle at 4 h post injection
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Based on the biodistribution results,

64

Cu-1 was selected for more detailed autoradiography

studies of infections sites. Thigh infections (E. coli) were generated in mice as described above,
and muscles were removed, sectioned, and imaged. Uptake of

64

Cu-1 was much higher in the

infected thigh muscles compared to the control left thigh (Figure 1.3.4). This significant
difference (p<0.0001) was quantified by recording the number of counts per mm2 from the
sections and these values are given in Figure 1.3.5A. A comparison of the %ID/g of 64Cu-1 in
abdominal and thigh muscles is given in Figure 1.3.5B. Further comparison was from in vivo
measurement of standardized uptake values (SUVs), which are ratios of the image-derived
radioactivity concentration and the whole-body concentration of injected radioactivity. With this
measurement, there is no significant difference between the uptake of 64Cu-1 in uninfected thigh
muscle and peripheral muscle, while the difference between uptake in infected and uninfected
muscle is significant (p=0.0064) (Figure 1.3.5C).

Figure 1.3.4 Representative images from ex vivo autoradiography of left and right thigh muscle sections (20 - 40
µm) from 64Cu-1 in CD-1 mice, at 4 h post injection
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Figure 1.3.5 Comparisons of 64Cu-1 uptake in CD-1 mice with an intramuscular infection (E. coli) in the right thigh
at 4 h post injection. (a) Quantitative results (counts per mm2) of 64Cu-1 in an ex vivo autoradiography study with
left and right thigh muscle sections (20 - 40 µm, n = 9 sections per muscle). (b) Abdominal vs. thigh muscle uptake
of 64Cu-1 in %ID/g. (c) SUV (standardized uptake value) calculations from in vivo imaging comparing peripheral
and thigh muscle.

1.3.4 Conclusions
Lipopolysaccharide is the primary constituent of the outer membranes of Gram-negative
bacteria, and the lipid A structure is well conserved among bacteria. Consequently, lipid A is a
logical target for bacterial recognition. We have measured the Kd of the base structure of
ceragenins for the lipid A portion of lipopolysaccharide as 0.59 µM7, and the affinity of this
structure for lipid A is greater than that of polymyxin B, the paradigm of small molecule binding
of lipid A. The affinity of ceragenins for lipid A is consistent with measurements of interactions
of the ceragenin base structure for intact cells; a labeled ceragenin was shown to preferentially
associate with Gram-negative bacteria over Gram-positive bacteria and eukaryotic cells7.
Translation of affinity of ceragenins to imaging of infection poses a challenge due to the
complex environments provided by in vivo applications including higher numbers of eukaryotic
cells relative to prokaryotes. Nevertheless, by conjugating ceragenins to NOTA and loading
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with

64

Cu, we have generated compounds that selectively label infected tissue in mice. These

conjugates display the expected ability to bind

64

Cu while retaining affinity for bacteria. This

affinity allows selective labeling of bacteria and may provide a means of identifying sites of
infection in patients that display associated symptoms without indications of localized infection.

1.3.5 Experiment Section
General: Reagents were purchased from Aldrich Chemical Co. unless otherwise noted.
Methylene chloride, THF, DMF, pyridine, and DMSO were dried by passage through a Glass
Contour solvent drying system containing a cylinder of activated alumina. Silica gel was used for
chromatography unless otherwise noted.
Instrumentation: 1H and 13C NMR spectra were recorded on a Varian Gemini 500 (500 MHz)
spectrometer. Proton chemical shift were referenced to tetramethylsilane (TMS). Carbon
chemical shifts were referenced to carbon resonance of solvents (CDCl3, CD3OD). High
resolution electron impact mass spectra (HR-MS) were obtained on a JOEL SX 102A
spectrometer.
Experiment:
BocHN

OH
10

Compound 10.To a solution of 3-amino-1-propanol (20.64 g, 0.275 mol) in 200 mL of DCM,
Boc2O (60 g, 0.275 mol) was added in portion. The solution was stirred overnight. 45 g of the
product was isolated through a column chromatography (SiO2). The yield was 94%. 1H NMR
(CDCl3, 500 MHz) δ 4.822 (br, 1 H), 3.636-3.668 (m, 2 H), 3.275-3.299 (m, 2 H), 3.097 (br, 1
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H), 1.633-1.677 (m, 2 H), 1.439 (s, 9 H);

13

C NMR (CDCl3, 125 MHz) δ 158.797, 59.391,

37.055, 33.122, 28.589; HRMS (ESI) calcd for C8H17NO3 [M+H]+: 176.1208, found: 176.1256.

BocHN

N
Boc

OH

11

Compound 11.To a solution of 10 (3.2 g, 18.3 mmol) in 20 mL of DCM, MsCl (2.4 g, 21 mmol)
and Et3N (2.12 g, 21 mmol) were added at 0 °C. The temperature was allowed to rise up to
room temperature. The solution was stirred for 30 mins. Then, 10 mL of water was used to
wash the solution. The aqueous layer was extracted with DCM three times. The combined
organic layer was dried over Na2SO4. After the solvent was removed, 3-amino-1-propanol
(10.32 g, 0.14mol) was added to dissolve the residue. The solution was stirred at 80 °C for 2 hrs.
3-amino-1-propanol was removed under vacuum. 50 mL of water was used to wash the solution.
The aqueous layer was extracted with DCM three times. The combined organic layer was dried
over Na2SO4. After removing the solvent, the residue was dissolved into 50 mL of DCM. Then,
Boc2O (4 g, 18.3 mmol) was added. The solution was stirred overnight. 4.8 g of the product was
isolated through a column chromatography (SiO2). The yield was 80%.

1

H NMR (CDCl3, 500

MHz) δ 3.475-3.054 (m, 8 H), 1.807-1.591 (m, 4 H), 1.413 (s, 9 H), 1.367 (s, 9 H);

13

C NMR

(CDCl3, 125 MHz) δ 163.851, 158.797, 83.078, 80.677, 79.704, 66.490, 46.368, 44.971, 37.284,
28.445, 28.430, 28.414, 27.772, 27.753, 27.110, 22.257; HRMS (ESI) calcd for C16H32N2O5
[M+H]+: 333.2311, found: 333.2316.

BocHN

N
Boc

N
Boc
8
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OH

Compound 8.To a solution of 11 (4.8 g, 14.4 mmol) in 50 mL of DCM, MsCl (2.0 g, 17.5 mmol)
and Et3N (1.8 g, 17.5 mmol) were added at 0 °C. The temperature was allowed to rise up to
room temperature. The solution was stirred for 30 mins. Then, 10 mL of water was used to
wash the solution. The aqueous layer was extracted with DCM three times. The combined
organic layer was dried over Na2SO4. After the solvent was removed, 3-amino-1-propanol (10.32
g, 0.14mol) was added to dissolve the residue. The solution was stirred at 80 °C for 2 hrs. 3amino-1-propanol was removed under vacuum. 50 mL of water was used to wash the solution.
The aqueous layer was extracted with DCM three times. The combined organic layer was dried
over Na2SO4. After removing the solvent, the residue was dissolved into 50 mL of DCM. Then,
Boc2O (3.2 g, 15 mmol) was added. The solution was stirred overnight. 6.2 g of the product was
isolated through a column chromatography (SiO2). The yield was 81%. 1H NMR (CDCl3, 500
MHz) δ 4.822 (br, 1 H), 3.754-3.117 (m, 12 H), 3.097 (br, 1 H), 1.696-1.568 (m, 6 H), 1.477 (s,
9 H), 1.437 (s, 9 H); 13C NMR (CDCl3, 125 MHz) δ 156.958, 156.436, 156.422, 80.541, 58.231,
44.158, 42.196, 37.658, 33.065, 31.310, 30.395, 28.827, 28.403, 28.383, 27.647; HRMS (ESI)
calcd for C24H47N3O7 [M+H]+: 490.3414, found: 490.3468.

BocHN

O

BocHN

NH2

BocHN

O

O

NHBoc

O
N
H

BocHN

O

O

5a

NHBoc

5b

Compound 7a: To a solution of 5a (4.67 g, 3.8 mmol) in acetonitrile (100 mL), potassium
carbonate (1.5 g, 3.8 mmol) and 6 (1.45 g, 3.8 mmol) were added sequentially. The mixture was
heated to reflux for 12 h. The mixture was allowed to cool to room temperature and water (50
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mL) was added. The product was extracted with ethyl acetate (100 mL), and the extract was
dried over sodium sulfate and concentrated under vacuum. Column chromatography (silica gel
with dichloromethane/methanol: 20:1 as eluent) gave the desired azide as 2.8 g (64% yield) of a
clear oil. 1H NMR (CDCl3, 500 MHz): δ 4.79 (br, 1 H), 3.6-3.7 (m, 18 H), 3.03-3.58 (m, 22 H),
1.55-2.11 (m, 17 H), 1.43 (s, 27 H), 1.20-1.31 (m, 9 H), 0.98-1.03 (m, 2 H), 0.88-0.94 (m, 8 H),
0.69 (s, 3 H).

13

C NMR (CDCl3, 125 MHz): δ 158.02, 156.23,156.07, 80.56, 79.26, 78.89, 78.63,

70.70, 70.67, 70.63, 70.61, 70.57,70.52, 70.15, 70.02, 66.40, 65.76, 50.61, 47.78, 47.05, 46.15,
42.60, 41.88, 41.84, 39.68, 39.43,38.64, 38.35, 35.66, 35.21, 34.91, 34.86, 33.16, 31.83, 30.57,
30.11, 29.69, 29.47, 29.27, 28.72, 28.61, 28.54, 28.48, 17.89, 14.11, 12.49. HRMS (ESI) calcd
for C59H108N8O14 [M+H]+: 1153.7985, found: 1153.8031.
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Compound 1: To a solution of 7a (2.8 g, 2.4 mmol) in THF (50 mL) and water (17 mL),
triphenyl phosphine (6.2 g, 24 mmol) was added. The mixture was stirred at room temperature
for 12 h. The THF was removed under vacuum, and the resulting mixture was exacted with
dichloromethane (3 x 50 mL). The combined extracts were dried over sodium sulfate and
concentrated under vacuum. A silica gel plug, washed with dichloromethane/methanol: 20:1,
was used to remove triphenylphosphine oxide and excess triphenylphosphine giving the desired
amine in crude form as 1.8 g (73% yield) of a clear oil. To a solution of the amine (0.3 g, 0.27
mmol) and bis-BOC NOTA (0.11 g, 0.28 mmol) in DMF (20 mL), COMU (0.14 g, 0.33 mmol)
and collidine (0.05 g, 0.416 mmol) were added. The mixture was stirred for 2 h. Water (20 mL)
60

was added, and the mixture was extracted with dichloromethane (3 x 50 mL). The combined
extracts were dried over sodium sulfate and concentrated under vacuum. Column
chromatography (silica gel with dichloromethane/methanol: 20:1 as eluent) gave the desired
conjugate as 0.25 g (65% yield) of a clear oil.

1

H NMR (CDCl3, 500 MHz): δ 4.79 (br, 1 H),

3.6-3.7 (m, 18 H), 3.03-3.58 (m, 28 H), 22-2.4 (m,12H), 1.55-2.11 (m, 17 H), 1.43 (s, 27 H),
1.39 (s, 18H), 1.20-1.31 (m, 9 H), 0.98-1.03 (m, 2 H), 0.88-0.94 (m, 8H), 0.69 (s, 3 H).

13

C

NMR (CDCl3, 125 MHz): δ 158.02, 156.23,156.07, 82.3, 81.18, 80.56, 79.26, 78.89, 78.63,
70.70, 70.67, 70.63, 70.61, 70.57,70.52, 70.15, 70.02, 69.78, 69.66, 69.59, 69.51, 69.50, 69.45,
66.48, 66.47, 66.45, 66.40, 65.76, 50.61, 47.78, 47.05, 46.15, 42.60, 41.88, 41.84, 39.68,
39.43,38.64, 38.35, 35.66, 35.21, 34.91, 34.86, 33.16, 31.83, 30.57, 30.11, 29.69, 29.47, 29.27,
28.78, 28.72, 28.61, 28.54, 28.48, 25.56, 17.89, 14.11, 12.49.

HRMS (ESI) calcd for

C79H145N9O19 [M+H]+: 1525.0657, found:1525.0721. The conjugate (0.25 g) was dissolved in a
solution of HCl in dioxane (4 M, 10 mL) and stirred at room temperature for 18 h. The solvent
was removed under vacuum, and toluene (50 mL) as added. Removal of the toluene under
vacuum (azeotropically drying the product) gave 1 (0.15 g, 91% yield) as a light yellow solid.
1

H NMR (CDCl3, 500 MHz): δ 4.79 (br, 1 H), 3.6-3.7 (m, 18 H), 3.03-3.58 (m, 28 H), 22-2.4 (m,

12H), 1.55-2.11 (m, 17 H), 1.20-1.31 (m, 9 H), 0.98-1.03 (m, 2 H), 0.88-0.94 (m, 8H), 0.69 (s,
3H). 13C NMR (CDCl3, 125 MHz): δ 170.72, 158.02, 156.07, 80.56, 79.26, 78.89, 70.70, 70.67,
70.63, 70.61, 70.57,70.52, 70.15, 70.02, 69.78, 69.66, 69.59, 69.51, 69.50, 69.45, 66.48, 66.47,
66.45, 66.40, 65.76, 50.61, 47.78, 47.05, 46.15, 42.60, 41.88, 41.84, 39.68, 39.43, 38.64, 38.35,
35.66, 35.21, 34.91, 34.86, 33.16, 31.83, 30.57, 30.11, 29.69, 29.51, 29.47, 29.35, 29.27, 28.78,
28.61, 28.54, 17.89, 14.11, 12.49. HRMS (ESI) calcd for C56H105N9O13 [M+H]+: 1112.7832,
found:1112.8031.
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Compound 7b: Phenylcarbonate 6 (30 mg, 0.075 mmol) was added to a mixture of tris-Boc
CSA-13 (5b) (73mg, 0.075 mmol) and potassium carbonate (21 mg, 0.15 mmol) in acetonitrile
(3 mL). The mixture was heated to reflux for 12 h. Water (5 mL) was added after the reaction
mixture had been cooled to room temperature. The resulting mixture was extracted with ethyl
acetate (3 x 5 mL), and the combined organic extracts were dried over sodium sulfate. The
solvent was removed under vacuum, and the product was purified via silica gel chromatography
(5% methanol in dichloromethane as eluent). Compound 7b was recovered as a clear oil (63 mg,
67% yield). 1H NMR (CDCl3, 500 MHz): δ 4.79 (br, 1 H), 3.6-3.7 (m, 18 H), 3.03-3.58 (m, 24
H), 1.55-2.11 (m, 17 H), 1.43 (s, 27 H), 1.20-1.31 (m, 21 H), 0.98-1.03 (m, 2 H), 0.88-0.94 (m,
11 H), 0.69 (s, 3 H).

13

C NMR (CDCl3, 125 MHz): δ 158.02, 156.23,156.07, 80.56, 79.26, 78.89,

78.63, 70.70, 70.67, 70.63, 70.61, 70.57,70.52, 70.15, 70.02, 66.40, 65.76, 50.61, 47.78, 47.37,
47.05, 46.15, 42.60, 41.88, 41.84, 39.68, 39.43,38.64, 38.35, 35.66, 35.21, 34.91, 34.86, 33.16,
31.83, 30.57, 30.11, 29.69, 29.47, 29.27, 28.72, 28.61, 28.54, 28.48, 27.61, 27.04, 25.63, 23.31,
22.95, 22.87, 22.48, 17.89, 14.11, 12.49.

HRMS (ESI) calcd for C67H124N8O14 [M+H]+:

1265.9237, found:1265.9648.
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Compound 2: To a solution of azide compound 7b (20 mg, 0.015 mmol ) in THF (2mL) and
H2O (0.5 mL), triphenyl phosphine (40mg, 0.15 mmol) was added. The mixture was allowed to
run for 12 h at room temperature. The THF was removed under vacuum, and the resulting
mixture was extracted with dichloromethane (3 x 10 mL). The combined organic layers were
dried over sodium sulfate and concentrated under vacuum. Column chromatography (silica gel
with dichloromethane/methanol (0.05% ammonium hydroxide): 20:1 as eluent) gave 15 mg
( 8 5 % y i e l d ) of t h e r e s u l t i n g amine product as a clear oil. The resulting amine (15 mg,
0.0125 mmol) and bis-BOC NOTA (5.2 mg, 0.0125 mmol) were dissolved in DMF (1 mL),
COMU (6.5 mg, 0.015 mmol) and collidine (2.3 mg, 0.0188 mmol) were added. The mixture
was stirred for 2 h. Water (2 mL) was added, and the mixture was exacted with dichloromethane
(3 x 5mL). The combined extracts were dried over sodium sulfate and concentrated under
vacuum. Column chromatography (silica gel with dichloromethane/methanol: 20:1 as eluent)
gave the desired conjugate as 12 mg (63% yield) of a clear oil, which was treated with 3 mL of 4
M HCl in dioxane. The reaction was allowed to run for 18 hours at room temperature. The
mixture solvent was removed under high vacuum to give the compound 2 (8mg,91% yield) as
white solid HCl salt formation. (48% total yield) 1H NMR (CDCl3, 500 MHz): δ 4.79 (br, 1 H),
3.6-3.7 (m, 18 H), 3.03-3.58 (m, 30 H), 22-2.4 (m,12H), 1.52-2.11 (m, 19 H), 1.43 (s, 27 H),
1.39 (s, 18H), 1.20-1.31 (m, 19 H), 0.98-1.03 (m, 2 H), 0.88-0.94 (m, 11H), 0.69 (s, 3 H).
63

13

C

NMR (CDCl3, 125 MHz): δ 173.2, 171.4, 158.02, 156.23,156.07, 82.3, 81.18, 80.56, 79.26,
78.89, 78.63, 70.70, 70.67, 70.63, 70.61, 70.57,70.52, 70.15, 70.02, 69.78, 69.66, 69.59, 69.51,
69.50, 69.45, 66.48, 66.47, 66.45, 66.40, 65.76, 50.61, 50.11, 47.78, 47.05, 46.15, 42.60, 41.88,
41.84, 39.68, 39.43,38.64, 38.35, 35.66, 35.21, 34.91, 34.86, 33.16, 31.92, 31.83, 30.57, 30.11,
29.69, 29.47, 29.31, 29.28, 29.27, 28.78, 28.72, 28.61, 28.54, 28.48, 26.61, 25.56, 22.78, 17.89,
14.11, 14.10, 12.49. HRMS (ESI) calcd for C64H121N9O13 [M+H]+: 1225.6980, found:1225.7132.
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Compound 9a: To a solution of 8 (4.89 g, 10 mmol) in THF (100 mL), were added
mesylchloride (1.2 g, 11 mmol) and triethylamine (1.2 g, 12 mmol) at 0 °C. The mixture was
allowed to warm to room temperature over 30 min. Water (50 mL) was added, and the product
was extracted using dichloromethane (3 x 50 mL). The combined extracts were dried over
sodium sulfate, and solvents were removed under vacuum. After the solvent was removed, the
oil was dissolved in DMSO (40 mL) and sodium azide (1.3 g, 20 mmol) was added, and the
resulting mixture was stirred at 80 °C for 12 h. The mixture was cooled to room temperature
and water (50 mL) and dichloromethane (100 mL) were added. The resulting organic solution
was dried over sodium sulfate and concentrated under vacuum. The aqueous layer was extract
with DCM three times and the combined organic phase was dried over Na2SO4. After dried
off the solvent, the crude azide compound was treated with triphenyl phosphine
(5.2g, 20 mmol) in THF (40 mL) and H 2 O (10 mL), the mixture was allowed to
run for 12 hours at room temperature. Then THF was removed, the aqueous layer was
exacted with DCM (3×50 ml). The combined organic layer was dried over Na2SO4. 3.2g of the
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target compound was isolated through a column chromatography. The yield was 68%.1H NMR
(CDCl3, 400 MHz) δ 3.16-3.31 (m, 6H), 3.06 (m, 2H), 2.58 (m, 4H), 1.64 (m, 4H), 1.41 (s, 19H),
1.25-1.3 (m, 2H), 1.0-1.12 (m, 7H), 0.68 (t, 3H).13C NMR (CDCl3, 125 MHz) δ 156.81, 156.52,
79.81, 79.65, 79.58, 28.4, 27.16, 25.93, 24.41, 23.64, 22.65. HRMS (ESI) calcd for C24H48N4O6
[M+H]+:489.3574, found:489.4132.
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Compound 10a: To a solution of 9a (3.2 g, 6.5 mmol) in acetonitrile (30 mL) were added
potassium carbonate (1.0 g, 7.6 mmol) and 6 (2.5 g, 6.5 mmol). The mixture was heated to
reflux and stirred for 12 hrs. The mixture was allowed to cool to room temperature, and water
(30 mL) was added. The product was exacted with ethylacetate (50 mL), and the resulting
solution was dried over sodium sulfate. After chromatography (silica gel, 3% MeOH:DCM) 2.7
g of 10a (55% yield). 1H NMR (CDCl3, 400 MHz) δ 3.6-3.7 (m, 16 H), 3.47 (t, 2 H), 3.36 (t, 2
H),3.16-3.31 (m, 6H), 3.06 (m, 2H), 2.58 (m, 4H), 1.64 (m, 6H), 1.41 (s, 15H), 1.25-1.3 (m, 2H),
1.0-1.12 (m, 7H), 0.68 (t, 3H)

13

C NMR (CDCl3, 125 MHz) δ 156.81, 156.52, 154.88, 79.81,

79.65, 79.58, 70.70, 70.67, 70.62, 70.61, 70.57, 70.31, 70.02, 69.85, 41.04, 28.35, 27.16, 24.41,
23.64, 22.65, 21.97. HRMS (ESI) calcd for C35H68N8O11 [M+H]+:777.5008, found:777.5121.
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Compound 3: To a solution of 10a (2.5 g, 3.2 mmol) in THF (50 mL) and water (10 mL), was
added triphenyl phosphine (2.6 g, 10 mmol). The mixture was stirred at room temperature for 12
h. The THF was removed under vacuum, and the remaining aqueous mixture was extracted with
dichloromethane (3 x 50 mL). The combined extracts were dried over sodium sulfate, and the
desired amine was recovered after chromatography (silica gel, 5% MeOH:DCM and 0.1%
NH4.OH) as 1.8 g (77% yield) of a clear oil. This amine (0.5 g, 0.66 mmol) and bis-Boc NOTA
(0.27 g, 0.66 mmol), COMU (0.3 g, 0.7 mmol) and collidine (0.1 g, 0.82 mmol) were dissolved
in DMF (20 mL). The mixture was stirred for 2 h, and cold water (20 mL) was added. The
product was exacted with dichloromethane (3 x 50 mL), and the combined extracts were dried
over sodium sulfate. The solvent was removed under vacuum, and after chromatography (silica
gel, 3% MeOH:DCM), the desired amide was isolated as 0.45 g (61% yield) of a clear oil.

1

H

NMR (CDCl3, 400 MHz) δ 3.6-3.7 (m, 16 H), 3.47 (t, 2 H), 3.36 (t, 2 H), 3.16-3.31 (m, 12H),
2.9-3.1 (m,12H), 3.06 (m, 2H), 2.58 (m, 4H), 1.64 (m, 4H), 1.43 (s, 27H), 1.41(s, 8H), 1.25-1.3
(m, 2H), 1.0-1.12 (m, 7H), 0.68 (t, 3H)

13

C NMR (CDCl3, 125 MHz) δ 170.71, 168.64, 159.47,

156.81, 156.52, 154.88, 81.18, 80.52, 79.81, 79.65, 79.58, 70.70, 70.67, 70.62, 70.61, 70.57,
70.31, 70.02, 69.85, 66.58, 66.53, 66.50, 66.46, 60.25, 58.06, 56.72, 51.10, 41.04, 28.42, , 27.16,
24.41, 23.64, 22.65, 21.97.

HRMS (ESI) calcd for C55H105N9O16 [M+H]+:1149.7679,

found:11149.7832. This amide (0.2 g) was dissolved in a solution of HCl in dioxane (4 M, 5 mL).
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The mixture was stirred for 18 h, and solvent was removed under vacuum. Toluene (50 mL) was
added to the resulting material and evaporated under vacuum to remove residual water.
Compound 3 was isolated as a light yellow solid (0.12 g, 90% yield. 1H NMR (D2O, 400 MHz) δ
3.96 (m, 4 H), 3.85 (m, 2 H), 3.2-3.6 (m, 34H), 2.9-3.1 (m, 10 H), 1.98 (m, 2 H), 1.93 (m, 2H),
0.68 (t, 3H).

13

C NMR (D2O, 125 MHz) δ 170.71, 168.64, 159.47, 71.51, 70.72, 69.71, 69.54,

69.41, 66.58, 66.53, 66.50, 66.46, 60.25, 58.06, 56.72, 51.10, 51.06, 46.71, 45.06, 44.63, 44.56,
44.30, 43.34, 43.27, 44.14, 39.90, 39.09, 36.49,, 28.35, 27.16, 25.93, 24.41, 23.64, 22.65. HRMS
(ESI) calcd for C32H65N9O10 [M+H]+:736.4854, found:736.5023.
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Compound 9b: To a solution of 8 (4.89 g, 10 mmol) in THF (100 mL), were added
mesylchloride (1.2 g, 11 mmol) and triethylamine (1.2 g, 12 mmol) at 0 °C. The mixture was
allowed to warm to room temperature over 30 min. Water (50 mL) was added, and the
product was extracted using dichloromethane (3 x 50 mL). The combined extracts were dried
over sodium sulfate, and solvents were removed under vacuum.

The resulting oil was

dissolved in octyl amine (10 mL), and the resulting mixture was stirred at 80 °C for 1 h. The
mixture was allowed to cool to room temperature, and water (50 mL) and dichloromethane
(100 mL) were added. The layers were separated and the aqueous layer was extracted with
dichloromethane (3 x 50 mL). The combined extracts were dried over sodium sulfate and
concentrated under vacuum. After chromatography (silica gel, 3% MeOH:DCM and 0.1%
NH4.OH), 4.6 g (78% yield) of the desired amine was isolated as a clear oil.

1

H NMR

(CDCl3, 500 MHz) δ 3.16-3.31 (m, 8 H), 3.06 (m, 2 H), 2.58 (m, 4 H), 1.64 (m, 6 H), 1.41 (s, 27
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H), 1.25-1.3 (m, 2 H), 1.0-1.12 (m, 10 H), 0.68 (t, 3 H)

13

C NMR (CDCl3, 125 MHz) δ 156.81,

156.52, 79.81, 79.65, 79.58, 28.4, 28.35, 27.16, 25.93, 24.41, 23.64, 22.65, 21.97, 13.42.
HRMS (ESI) calcd for C32H64N4O6 [M+H]+:848.6106, found:848.6183.
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Compound 10b: To a solution of 9b (4.6 g, 7.6 mmol) in acetonitrile (20 mL) were added
potassium carbonate (3.0 g, 7.6 mmol) and 6 (2.9 g, 7.6 mmol). The mixture was heated to
reflux and stirred for 12 h. The mixture was allowed to cool to room temperature, and water (30
mL) was added. The product was exacted with ethylacetate (50 mL), and the resulting solution
was dried over sodium sulfate. After chromatography (silica gel, 3% MeOH: DCM) 3.8 g of 10b
(56% yield). 1H NMR (CDCl3, 500 MHz) δ 3.6-3.7 (m, 16 H), 3.47 (t, 2 H), 3.36 (t, 2 H),3.163.31 (m, 8 H), 3.06 (m, 2H), 2.58 (m, 4H), 1.64 (m, 6H), 1.41 (s, 27 H), 1.25-1.3 (m, 2 H), 1.01.12 (m, 10 H), 0.68 (t, 3 H).

13

C NMR (CDCl3, 125 MHz) δ 156.81, 156.52, 154.88, 79.81,

79.65, 79.58, 70.70, 70.67, 70.62, 70.61, 70.57, 70.31, 70.02, 69.85, 50.63, 41.04, 28.4, 28.35,
27.16, 25.93, 24.41, 23.64, 22.65, 21.97, 13.42. HRMS (ESI) calcd for C43H84N8O11
[M+H]+:889.6260, found:889.6254.
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Compound 4: To a solution of 10b (3.8 g, 4.3 mmol) in THF (50 mL) and water (17 mL), was
added triphenyl phosphine (2.3 g, 8.6 mmol). The mixture was stirred at room temperature for
12 h. The THF was removed under vacuum, and the remaining aqueous mixture was extracted
with dichloromethane (3 x 50 mL). The combined extracts were dried over sodium sulfate, and
the desired amine was recovered after chromatography (silica gel, 5% MeOH:DCM and 0.1%
NH4.OH) as 2.5 g (71% yield) of a clear oil. This amine (0.5 g, 0.58 mmol) and bis-Boc NOTA
(0.24 g, 0.58 mmol), COMU (0.3 g, 0.7 mmol) and collidine (0.1 g, 0.82 mmol) were dissolved
in DMF (20 mL). The mixture was stirred for 2 h, and water (20 mL) was added. The product
was exacted with dichloromethane (3 x 50 mL), and the combined extracts were dried over
sodium sulfate. The solvent was removed under vacuum, and after chromatography (silica gel, 3%
MeOH:DCM), the desired amide was isolated as 0.40 g (55% yield) of a clear oil.

1

H NMR

(CDCl3, 500 MHz) δ 3.6-3.7 (m, 16 H), 3.47 (t, 2 H), 3.36 (t, 2 H), 3.16-3.31 (m, 14 H), 2.9-3.1
(m,12 H), 3.06 (m, 2 H), 2.58 (m, 4 H), 1.64 (m, 6 H), 1.43 (s, 27 H), 1.41(s,18 H), 1.25-1.3 (m,
2 H), 1.0-1.12 (m, 10 H), 0.68 (t, 3 H).

13

C NMR (CDCl3, 125 MHz) δ 170.71, 168.64, 159.47,

156.81, 156.52, 154.88, 81.18, 80.52, 79.81, 79.65, 79.58, 70.70, 70.67, 70.62, 70.61, 70.57,
70.31, 70.02, 69.85, 66.58, 66.53, 66.50, 66.46, 60.25, 58.06, 56.72, 51.10, 50.63, 41.04, 28.4,
28.35, 27.16, 25.93, 24.41, 23.64, 22.65, 21.97, 13.42. HRMS (ESI) calcd for C63H121N9O16
[M+H]+:1260.8931, found:1260.9032. This amide (0.15 g) was dissolved in a solution of HCl in
dioxane (4 M, 5 mL). The mixture was stirred for 18 h, and solvent was removed under vacuum.
Toluene (50 mL) was added to the resulting material and evaporated under vacuum to remove
residual water. Compound 4 was isolated as a light yellow solid (0.09 g, 90% yield).1H NMR
(D2O, 500 MHz) δ 3.96 (m, 4 H), 3.85 (m, 2 H), 3.2-3.6 (m, 36 H), 2.9-3.1 (m, 10 H), 1.98 (m, 2
H), 1.93 (m, 2 H), 1.0-1.12 (m, 10 H), 0.68 (t, 3 H). 13C NMR (D2O, 125 MHz) δ 170.71, 168.64,
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159.47, 71.51, 70.72, 69.71, 69.54, 69.41, 66.58, 66.53, 66.50, 66.46, 60.25, 58.06, 56.72, 51.10,
51.06, 50.83, 46.71, 45.06, 44.63, 44.56, 44.30, 43.34, 43.27, 44.14, 39.90, 39.09, 36.49, 31.04,
28.57, 28.35, 27.16, 25.93, 24.41, 23.64, 22.65, 21.97, 13.42. HRMS (ESI) calcd for
C40H81N9O10 [M+H]+:848.6106, found:848.6183.
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1.4 Maghemite, Silver, Ceragenin Conjugate Particles for Selective Binding and Contrast
of Bacteria
1.4.1 Introduction
Interest in synthetic control, manipulation, and understanding of inorganic nanoparticles has
increased alongside the enthusiasm, development and research in the biomedical field in recent
years. Because of the wide variety of uses, such as in MRI contrast agents, CT contrast agents,
thermal ablation targets, antimicrobials, and delivery platforms for RNA, DNA, peptides,
fluorescent markers, and other small molecules, inorganic nanoparticles are being synthesized
and studied regularly.

1-7

The highly specific organization of inorganic nanoparticles with

reference to composition, morphology, resonance frequencies, shell thickness, and surface
chemistries as well as their cost-effective and effortless bulk synthesis make them quintessential
for these applications. 8-10 Recently various hybrid nanoparticles have been developed to carry
out multiple functions, such as in therapeutic treatment of disease.11-12
One such inorganic nanoparticle that has been used clinically with great success as a T2
contrast agent for magnetic resonance imaging (MRI) were the superparamagnetic iron oxide
nanoparticles (SPIONs). Products like Feridex, Resovist, and Combidex, which have been used
in the diagnosis of spleen, liver, and bone marrow related ailments, contain SPIONs as the
primary active component13. They may be coated in starch, dextran, silicones, polyethylene
glycol, albumin, and many other hydrophilic surfactants and vary in size from 30 to 150 nm14.
One characteristic shared among all MRI contrast agents is that they need to be paramagnetic,
meaning they only possess a magnetic moment in the presence of a magnetic field. 13
Of all inorganic nanoparticles, silver has proved to be an effective antimicrobial and
therapeutic carrier agent, successfully deactivating bacteria through several different mechanisms.
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This makes developing resistance very challenging for antimicrobials15. Silver Nanoparticles can
serve as a reservoir for silver ions which bind to proteins causing cell death through structural
modifications to the cell wall of bacteria and nuclear membranes. Toxicity is a common concern
for all in vivo drug delivery applications. In a study by IlJe Yu et al., rats orally received between
30 and 1000mg/kg/day silver nanoparticles over 28-days to research silver toxicity. After
exposure of 300 mg/kg/day, only minor liver damage was detected and there were no statistically
significant differences in total erythrocyte numbers or ratios.

16

In 2011, a similar study

intravenously exposed rats to between 4 and 40 mg/kg of silver nanoparticles. It was found that
exposure to under 10 mg/kg did not significantly affect platelet count, WBC count, RBC counts
or hemoglobin and proved that such doses would not be dangerous, including no side-effects for
biomedical applications17. Lately, silver has been incorporated into many products such as
medical device coatings, wound dressings, dental resins, and washing machines due to its
antimicrobial nature and biocompatibility at limited concentrations.2,10,18 Along with many other
noble metal nanoparticles, Silver’s robust functionalization chemistry, large surface area/volume
ratio, readily tunable morphology, and ease of bulk synthesis offer an excellent vehicle for small
molecule delivery19. Moreover, they offer decreased degradation of the therapeutic agent and
high-density surface ligand attachment. 20-22
Recently, studies have observed the antimicrobial characteristics of silver applied together with
an array of other elements. Melaiye et al., encapsulated silver (i)-imidazole cyclophane gem-diol
complexes in tecophilic nanofibers and thereby developed a mechanism of implementing silver’s
antimicrobial characteristics to counter infections in burn wounds. The silver mats demonstrated
to be an effective bacteria killer and exhibited an extended release of silver. 23 Similarly, within
30 in of application, silver organoalkoxysilane Nano membranes containing silver nanoparticles
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presented inhibition of Bacillus anthracis, Escherichia coli, Staphylococcus aureus, and Brucella
suis and prevented any additional colonization.24 Silver nanoparticles have also exhibited
substantial antimicrobial tendencies through attachment to magnetic hybrid colloids containing
an iron oxide core and a silica shell. Freed Ag+ ions rupture the bacterial membranes as silver
nanoparticles bind to the bacteria, thus effectively destroying the bacteria.

25

Magnetic-silica

Janus nanorods lined with silver nanoparticles was shown to be having magnetic sensitivity,
biocompatible, and demonstrate antimicrobial activity in short-term as well as long-term
timeframes. 26
Antimicrobial peptides, which are capable of circumventing traditional resistance mechanisms,
are a promising means of controlling bacterial growth through membrane selectivity and novel
modes of action; however, their high cost of bulk synthesis and weak structural stability in the
presence of proteases are some of the constraints to the general clinical use of these peptides.
Recent mimics of antimicrobial peptides, CSAs, or ceragenins have been produced which offer
heightened stability and easy synthesis while mirroring the selectivity and antimicrobial
characteristics of antimicrobial peptides. CSAs are shown to be effective against streptococcus
mutans, Porphyromonas species and other periodontopathic bacteria as well as tobramycinresistant Pseudomonas aeruginosa, vancomycin-resistant S. aureus (VRSA), and drug resistant
strains of Helicobacter pylori.27-29 This proposal in this report contains a novel theragnostic
conjugate nanoparticle displaying selective binding of bacteria, antimicrobial efficacy and T2
MRI negative contrast capability. The Diagnostic Antimicrobial Nanoparticles (DANs)
mentioned incorporate the attributes of silver, SPIONs, and synthetic antimicrobial peptides,
combining them into an individual spherical nanostructure. An array of diverse synthesis
procedures provides the creation of a reduced silver shell, an iron oxide core, and CSA-124
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surfactant. The synthetic mechanism and products are known to be developed through several
methods: transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), inductively coupled plasma optical emission spectrometry
(ICP-OES), High performance Liquid Chromatography-Electrospray Ionization tandem Time of
Flight Mass Spectrometry (HPLC-ESI-TOF-MS), ultraviolet-visible spectroscopy (UV-VIS),
and DC magnetization and susceptibility. This study’s objective is to provide a feasible synthesis
procedure that consistently synthesizes DANs and demonstrates the same selective diagnostic
potential.
1.4.2 Synthesis of CSA-124
To generate the desired CSA-124, the key intermediate 1.20 described above was reacted with
γ-thiobutyrolactone in presence of basic solution to form compound 1.38. Deprotection of the
remaining amines gave CSA-124 (Scheme 1.4.1).
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Scheme 1.4.1 Synthesis of CSA.124
Reagents: a) 4-Butyrothiolactone thiolan-2-one, NaHCO3, MeOH, H2O, 74% yield.; b) HCl/Dioxane, 91% yield.

1.4.3 Synthesis, Characteristic and Bioactivity of DANs
This study was accomplished by Dr. Hayes’s group in Cain department of Biochemistry and
Agricultural Engineering, Louisiana State University and LSU Agcenter. They synthesized the
Diagnostic Antimicrobial Nanoparticles (DANs) and qualified characteristic and bioactivity
using specific methods including Fourier transform infrared spectroscopy (FT-IR), UltravioletVisible spectroscopy (UV-Vis), X-ray diffraction, Dynamic light scattering (DLS), Transmission
electron microscopy (TEM), CSA quantification by high performance liquid chromatographyelectronspray ionization tandem time of flight mass spectrometry (HPLC-ESI-TOF-MS),
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Inductively coupled plasma optical emission spectrometry (ICP-OES), DC magnetization and
susceptibility Contrast concentration dependence, Magnetic resonance imaging and Minimum
inhibitory concentration.
1.4.4 Results and Discussion
The DANs synthesis is a multi-step procedure and is summarized in Figure.1.4.1. The key part
of the DAN is an iron nanoparticle with a polyacrylic surface ligand (Fe-PAA) synthesized
through thermal reduction of iron oxide in an organic solvent. After synthesis, the polyacrylic
acid

surfactant

is

improved

with

cysteamine

through

an

ethyl-dimethyl-

aminopropylcarbodiimide (EDC) chemistry reaction (depicted in Figure.1.4.2), resulting in a
distal thiol group in the polyacrylic that will readily bind with gold and silver. The cysteamine
“activated” product is then reacted with gold nanoparticles, or “seeds”, which incorporate with
functionalized Fe-PAA through thiol linkages (33). This seeded surface with nucleation sites for
silver reduction and shell formation results in a colloidal shell several nanometers thick. Finally,
the CSA-124 is attached to the silver shell via its thiolated ethylene glycol side chain providing a
uniform orientation of the compound with two primary amines on the distal portion of the
molecular free to interact with the environment.
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Figure.1.4.1 An overview of the synthesis process is exhibited. Fe-PAA NPs are synthesized; they are then
functionalized and seeded with gold NPs. Silver irons from AgNO3 are reduced onto the gold particles. Finally
CSA-124 is bound to the surface of the silver shell.
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Figure.1.4.2 Functionalization schematic of the PAA surfactant through an EDC/Sulfo-NHS workup. Carboxylic
acids are activated with EDC then functionalized with cysteamine, resulting in terminal thiols allowing for strong
gold seed adhesion.

Functionalization of the iron with polyacrylic acid affords for a hydrophilic particle which is
capable to increase colloidal solubility in the follow on aqueous reactions. Furthermore the PAA
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surfactant affords a platform for gold seeding and colloidal shell formation. The
functionalization procedure of PAA was optimized from of the protocol Ken-Tye Yong et al.
developed for the functionalization of carboxylate modified polystyrene beads.8 Firstly, the
carboxyl groups of the PAA were activated by ethyl-dimethyl-aminopropylcarbodiimide (EDC)
and N-hydroxysulfosuccinimide (Sulfo-NHS), and then reacted with the primary amine groups
of cysteamine hydrochloride (CH), forming an amide bond linkage. An EDC/Sulfo-NHS workup
is a well-established, moderate method for bonding molecules through their carboxylic and
amine groups and has also been used in CA/BMPA-coating magnetic nanoparticles,34 protein
coupling35, and protein film deposition.36 Once bound to the NP surface, the cysteamine provided
a primary thiol group that was ideal for the attachment of colloidal gold utilized in shell growth.
The method of colloidal attachment of gold nanoparticles to the thiol-functionalized PAA and
silver reduction was developed according to a method previously reported by Jackson and Halas9.
In our modified procedure, silver from AgNO3 was reduced onto the gold seed nucleation sites
bound to the PAA through cysteamine. This method affords adequate control over shell thickness
while sustaining colloidal stability in follow-on aqueous CSA functionalization reactions. The
CSA functionalization reaction takes place immediately following silver shell reduction to add
bulky surface groups offering steric hindrance and bound surface charges to reduce
agglomeration of the finished particles. If surface functionalization is not conducted within hours
of the silver reduction step, agglomeration of particles will occur rapidly. The composition of the
nanoparticles was analyzed using FT-IR, ICP-OES, and UV-Vis. FT-IR was used to verify the
addition of cysteamine to the carboxy terminus of the polyacrylic acid surfacetant on the Fe-PAA
NP. In this reaction, a carboxyl group is transformed into an amide bond (as seen in Figure.
1.4.3). The FT-IR peaks for carboxyl and amide groups are normally found at 1780-1710 cm-1
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and 1690-1620 cm-1, respectively37. In the FT-IR spectra of Fe-PAA NPs in Figure.3a there is a
clear peak at 1726 cm-1 indicative of the carboxyl group. In Figure.1.4.3 the 1726 cm-1maxima
peak is extremely reduced while a clear peak arises with a 1619 cm-1 maxima presenting that
many, though not all, of the carboxyl groups have been transformed to amide.

Figure.1.4.3 The FT-IR spectra shown indicate a shift in bond energy upon functionalization of Fe-PAA with
cysteamine.

Using ICP-OES, concentrations of iron, gold, and silver were monitored during the whole
synthesis process. With this information and the known sample volumes it was possible to track
the mass balance of each element. ICP-OES data indicates that the compositions of DANs are
76.64% silver, 22.75% iron, and 0.61% gold. Based on the mass balance of iron, it was measured
that the synthesis procedure from Fe-PAA NPs undergoing functionalization, gold seeding, and
silver coating resulted in a 8.6% yield with the bulk of losses due to centrifugal purification. It is
supposed that substituting magnetic separation for centrifugation during the purification process
could minimize these losses. Iron was selected to be the element monitored for percent yield
because it was the only element used in the first step and no introduced again throughout the
process.
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Figure.1.4.4 UV-Vis absorption spectra of DANs at different stages of development are shown. Series (a) shows FePAA NP, (b) shows Au-Fe-PAA np, and (c) shows Ag- Fe-PAA.

UV-Vis spectroscopy was applied to monitor to process progress between steps. After NPPAA functionalization, curve “a” in Figure 1.4.4 was obtained. This curve worked as a baseline
or comparison point for subsequent determinations. Curve “b” stands for the UV-Vis spectra
obtained after purification of gold seeded Fe-PAA NPs. This curve clearly varies the baseline
curve and closely paralles the absorbance spectra of a gold NP control. The similarity between
the Au-MNP an gold seed control curves demonstrates the assertion that gold seeds were
successfully attached to the PAA coating of the iron NPs. Cure “c” describes the absorbance
spectra obtained after silver was reduced onto the Au-Fe-PAA. As with the gold seeded NPs, the
silver coated NPs curve is significantly different from both the previous curves and indicates the
clear red shifting commonly associated with metal nanoshell synthesis.9This strongly
demonstrates that a silver shell was successfully reduced onto the particle surface, thus
supporting the ICP-OES findings.
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Figure.1.4.5. X-ray diffraction pattern of DAN core is representative of Silver and Maghemite.

To identify the exact structure of the DAN’s iron oxide core, X-ray diffraction was employed.
A powder diffraction pattern of the core-shell nanoparticles is displayed in Figure. 1.4.5. The
reflections due to the iron oxide core are indicated as blue lines and the reflections due to the
silver shell are indicated as black lines. The indicated reflections present that the iron oxide core
is maghemite. This is compliance with the brown color of the core nanoparticles.

Figure 1.4.6 TEM images of the nanoparticles at three stages of development are shown: (a) Fe-PAA nanoparticle,
(b) Au-Fe-PAA, and (c) Ag-Fe-PAA with CSA-124 surfactant.

The shape and size of nanoparticles at different stages of synthesis were measured using a
combination of TEM and DLS. The TEM images displayed in Figure.1.4.6 indicates the growth
of the nanoparticles as gold seeds were attached (Figure 1.4.6 b) and a silver shell was reduced
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onto the Fe-PAA NP (Figure.1.4.6c). It is also obvious that the Fe-PAA NPs the growth of the
nanoparticles as gold seeds were attached (Figure.1.4.6b) and a silver shell have a crude
spherical morphology that became more regular and smooth as gold and silver were added in
following processes.

Table 1.4.1 Nanoparticle diameters as determined by TEM.
Nanoparticle

Average diameter (nm)

Fe-PAA NP

9.4 ± 0.6

Au seeded Fe-PAA NP

20.5 ± 4.4

DAN

33.4 ± 6.1

Hydrodynamic diameters as determined by DLS
Fe-PAA NP

45.6 ± 1.0

DAN

53.1 ± 1.2

Analysis of the TEM images with Advanced Metamorphic was used to determine nanoparticle
size and is exhibited in Table 1.4.1. One sample t-test analysis of these values discovered that the
diameter increase after gold seeding was not statistically significant (P>0.05). Hydrodynamic
diameters, as measured through DLS, are also included in Table 1.4.1. As expected from a
relatively monodisperse product there is adequate agreement between the values generated from
the TEM image and the DLS results. As the multi-step synthesis continues larger particles with
larger hydrodynamic diameters are produced as a result of the addition of the silver coating and
CSA-124 addition.
A standard curve of integrated peak area vs. CSA concentration was constructed using HPLCESI-TOF-MS in order to quantify the CSA bound to colloidal silver. CSA was then displaced
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from the DAN surface and analyzed, again using HPLC-ESI-TOF-MS. The corresponding CSA
concentration was measured to be 1.34 mg/L for a 500 uL sample, or 4.01 X 1014 CSA molecules.
Using ICP-OES it was measured the same 500 uL sample with roughly 5.26 X 1012 DANs, thus
we suggest there are on average 76.1 CSA-124 molecules bound to each DAN. As the packing
density and uniformity of the CSA 124 surfactant layer is crucial to both particle stability and
bacterial adhesion, future work will perform the optimization of this process. A hysteresis loop
of the DANs is presented in Figure.1.4.7. The DAN magnetization was determined as a function
of applied field from 0 to ±90,000 Oe. As seen in the picture, the magnetization of DANs
increases rapidly with the applied field, tending toward saturation at fields >5000 Oe. The
maximum magnetization is approximately 12 emu/g NP, which is 54 emu/g Fe. This value is be
consistent with the iron oxide T2 contrast agents currently in clinical use; Feridex and Combidex
have magnetizations of 45 emu/g Fe and 61 emu/g Fe respectively

13

. DAN magnetic moment

was also assessed with respect to temperature and observed to have a slightly inverse relationship,
however still maintained an adequate magnetic moment at physiological conditions, dropping
less than 20% over a 300 K increase.
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Figure.1.4.7 The hysteresis loop in graph (b) shows NP magnetization as a function of magnetic field.

This graph displays an expanded view of the low-field region of the magnetization in which a
hysteresis is observed with a remnant magnetization, Mr ~3.0 emu/gm, and a coercive field, Hc ~
300 Oe. The data indicates that the majority of the nanoparticles are paramagnetic and at least
some subsets of the nanoparticles have a ferromagenetic component to their magnetization. This
seems to be a result of the size distribution of the particles used in the iron core, some of which
will be above the crucial transition size from superparamagnetic to ferromagnetic, roughly 10
nm38.
In Figure.1.4.8, a clear correlation is presented between nanoparticle concentration and MRI
contrast, known as negative contrast. The paramagnetism of the NP’s generates the relaxivity of
nearby water molecules to drop, and a decrease in relaxivity causes lower pixel intensity. Using
ImageJ, the pixel intensity of each tube was determined then plotted against particle
concentration. On average, pixel intensity drops by 16.7 gray scale units for each additional ppm
DAN. Figure.1.4.8 also displays the similar contrast of DANs and Fe-PAA Np presenting that
the maghemite core is not compromised by the formation of the silver shell. In fact, DANs seem
as though they may have slightly increased contrast ability. This can potentially be demonstrated
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by Dr. Vuong et al. who proposed that surrounding a paramagnetic NP with a shell prevents it
from directly coordinating with the select few neighboring water molecules but rather allows its
impacts to be distributed over a greater surface area and thus affecting a greater number of water
molecules. This causes a reduction of the relaxation time of a greater number of water molecules
correlating with a greater negative contrast39.

Figure.1.4.8 MRI of NPs dispersed in agarose at various concentrations (left).Graph of resulting pixel intensity for
each sample concentration (right).

Determination of in vitro contrast of bacteria by DANs was evaluated by exposing S. aureus to
DANs, filtering this mixture through a syringe filter, suspending this filter in a block of agarose,
and imaging with MRI, seen in Image Figure.1.4.9c. Filter pores, 450 nm, were used to be large
enough to allow DANs to pass unhindered yet retain all bacteria. As a negative control, S. aureus
was also exposed to DANs without CSA-124, (Fe core with silver shell only) and filtered,
Figure.1.4.9b. A positive control of total DAN capture using a 200 nm filter that captured bulk of
the DAN’s on the filter media can be seen in Figure.1.4.9a. As expected, Figure.1.4.9a displays
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the greatest contrast, Figure.1.4.9b displays no contrast and Fig1.4.9c displays moderate contrast.
This suggests that DAN attachment does take place, though the efficiency of the attachment is
far below 100%. This may arise from variation in the particle CSA-124 functionalization. As
described above the average functionality is 76.1 CSA/particle but distribution is currently
unknown, as such, large numbers of particles may have little or no CSA attached. The images
also suggest that DANs devoid of CSA do not adhere to the S. aureus, nor are they rapped in the
filter. To assure the attachment of CSA-124 to the NP surface did not influence filter
permeability, fully conjugated DANs in DI were filtered and also resulted in no contrast.

Figure 1.4.9 Magnetic resonance images of syringe filters suspended in agarose. Image (a) is a positive control,
image (b) is a negative control, and image (c) is the treatment.

The minimum inhibitory concentration found for DANs indicates they are slightly more
effective against S. aureus than E. coli at 12 ppm and 24 ppm respectively. Ruparelia et al.
measured the average MIC of SNPs against four different strains of E. coli and three different
strains of S. aureus40. The MIC of SNPs against both S. aureus and E. coli was found to be 120
ppm. Our own MIC assay using the above protocol with cellulose stabilized-SNP was found to
be 250 ppm. This makes DANs roughly ten times more effective against S. aureus and five times
more effective against E. coli comparable with the results of Ruparelia et al.
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1.4.5 Conclusions
The results in this study demonstrate that the synthesis process described above successfully
forms the desired iron containing, silver shell nanoparticle with a ceragenin monolayer surface
functionalization. The FT-IR spectrums indicate the addition of a mercapto group to the Fe-PAA
NP. ICP-OES supported the final product is comprised of 76.64% siver, 22.75% iron, and 0.61%
gold with around 8% total yield. Both TEM and DLS results illustrate predictable growth of the
particle with each additive process step. These results demonstrate that gold and silver were
successfully deposited onto the Fe-PAA NPs, yielding a final nanoparticle of 32.474 ± 1.83 nm
diameter and 53.053 ± 1.202 nm hydrodynamic diameter. Additionally, these particles were
found to be predominantly paramagnetic and possess a strong magnetic moment of 54 emu/g Fe.
These characteristics are representative of clinically adopted T2 MRI contrast agents, making
DANs a good potential candidate for diagnostic application. MRI of DANs and maghemite core
NPs at different concentrations indicate a 16.7 gray scale unit reduction in pixel intensity for
each ppm DAN. DANs have also suggested an ability to adhere and contrast S. aureus in vitro.
Finally, DANs have been exhibited to inhibit S. aureus at 12 ppm and E. coli at 24 ppm, five
times more effectively than silver alone. The results presented in the report demonstrate DANs to
be a potentially viable diagnostic contrast agent for treating deep tissue infection.

1.4.6 Experiment Section
General: Reagents were purchased from Aldrich Chemical Co. unless otherwise noted.
Methylene chloride, THF, DMF, pyridine, and DMSO were dried by passage through a Glass
Contour solvent drying system containing a cylinder of activated alumina. Silica gel was used for
chromatography unless otherwise noted.
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Instrumentation: 1H and 13C NMR spectra were recorded on a Varian Gemini 500 (500 MHz)
spectrometer. Proton chemical shift were referenced to tretramethylsilane (TMS). Carbon
chemical shifts were referenced to carbon resonance of solvents (CDCl3, CD3OD). High
resolution electron impact mass spectra (HR-MS) were obtained on a JOEL SX 102A
spectrometer.
Experiment:
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Compound 1.38 To a solution of 1.20 (1.2g, 1 mmol) in MeOH (10 mL) with stirring, 4butyrothiolactone thiolan-2-one, 10 mL of Saturated NaHCO3 solution were added respectively.
The mixture was allowed to react overnight at room temperature. After dried off MeOH via
rotavapor, the residue was filled with 20 mL of DI water and extracted with EtOAc (25 mL × 3).
After washing the combined organic phase with brine, the mixture was dried over Na2SO4. 0.95g
of the product was isolated through a column chromatography (SiO2). The yield was 74%. 1H
NMR (CDCl3, 500 MHz): δ 5.63 (d, 1 H), 5.12 (br, 1 H), 4.8 (br, 1 H), 3.6-3.7 (m, 18 H), 3.033.58 (m, 26 H), 1.55-2.11 (m, 19 H), 1.43 (s, 29 H), 1.20-1.31 (m, 21 H), 0.98-1.03 (m, 2 H),
0.88-0.94 (m, 11 H), 0.69 (s, 3 H).

13

C NMR (CDCl3, 125 MHz): δ 158.67, 158.02,

156.23,156.07, 80.56, 79.26, 78.89, 78.63, 70.70, 70.67, 70.63, 70.61, 70.57,70.52, 70.15, 70.02,
66.40, 65.76, 47.78, 47.37, 47.05, 46.15, 42.60, 41.88, 41.84, 39.68, 39.43, 39.41, 38.64, 38.35,
35.66, 35.21, 35.01, 34.91, 34.86, 33.16, 31.83, 30.57, 30.11, 29.69, 29.47, 29.27, 28.72, 28.61,
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28.54, 28.48, 27.61, 27.21, 27.04, 25.63, 23.35, 23.31, 22.95, 22.87, 22.48, 17.89, 14.11, 12.49.
HRMS (ESI) calcd for C69H128N6O14S [M+H]+: 1297.9209, found: 1297.9289.
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CSA-124 0.9g of 1.38 was dissolved into 5 mL of 4 M HCl/Dioxane solution. The solution
was stirred overnight at RT. After removing the solvent, 50 mL of toluene was poured into the
residue. 0.56g of CSA-124 was obtained by azeotropic removing the solvent in 91% yield. 1H
NMR (CDCl3, 500 MHz): δ 8.26 (br, 4 H), 8.12 (br, 2 H), 4.79 (br, 1 H), 3.6-3.7 (m, 18 H), 3.033.58 (m, 26 H), 1.55-2.11 (m, 21 H), 1.20-1.31 (m, 21 H), 0.98-1.03 (m, 2 H), 0.88-0.94 (m, 11
H), 0.69 (s, 3 H);

13

C NMR (CDCl3, 100 MHz): δ 158.53, 158.02, 80.56, 79.26, 78.89, 78.63,

70.70, 70.67, 70.63, 70.61, 70.57,70.52, 70.15, 70.02, 66.40, 65.76, 47.78, 47.37, 47.05, 46.15,
42.60, 41.88, 41.84, 39.68, 39.43, 39.41,39.22, 39.21, 38.35, 36.32, 35.66, 35.21, 34.91, 34.86,
33.16, 31.83, 30.57, 30.11, 29.69, 29.47, 29.27, 28.72, 28.61, 27.61,27.23, 27.04, 25.63, 23.53,
23.31, 22.95, 22.87, 22.48, 17.89, 14.11, 12.49. HRMS (ESI) calcd for C50H97N5O7S [M+H]+:
997.7636, found: 997.7832.

92

1.4.7 References
1. Mahmoudi, M.; et al., ACS Nano , 2011,5 (9), 7263–7276.
2. Kim, J. S.; et al., Nanomed.-Nanotechnol. Biol. Med. 2007, 3 (1), 95–101.
3. Agasti, S. S.; et al., J. Am. Chem. Soc. 2009, 131 (16) 5728-+.
4. O’Neal, D. P.; et al., Cancer Lett. 2004, 209 (2), 171–176.
5.

Cheng, K.; et al., Circ. Res. 2010, 106 (10), 1570-U54.

6. Chertok, B.; et al., Biomaterials. 2008, 29 (4) , 487–496.
7. Qureshi, A.T. et al., Biomaterials. 2013) ,34 (31), 7799–7810.
8. Yong, K. T. et al., Colloids Surf. – Physicochem. Eng. Aspects. 2006, 290,
89–105.
9. Jackson, J.B.; Halas, N. J. J. Phys. Chem. B. 2001, 105 (14), 2743–2746.
10. Pal, S.; Tak, Y. K.; Song, J. M. Appl. Environ. Microbiol. 2007, 73, 1712–1720.
11. Chen,X.; Gambhir, S. Acc. Chem. Res. 2011, 44, 841–1134.
12. Narayanan, S.; Sathy, B.N. Mony, U. M.; Koyakutty, S.V.; Menon, Nair, D. Biocompatible
Magnetite/Gold Nanohybrid Contrast Agents via Green Chemistry for MRI and CT Bioimaging.
Applied Material Interfaces, 2011.
13. Koyakutty,S.; Nair, V.; Menon, D. Biocompatible Magnetite/Gold Nanohybrid Contrast
Agents via Green Chemistry for MRI and CT Bioimaging. Applied Material and Interfaces,
2011, 16, 2015-2023.
14. Na, H. B.; Song, I. C.; Hyeon, T. Adv. Mater. 2009, 21 , 2133–2148.
15. Babes, L. et al., J. Colloid Interface Sci. 1999, 212 , 474–482.
16. Becker, R. O. Met.-Based Drugs. 1999, 6, 311.
17. Kim, Y. S. et al., Inhalation Toxicol. 2008, 20 , 575–583.
93

18. Tiwari, D. K.; Jin, T. J. Behari, Toxicol. Mech.Methods. 2011, 21, 13–24.
19. Jung, W. K. et al., Appl. Environ. Microbiol. 2008, 74, 2171–2178.
20. Katz, E.; Willner, I.; Angew. Chem. – Int. Ed. 2004,43 , 6042–6108.
21 Ghosh, P. et al., Adv. Drug Deliv. Rev. 2008, 60, 1307–1315.
22. Seferos, D. S. et al. Nano Lett. 2009, 9, 308–311.
23. Emerich,D. F.; Thanos, C.G. Biomol. Eng. 2006, 23, 171–184.
24. Melaiye, A. et al., J. Am. Chem. Soc. 2005,127, 2285–2291.
25. Umar, S. et al., Nanoscale Res. Lett. 2013, 8,164.
26. Park, H. H. et al., J. Mater.Chem. B. 2013.
27. Zhang, L. et al., J. Mater. Chem. 2012, 22, 23741–23744.
28. Leszczynska, K. et al., BMC Microbiol. 2009, 9.
29. Bucki, R. et al., J. Antimicrob. Chemother. 2007, 60, 535–545.
30. Leszczynska, K. et al., J. Appl. Microbiol. 2011, 110 , 229–238.
31. Ling, M. M.; Wang, K. Y.; Chung, T. S.; Ind. Eng. Chem. Res. 2010,49, 5869–5876.
32. Andrews, J. M. J. Antimicrob. Chemother. 2011, 48 (suppl 1) ,5–16.
33. Wiegand, I. Hilpert, K. R.E. Hancock, Nat. Protoc. 2008, 3, 163–175.
34. Brust, M. et al., J. Chem. Soc. Chem. Commun. 1994, 7, 801–802.
35. Lattuada, M.; Hatton, T. A. Langmuir. 2007, 23, 2158–2168.
36. Grabarek, Z. J. Gergely, Anal. Biochem. 1990, 185, 131–135.
37. Tengvall, P. et al., Colloids Surf. B – Biointerfaces 2003, 28, 261–272.
38. Merlic, C. IR Absorption Table. WebSpectra 2000.
39. Dutz, S. et al., J. Magn. Magn. Mater. 2007, 308, 305–312.
40. Vuong, Q. L. et al., Adv. Healthcare Mater. 2012, 4, 502–512.
94

41. Ruparelia, J. P. et al., Acta Biomater. 2008, 4, 707–716.

1.5 Ceragenin Mediated Selectivity of Antimicrobial Silver Nanoparticles
1.5.1 Introduction
A major source of difficulty in infection treatment is the broad-spectrum activity of prescribed
antibiotics. With the intent to eliminate pathogenic microbes, many antibiotics also kill or inhibit
natural microbial flora.1 Indigenous microbes assist in nutrient uptake and provide protection
from colonization by pathogenic microorganisms. When these natural bacterial populations are
compromised, opportunistic pathogens, such as C. albicans, C. difficile, and S. aureus, often
hinder post-treatment recovery and necessitate additional treatment.1-4 Selective antimicrobial
agents seek to treat pathogenic infections while leaving the native microbes uncompromised.
Advances in inorganic nanoparticle chemistry have led to a substantial increase in the types
and applications of nanoparticles.5-8 Nanoparticles can be manufactured from diverse materials
into a variety of shapes, sizes, and surface chemistries. One particularly relevant use of
nanoparticles is as vehicles for drug delivery.7 Nanoparticles offer a high surface area-to-volume
ratio, allowing high drug carrying capacity, and can be made to target infected tissues for
sustained drug delivery9-11. Ligands associated with nanoparticles are also less susceptible to
degradation than those free in solution11. Additionally, amphiphilic molecules with thiol groups
spontaneously assemble on noble metals like silver or gold.12-13It has been shown that
nanoparticles less than 200 nm in diameter are more likely to remain in circulation in vivo than
nanoparticles larger than 200 nm.11 Taken together, the composition, morphology, and surface
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chemistry of nanoparticles is highly customizable, making them ideal candidates for selective
antimicrobials.
Silver has long been known to possess antimicrobial properties and silver nanoparticles (SNPs)
and other silver nanomaterial compositions have shown comparable antimicrobial properties.5,1418

Currently, silver is employed as an antimicrobial in several products, including bandages,

antibacterial gels, and catheters.19 Silver impacts microbial systems through disrupting multiple
key cellular functions such as cell wall and nucleic acid synthesis, translation, protein folding,
and membrane ion pumps. Without these crucial functions, microbial cell division inhibition or
cell death often occurs. This combination of potent antimicrobial activity and limited patient
cytotoxicity makes SNPs a favorable alternative to traditional antibiotics as a treatment for
infections.
Natural cationic peptides show significant antimicrobial properties with low rates of resistance
and various levels of selectivity. Many, however, are susceptible to protease activity, restricting
their utility as standalone antibiotics in vivo.20, 21 CSA-124, a ceragenin used in this study, has
been synthesized with a terminal thiol group, enabling specific covalent bonding to noble metals.
In this study, we present the synthesis of a CSA-124 conjugated SNP (CSA-SNP) with
improved antimicrobial activity and physical selectivity for S. aureus. The composition and
physical properties of the CSA-SNP are analyzed through the following: dynamic light scattering
(DLS), transmission electron microscopy (TEM), inductively coupled plasma-optical emission
spectrometry (ICP-OES), and liquid chromatography-electrospray ionization tandem mass
spectrometry (LC-ESI-MS). The antimicrobial efficacy is determined with time-kill assays and
standard minimum inhibitory concentration/minimum bactericidal concentration (MIC/MBC).
Mammalian cytotoxicity of the CSA-SNP’s is quantified with flow cytometry and live/dead
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staining, and hemolytic characterization is analyzed via an ASTM standard. Physical selectivity
is validated both quantitatively and qualitatively through laser trapping analysis and confocal
microscopy.

1.5.2 Synthesis of CSA. 124
CSA.124 was readily to synthesize using the method described in Chapter 1.4.
1.5.3 Characteristic and Bioactivity of CSA-SNP
This study was accomplished by Dr. Hayes’s group in Cain department of Biochemistry and
Agricultural Engineering, Louisiana State University and LSU Agcenter. They qualified the
CSA-SNP characteristic and bioactivity using specific methods including Conjugating silver
nanoparticles with CSA-124, Dynamic light Scattering (DLS), Transmission Electron
Microscopy (TEM), CSA quantification, Cytotoxicity Analysis, Hemolytic Characterization,
Brightfield Imaging of Cell Morphology, Time-Kill Assay,Confocal Imaging, Image Analysis,
Optical trapping and Minimum Inhibitory Concentration and Minimum Bactericidal
Concentration.
1.5.4 Results and Discussion

Figure 1.5.1 TEM of CSA-SNP (left) and CSA-124 structure (right).
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Nanoparticle size was measured through TEM image analysis and DLS (Figure 1.5.1). These
results are shown in Table 1.5.1. As expected, the hydrodynamic diameter determined via DLS is
greater than the diameter determined via TEM in presence of solvated surfactant on the particle
surface because the former is a weight-average technique. It is also noteworthy that the
hydrodynamic diameter increased as the positively charged CSA-124 molecules were added to
the system, indicating self-assembly on the nanoparticle surface. Whereas precise size and
distribution of CSA-SNPs are not crucial in these experiments, they are relevant to colloidal
stability and in vivo biocompatibility. Larger particles are more likely to precipitate from
solution, potentially irreversibly aggregating and increasing apparent size.

Table 1.5.1 Nanoparticle Characterization
Parameter
SNP diameter via TEM analysis (nm)
Hydrodynamic diameter (nm)
Zeta potential (mV)

HPC-SNP

CSA-SNP

68 ± 18

64 ± 38

81.9 ± 9.4

102.2 ± 2.3

-18.23 ± 0.83

-8.34 ± 1.05

Besides, nanoparticles possessing a diameter greater than 200 nm are more liable to activate
the complement system and thus be cleared from the circulatory system. 34 Nanoparticles with a
diameter under 100 nm are capable of penetrating blood vessel pores, and NPs under 20 nm can
access interstitial spaces.11 This characteristic has been termed the enhanced permeability and
retention (EPR) effect. 35, 36
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As anticipated, the nanoparticle obtains positive charge after the addition of CSA, due to the
three ammonium groups on CSA-124 in neutral media. This data sustains the fact that CSA was
successfully conjugated to the nanoparticle surface. It is also significant because the nature of the
surface charge also affects the nanoparticles’ in vitro and in vivo interactions. When particles
have a moderately neutral charge, they will be more likely to agglomerate, resulting in shorter
shelf lives, a lower solubility threshold, and an increased probability of removal from in vivo
circulation.37 Once in the body, nanoparticles are sensitive to opsonization, recognition, and
removal by the mononuclear phagocyte system (MPS). In a general way, neutral to negatively
charged nanoparticles with hydrophilic polymer surfaces exhibit prolonged circulation times. 34
A high quality of the CSA-SNP is easy to conjugate with noble metal nanoparticle. CSA-124
has been specifically prepared with a thiol-terminated polyethylene glycol side chain that
favorably binds to noble metals. The SmartSilverAS silver nanoparticles, from this point termed
as SNPs, used for this procedure are stabilized with hydroxypropyl cellulose (HPC), which
affords the nanoparticles with high solubility in aqueous and organic alcohol solvent systems and
increases biocompatibility. Due to CSA-124 has greater thermodynamic and steric stability than
HPC on the surface of the SNPs, CSA-124 spontaneously displaces a portion of the HPC
molecules.
For the quantification of CSA-124 bound to the SNP surface, we first built a standard curve of
integrated peak area versus known CSA concentration using HPLC-ESI-TOF-MS. The CSA was
displaced from the SNP surface using DTT; the particles were separated by centrifugation and
analyzed using HPLC-ESI-TOF-MS. The corresponding CSA concentration was measured to be
1.5 mg/L for a 500 µL sample, or 4.52 × 1014 CSA molecules. Using ICP-OES and estimates of
particle size from TEM, we measured the same 500 µL sample contained 1.32 × 1011 SNPs, and
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thus, we come to conclusion that there are on average 3424 CSA-124 molecules bound to each
SNP38.

Figure 1.5.2 MIC and MBC of CSA-SNP against various bacteria.

The antimicrobial results for the minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) are illustrated in Figure 1.5.2. As the chart indicates, CSASNPs demonstrate similar efficacy against S. aureus (MIC 15 ppm), E. faecalis and E. coli (MIC
30 ppm), and P. aeruginosa (MIC 60 ppm). Our own measurement of the MIC of SNPs was
obtained using the same protocol as above and found to be roughly 250 ppm for both S. aureus
and E. coli. Whereas this study demonstrates that a CSA-SNP conjugate is a more potent
antimicrobial than an SNP alone, it does not attempt to illustrate the mechanistic roles of each
component, as potential mechanisms of each have previously been published. Although SNPs
have been demonstrated to disrupt cell wall synthesis, membrane ion pumps, translation, and
nucleic acid synthesis,5,14-17,25,39 antimicrobial properties of CSA have been attributed to
membrane disruption through depolarization and permeabilization. It is also noteworthy; Kim et
al. reported that SNPs alone inhibited E. coli 10 times more effectively than S. aureus,
suggesting the CSA may impart SNPs with some mechanism of selectivity.14 Further evidence of
physical selectivity was provided by confocal imaging of cocultures of these bacteria. Statistical
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analysis using MATLAB demonstrated that CSA-SNPs were more likely to be near S. aureus
than E. coli. This could result in part to electrostatic attraction between the cationic CSA and the
negatively charged peptidoglycan, which Gram-positive bacteria express in much greater
quantities.40 It has been well demonstrated that various cell types present different membrane
constituents to its surrounding environment, which affects how the cell responds to extracellular
foreign bodies, a concept known as cell vision. This phenomenon influences the surface binding,
cellular uptake, and internal fate of nanoparticles and in part explains the drastic differences in
NP response among different cell types.41,42 Further antimicrobial characterization was given
through a time-Kill study, depicted in Figure 1.5.3.

Figure 1.5.3 Time –kill assay showing increased inhibition of S. aureus versus E. coli due to CSA-SNPs. Percent
inhibition is with respect to unexposed live controls.

As described in Figure 1.5.3, minimal inhibition is seen at 5 ppm, and efficacy increases as
concentration increases. Note that inhibition results of the time-kill assay change slightly from
those of the MIC, as this was a 4 h study and MIC is a 24 h study. The results of the time-kill
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assay echo those of the MIC/MBC in that S. aureus depicts increased sensitivity to CSA-SNPs
compared to E. coli.

Figure 1.5.4 (A) Cytotoxicity of CSA-SNPs. (B) Hemolytic activity of CSA-SNPs.

The concentration dependent toxicity of CSA-SNPs to mouse 3T3 fibroblasts was measured by
cell treatment followed by flow cytometry and is shown in Figure 1.5.4. The CSA-SNPs display
very limited toxicity below 39.8 ppm and reach the 50% viability threshold at ~ 50 ppm. The
differences between the live control and the 39.8 and 55 ppm samples were observed to be
significant by one-way ANOVA with Bonferroni’s posttest (p < 0.05). The hemolytic assay
displays nearly identical results with increasing hemolysis at 37.5 ppm and slightly over 50%
hemolysis occurring at 50 ppm. The differences between the TBH, 37 ppm, and 50 ppm samples
were observed to be significant from all other samples as determined by one-way ANOVA with
Bonferroni;s posttest (p < 0.05). These findings suggest about a 3-fold difference between MIC
and EC50tox for S. aureus and 3T3 cells, respectively. Simultaneous testing of SNPs alone
presented little cytotoxicity up to 200 ppm. This result is supported by the work of Jain et al.,
who reported that the IC50 for SNPs against Hep G2 cells to be 251 ppm. These findings suggest
that CSA-SNPs are approximately 5 times more toxic to 3T3 cells than SNPs alone43.
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Figure 1.5.5 Bright-field images of 3T3 fibroblasts that received (a) 0 ppm of CSA-SNP, (b) 15 ppm of CSASNP, and (c) 37 ppm of CSA-SNP.

The cytotoxic effects of CSA-SNPs were also qualitatively evaluated via bright-field imaging.
In Figure 1.5.5a, the representative spindle morphology of healthy 3T3 fibroblast cells can be
found. In Figure 1.5.5b, representing the MIC of S. aureus at 15 ppm of CSA-SNP, the cells
seem to have slightly reduced size but retain their characteristic spindle morphology. CSA-SNP
at 37 ppm results in stark contrast in cell morphology indicative of cytotoxicity. These results are
compliance with those from the hemolysis and flow cytometry studies.

Figure 1.5.6 confocal imaging of (red) S. aureus, (green) E. coli, and (blue) nanoparticles. (A and B) CSA-SNPs
and (C and D) unmodified SNPs.(B and D) Enlarged segments of A and C, respectively.
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Qualitative image analysis of the confocal overlays (Figure 1.5.6) illustrates that the CSASNPs are distributed spatially closer to S. aureus cells than to E. coli cells. Analysis of these
images presents the closest S. aureus and E. coli to each SNP; histograms and simple statistics
are shown in Figure 1.5.7 and Table 1.5.2, respectively.

Figure 1.5.7 Histograms of (top) experimental and (bottom) negative control distances from SNPs to (left) S.
aureus and (right) E. coli.

Table 1.5.2 Statistics from Quantitative Image Analyses
Samples

av distance from NP to cell (µm)

CSA-SNP to S. aureus

1.283 ± 1.994

CSA-SNP to E. coli

3.489 ± 3.883

SNP (neg. control) to S. aureus

4.864 ± 4.393

SNP (neg. control) to E. coli

3.991 ± 4.165
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Table 1.5.2 demonstrates the distribution of distances for both experimental and negative
control groups. The difference in average distance between CSA-SNP and S. aureus versus CSASNP and E. coli is statistically significant, as is the difference in average distance between the
CSA-SNP treatment samples and the SNP negative control samples (two-way t test, p < 0.05).
More than 70% of the CSA-SNPs are within 2 µm of an S. aureus cell, while less than 40% of
CSA-SNPs are within 2 µm of an E. coli cell. CSA-SNPs, on average, are closer to S. aureus
than to E. coli. The standard deviations show less dispersion among the CSA-SNP to S. aureus
data than the CSA-SNP to E. coli data. Ripley’s K-function clustering analysis shows that the
CSA-SNPs are spatially clustered, particularly on shorter scales.
The negative control data indicate no significant difference between the SNP to S. aureus
distance and the SNP to E. coli distance. This is distinguished by large standard deviations for
both negative control groups. Nevertheless, statistically, the mean CSA-SNP to S. aureus
distance is significantly different from SNP to S. aureus average distance. Selectivity was then
qualitatively explained on the scale of single cells through video observation and optical trapping
technology. Optical trapping has the capability to manipulate small living biological objects,
such as single bacterial cells, as well as inanimate particles. The infrared wavelength is
minimally invasive to living cells. The optical trapping at a cellular level affords insight into
biological interactions. Thus, optical trapping of CSA-SNP and S. aureus was conducted to
further investigate the interactions and potential selectivity.
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Figure 1.5.8 S. aureus (indicated with arrows) adhering to CSA functionalized MP.

An optical trap was used to indicate the adhesion of CSA-MP to S. aureus (Figure 1.5.8). A
single bacterium was trapped in one specific trap, and CSA-MP was simultaneously trapped in
another trap. The bacteria were then allowed to touch and reside for several seconds, and then the
two traps were removed. The result indicated the S. aureus remained attached and could not be
displaced by the force of the optical trap. The video indicates that three separate bacteria can
attach and bind to one CSA functionalized particle. Repeated trials showed that interactions
generally formed within periods of <2 s. As a control, the procedure was repeated with
nanoparticles lacking CSA-124 surfactant. The nanoparticles without CSA-124 did not reveal
adhesion to S. aureus, even when extending the residence time beyond 10 s.

1.5.5 Conclusions
Since Silver was approved by the FDA in the 1920s43, it has been applied clinically as a broadspectrum antimicrobial. Recent research demonstrates that there are many drawbacks to broadspectrum antimicrobials including longer recover times, increased risk of further infection, and
higher incidence of drug resistance. The data presented indicate that the antimicrobial qualities of
silver can be supplemented via conjugation with selective ligands such CSA-124. Whereas SNPs
alone have an MIC of 120 ppm against S. aureus, CSA-SNPs present an MIC of 15 and 30 ppm
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toward S. aureus and E. faecalis, respectively, and an MIC of 30 and 60 ppm toward E. coli and
P. aeruginosa, respectively. This study further demonstrates that the functionalization of CSA to
the nanoparticle surface imparts spatial selectivity in favor of S. aureus over E. coli; nevertheless,
spatial selectivity does not necessarily imply antimicrobial selectivity. These findings were
further supported through MATLAB analysis of confocal images, presenting that while in
coculture, 70% of CSA-SNPs were within 2 µm of an S. aureus cell while less than 40% were
within 2 µm of an E. coli cell. Video images of laser captured nanoparticle interactions with both
bacteria also indicate clear selectivity for the Gram-positive S. aureus over the Gram-negative E.
coli.
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Chapter 2
Structural Improvement and Synthesis of Cyclopentenone Prostaglandins
2.1 Introduction
2.1.1 Prostaglandins
Prostanoids are natural subclass of eicosanoids, or signaling molecules, generated mainly from
metabolic oxidation of arachidonic acid (AA).1-3They are unsaturated carboxylic acids with 20carbon atoms in their skeleton. They are divided into two types: prostaglandins (PGs), which
contain a cyclopentane ring, and thromboxanes, which contain a cyclohexane ring.4
PGs were first found by Euler et al. in 1930s and first characterized in 1950s.5,6 As shown in
Figure 2.1, every prostaglandin is named with the prefix ‘PG’ followed by a letter A-K
depending on the nature and position of the substituents on the cyclopentane ring. Furthermore, a
numerical subscript (1-3) is used to denote the total number of double bonds in the hydrocarbon
substituents. A Greek subscript (α or β) is used with the PGF series to describe the
stereochemistry of the hydroxyl group on C9. A key feature of prostaglandins is the five
membered ring encompassing C8 to C12.
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Figure 2.1 Nomenclatures of Prostaglandins.

According to mechanisms of their biological actions, PGs are divided into two groups:
conventional PGs and cyclopentenone PGs. Herein, cyclopentenone PGs will be explored in
detail since this chapter is mainly about synthesis of these PGs. As the name suggests,
cyclopentenone prostaglandins (cyPGs) contain a highly reactive α,β-unsaturated carbonyl group
in their cyclopentenone ring.7 They are electrophilic compounds and have the ability to form
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covalent adducts with nucleophilic residues, such as cysteine in proteins through Michael
addition, as shown in Figure 2.2. CyPGs are biologically generated from unsaturated fatty acids,
such as arachidonic acid from membrane-bound phospholipids via the action of phospholipases
and linolenic acid from the diet via the action of elongase. These unsaturated fatty acids can be
converted into different PGs enzymatically and non-enzymatically. The enzymatic pathway in
fact is the metabolism via cyclooxygenases (COXs) to produce PGH1 and PGH2. PGH2 is further
transformed to PGE2 and PGD2 by different prostaglandin synthases. The non-enzymatic
pathway is the epimerization of isoprostanes to produce PGE2 and PGD2. Finally, these parent
PGs are dehydrated or undergo an albumin-dependent pathway to yield cyPGs (such as PGA2
and 15d-PGJ2).9-13 Since the unsaturated carbonyl group in the cyclopentenone ring is reactive,
cyPGs react with nucleophilic groups (such as thiol or amino groups) in amino acid residues of
proteins by Michael’s addition, resulting in alterations of protein function.14-17

Figure 2.2 Formation of cyPGs and covalent binding to proteins through Michael addition. Adapted from ref[8].
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2.1.2 Functions of Cyclopentenone Prostaglandins
Due to their α,β-unsaturated carbonyl group, can easily form Michael adducts with free
nucleophilic groups, cyPGs are potent bioactive lipid mediators and have important roles in the
resolution of inflammation and the regulation of cell proliferation and cellular redox status
(tumorigenesis). As a result, cyPGs possess three main potentially therapeutic properties: antiinflammatory, antiproliferative and antiviral.
2.1.3 Regulation of Inflammation
CyPGs play an essential role in the regulation of the inflammation response through their
ability to in covalently modify the related key proteins. CyPGs are present at low levels in
normal conditions and get increased in situations of chronic inflammation, especially when
associated with COX-2 expression. Recent researchers suggested that cyPGs play a protective
role in pathophysiological process and considered potentially useful drug-candidates. CyPGs are
generated in the defense mechanisms and then participate in the resolution of inflammation.
They act as a switch between inflammatory factor and pro-resolving mediator, reduce the activity
of pro-inflammatory transcription factors, such as nuclear factor kappa B (NF-κB) and activator
protein 1 (AP-1), and are involved in modification of proteins involved in inflammatory
resolution. Martínez et al. illustrated how 15d-PGJ2 displayed a biphasic effect on cell activation
of mesangial cells to cytokine stimulation. In detail, 15d-PGJ2 led to an amplification of NO and
iNOs with nanomolar concentrations in the early stages of the inflammatory response and
inhibited proinflammatory gene expression with micromolar concentrations during late stages.18
Fernandez-Bustamante et al. demonstrated that 15d-PGJ2 contributed in counteracting ongoing
lung inflammation in early endogenous conditions but also worked as an early biomarker of lung
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inflammation.19 Pe´rez-Sala et al. identified a novel site binding site for 15d-PGJ2 with the AP-1
that contributes to the cellular response to pro-inflammatory agents.20
2.1.4 Antiproliferative Activity and Antitumoral Activity
CyPGs, such as 15d-PGJ2, suppress proliferation of cancer cells, induce apoptosis in various
cancer cells and show great potential antitumor activity due to their involvement in inhibition of
transcription factor AP-1 or activation of peroxisome proliferator activated receptor gamma
(PPARγ). Kim et al. reported 15d-PGJ2 inhibited the bone loss that is associated with breast
cancer as well as bone metastasis and estrogen deficiency caused by cancer.21 Ciucci et al.
demonstrated 15d-PGJ2 induced inhibition of constitutive IκB-kinase and NF-κB activities in
ER-negative breast cancer cells.22 PGA and analogues also inhibited DNA synthesis and
proliferation of tumor cells substantial potently. They were able to inhibit the proliferation of
tumor cells in vitro, including melanoma and leukemia cells.23-25 Garzón et al. demonstrated that
PGAs potently activate heat shock factor (HSF) and induce the transcription of heat shock
protein 70 (Hsp70) due to their electrophilic nature. These effects have been verified to correlate
with the antiproliferative actions of PGA1.26,

27

Pavithra et al. proposed PGA2 also had an

antiproliferative effect, inducing the binding of Hsp 70 to the 5’-UTR of the mRNA of tumor
suppressor SMAR1, and leading to an increase in SMAR1 protein levels.28
2.1.5 Antiviral Properties
CyPGs have been reported to have antiviral activity against poliovirus, Sendai and HIV virus
via their interactions with the cells or the targets.29-32 Santoro et al. found several cyPGs
displayed antiviral effects and inhibited viral replication factors, such as NF-κB.29 Suzuki et al
demonstrated △7-PGA1 methyl ester and PGA1 methyl ester reacted with thiol nucleophiles via

covalent modification to inhibit cell growth.30 Hayes et al. illustrated that, PGA1 and PGA2
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inhibited the replication of HIV-1 in infected human monocyte-derived macrophages and
reduced the replication of HIV in lately infected U1 cells31, due to electrophilic groups in cyPGs.
Kalantari et al. reported cyPGs directly inhibited HIV-1 proteins via covalently direct bindings.33
2.1.6 Synthesis of Cyclopentenone Prostaglandins
To further understand the relationships between the chemical structures and the extraordinary
bioactivities of cyPGs, organic synthesis of cyPGs and analogues greatly facilitated the
evaluation of their activities in diverse biological systems and exploration of their applications in
pathophysiological and pharmacological fields.
As shown in Figure 2.1, cyPGs have a cyclopentenone ring as the key point, and two side
chains with three or four stereo-centers, including the α-chain containing carboxy group (C-1 to
C-7) and the ω-chain containing hydroxyl group (C-13 to C-20). Based on these chemical
structures of cyPGs, total synthesis could be completed with Djuric’s strategy.34The core
cyclopentenone ring was synthesized with certain substitutes in appropriate positions as one of
the side chains, then the second chain (α- or ω-side chain) was introduced in a following step.
Last, 1,4-addition of the ω-chain on the appropriate Cyclopentenone was done, followed by in
situ trapping with the required α component as the electrophile gave the target molecule.
Egger et al. explored the synthesis of 15d-PGJ2 in their previous research.35-37 They utilized the
1, 5-pentanediol as the initial reagent, protected one of the alcohols, left the other subjected to
oxidation to yield aldehyde. They obtained the cyclopentanone after several following steps,
installation of ω-side chain, removed protecting group of the ether, and finally stepwise oxidized
the alcohol to acid to complete the synthesis.
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Considering this previous research, we used inexpensive glycols as the initial reactants and
follow the main strategy mentioned above to carry out cyPGs synthesis, especially the PGA and
analogues.
2.2 Synthesis and Modification of Cyclopentenone Prostaglandins
2.2.1 The Target Cyclopentenenone Prostaglandin to Synthesize and Modify
Recently, Egger and co-workers evaluated the activity of EI and EC (Figure 2.3) in reducing
the secretion of proinflammatory cytokines IL-6 and IL-12 by dendritic cells in response to a
TLR4 agonist. EC has been identified as the most active compound. Furthermore, another similar
cyclopentenone prostaglandin, 15d-PGJ2(Figure 2.3) is reported as the anti-inflammatory
prostaglandin. This cyclopentenone prostaglandin also exhibits extraordinary biological activity
in the modulation of inflammatory and apoptotic process. Due to their high bioactivity, EC was
chosen as a target compound of cyclopentenone prostaglandin to synthesize and modify.
O
O

O

O
O

O
OH

HO

OH

C5H11
EC

C5H11

O

C5H11
15d-PGJ2

EI

CO2H

Figure 2.3 Structure of EC, EI and 15d-PGJ2

2.2.2 Synthesis of EC
In 2005, Jung and Kobayashi developed the total synthesis of EC in 20 steps with 0.19% total
yield and 14 steps with 0.13% total yield respectively, using chiral cyclpentadiene as starting
material. In 2013, Egger and co-workers completed total syntheis of EC in just 11 steps with up
to 5.4% total yield. Two years later, Lu devevopled an efficient synthetic route for EC ester in 8
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steps with 10% total yield. We followed Egger’s synthetic stategy of the total synthsis of EC in
our study using (Z)-dec-4-en-1-ol as starting material.
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Scheme 2.1 Synthesis of compound 2.9
Reagents: a) Oxalyl chloride, TEA, DMSO, 87%; b) LiClO4, TMS-quinidine, Acetyl chloride, DIPEA, 61%; c) nBuLi, Diisopropylamine, Methyl acetate, THF, 74%; d) 4-Acetamidobenzensulf-only azide, TEA, DCM, 96%; e)
TESCl, DMF, 88%; f) Rh2(s-PTAD)4, DCM, 59%; g) NaCl, DMSO, 140 oC, 65%; h) DBU, DCM, 93%;

The first step was a classic swern oxidation to form corresponding aldehyde 2.2, which was
converted to β-lactone 2.3 in 61% yield and 92% ee, as determined by SFC analysis. Opening of
compound 2.3 with methyl acetate enolate afforded β-ketoester 2.4 in 74% yield. Compound 2.4
was subjected to sequential diazotization providing compound 2.5, which was protected by
TESCl to form compound 2.6. Rh-catalyzed C-H insertion reaction using [Rh2(OAc)4] gave the
cyclized product resulting from insertion into the homoallylic C-H bond. This tartgent compound
121

2.7 was obtained as a 4:1 mixture of diastereomers as determine by analysis of the crude NMR
spectra, which indicated a preference of the desired C11-C12 cis product. Decarboxylation of
Compound 2.7 gave compound 2.8, which was treated with DBU to form the key intermediate
compound 2.9.
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Scheme 2.2 Synthesis of compound 2.11

Reagents: a) i) O3, NaHCO3, MeOH/DCM, -78 oC then TEA, Ac2O, PhH, 0 oC; ii) Ph3PCHCHO, toluene, 70 oC,
55%; b) (S)-2-(diphenyl[(trimethylsilyl) oxy] pyrrolidine, H2O2, DCM, RT, 51%.

To prepare the side chain part, we started with cyclopentene and underwent ozone oxidation
and wittig reaction to form compound 2.10.

epoxidation of

hydrogen peroxide gave the

corresponding compound 2.11 as a synthetic side chain block.
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Scheme 2.3 Synthesis of EC
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2.12

Reagents: a) i) LiN(SiMe3)2, THF, -78 oC; ii) MeSO2Cl, TEA, DCM, -78 oC, then Al2O3, DCM, RT, 64%; b)
Novozyme (lipase on acrylic resin), PBS, 70%.

Within compound 2.9 and compound 2.11 in hands, installation of the C8 side chain of
cyclopentenyl ring was performed with a modification of a procedure by Kobayashi, involving
the aldol addition of these two key intermediate, followed by a trans-selective elimination to
form dienone 2.12. Enzymatic hydrolysis of the methyl ester in PBS gave the target acid EC.

2.2.3 Modification and Synthesis of Cyclopentenone Prostaglandin

Modification of cyclopentenone prostaglandin
Since we successfully synthesized the most active cyclopentenone prostaglandin in reducing
the secretion of pro-inflammatory cytokines IL-6 and IL-12 by dendritic cells in response to a
TLR4 agonist, several similar structural cyclopentenone prostaglandins were designed and
synthesized (Figure 2.4).
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Figure 2.4 Structure of derivatives of EC

As one of oxidized phospholipids (OxPLs), PECPC (shown in Figure 2.4) has been shown to
act as an anti-inflammatory agent in reducing the secretion of the pro-inflammatory cytokinies
IL-6 and IL-12. According to the cyclopentenone prostaglandins structural specification, we
induced one chlorine element at position 2 to design a new cyclopentenone prostaglandin 2.12
(shown in Figure 2.4). Otherwise, we designed and synthesized one new EC derivative called
EC-Biotin, which was modified through coupling with Biotin mediated by a PEG linkage chain.
We proposed these modifications could possibly to improve bioactivity as anti-inflammatory
agents due to increasing nucleophilicity of molecule and be easy to identify as a biomarker
during metabolic activities.
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Synthesis of designed cyclopentenone prostaglandins
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Scheme 2.4 Synthesis of PECPC
Reagents: a) 2,4,6- Cl3C6H2COCl, DMAP, lyso-PC, CHCl3, 59%.

To synthesize PECPC, we used EC as starting material, followed an esterification reaction with
lyso-pc to form the target product.
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Scheme 2.5 Synthesis of Compound 2.13
Reagents: a) m-CPBA, DMF/HCl, DMF, 63%; b) i) LiN(SiMe3)2, THF, -78 oC; ii) MeSO2Cl, TEA, DCM, -78 oC,
then Al2O3, DCM, RT, 61%; c) Novozyme (lipase on acrylic resin), PBS, 68%.

To synthesize compound 2.13, we used the key intermediate 2.9 as starting material. The
compound 2.9 was treated with m-CPBA in the 6.6 M of DMF/HCl solution at 0 oC to give
compound 2.14. With this key intermediate 2.14 in hands, the same synthetic pathway as
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synthesis of EC mentioned in scheme 2.3 was conducted to form successfully the target
compound 2.13.
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Scheme 2.6 Synthesis of EC-Biotin
Reagents: a) Biotin.OSu.X, TEA, DCM, 90%; b) Zn, AcOH, MeOH, THF, 88%; c) EC, EDCI, HOBt, CHCl3, 92%.

Compound 1.12 was treated with Biotin.OSu.x in presence of basic condition to obtain
coupling product Compound 2.16. Reduction of Zn afforded the corresponding amine 2.17,
which was underwent a peptide coupling reaction to form the EC-Biotin.

2.3 Study of Bioactivities of EC and Its Derivatives in Reducing Secretion of
Pro-inflammatory Cytokines IL-6 and IL-12
EC and its derivatives were sent to Dr. Freigang’s Group in Institute for Integrative Biology,
ETH Zurich for their bioactivities in reducing secretion of pro-inflammatory cytokines IL-6 and
IL-12 respectively.
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2.4 Results and Discussion
The preliminary bioactivity of EC in reducing secretion of pro-inflammatory cytokines IL-12
had been accomplished in Dr. Feigang group (Figure 2.3).

Figure 2.3 Effect in Reducing Secretion of Pro-inflammatory Cytokines IL-12.

As expected, the fresh EC elicited a strong effect in the inhibitory of secretion of proinflammatory cytokines IL-12. Figure 2.3 indicated that various concentrations of EC, range
from 0.01 µM to 10 µM, inhibited the secretion of pro-inflammatory cytokines IL-12. In the
experiment, we also qualified the inhibitory effect of EC in reducing the secretion of proinflammatory cytokines IL-12 using different solvent such as EtOH, DMSO, Med, PBS/ tween
and EtOH/Crem. They showed a similar and strong inhibitory effect. In Figure 2.3, we observed
a dose-dependent decrease in the secretion of the pro-inflammatory cytokines IL-12. Further
investigation of the inhibitory effect of other derivatives will be conducted in the due course.
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2.5 Conclusions
In general, we successfully prepared the cyclized oxidized phospholipids PECPC and the
corresponding free carboxylic acids EC in our lab. We also were managed to synthesize two
designed derivatives in an effective and efficient route. The route we developed provides ChloroEC in 13 steps (0.88% yield) and EC-Biotin in 15 steps (0.99% yield), respectively. As the most
bioactive compound in reducing the secretion of pro-inflammatory cytokines IL-6 and IL-12, EC
was investigated for the inhibitory effect in various concentrations and in several solvent systems.
Further studies on inhibitory of secretion of pro-inflammatory cytokines IL-6 and IL-12 for
derivatives are in progress.

2.6 Experiment Section
General: Reagents were purchased from Aldrich Chemical Co. unless otherwise noted.
Methylene chloride, THF, DMF, pyridine, and DMSO were dried by passage through a Glass
Contour solvent drying system containing a cylinder of activated alumina. Silica gel was used for
chromatography unless otherwise noted.
Instrumentation: 1H and 13C NMR spectra were recorded on a Varian Gemini 500 (500 MHz)
spectrometer. Proton chemical shift were referenced to tetramethylsilane (TMS). Carbon
chemical shifts were referenced to carbon resonance of solvents (CDCl3, CD3OD). High
resolution electron impact mass spectra (HR-MS) were obtained on a JOEL SX 102A
spectrometer.
C5H11
O
2.2
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Compound 2.2 To a solution of oxalyl chloride(1.82 mL, 20.8 mmmol, 1.30eq.) in DCM (30
mL) at -78 oC, was added over a period of 10 min a solution of DMSO (3.0 mL, 41.6 mmol, 2.6
eq) in DCM (5 mL). The mixture was stirred for 30 min and then a solution of (z)-dec-4-en-1-ol
(3 mL, 16 mmol, 1.00eq) in DCM (20 mL) was added. The miture was stirred at -78 oC for 2 h,
then a solution of TEA (10 mL, 64 mmol, 4.00eq) in DCM (5 mL) was added and the mixture
stirred for another 45 min at -78 oC, before it was allowed to reach room temperature. The
mixture was treated with water (15 mL) and the layers were separated. The aqueous layer was
extracted with DCM (3X 10 mL) and the combined organic layers were washed with brine (25
mL), dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash column
chromatography (SiO2, pentane/Et2O, 10:1) gave aldehyde 2.2 (2.0g, 158 mmol, 87% yield) as a
colorless oil. TLC: Rf=0.64 (hexane/EtOAc, 5:1, Vanillin). 1H NMR (400 MHz,CDCl3): δ= δ
9.77(t,j = 1.6Hz, 1H), 5.48-5.38 (m, 1H), 5.37-5.28 (m, 1H), 2.52-2.44 (m, 2H), 2.41-2.38 (q,J=
7.1 Hz, 2H), 1.40-1.23 (m, 6H), 0.88 (t, J= 6.9Hz, 3H).

13

C NMR (100 MHz, CDCl3): δ= δ

202.39, 131.89, 127.14, 44.00, 31.64, 29.38, 27.34, 20.23, 14.19, HRMS (ESI) calcd for C10H18O
[M+H]+: 155.1436, found: 155.1434.
O

O
C5H11
2.3

Compound 2.3 To a 100mL-flask equipped with a big stirring bar and dried lithium perchorate
(2.2g, 2.1 mmol, 3.00 eq) was added Et2O (20 mL), followed by a solution of TMS-quinidine
(0.35g, 0.9 mmol, 0.12 eq) in DCM (30 mL). The mixture was stirred at room temperature until a
clear solution has formed and then cooled to -78 oC before i-Pr2NEt (3.0 mL, 17.3 mmol, 2.50 eq)
was added, followed by a solution of decenal 2-2 (1.0g, 7.0 mmol, 1.00 eq) in DCM (15 mL). A
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solution of acetyl chloride (1mL, 14 mmol, 2.50 eq) in DCM (2X 3 mL) was then added over 4h
via a syringe pump and the mixture kept stirring at -78 oC for 8 h. After full consumption of the
starting material, the now yellow, turbid reaction mixture was quenched at -78 oC with Et2O (10
mL) and then allowed to reach room temperature, before it was filtered through a pad of silica,
that was afterwards carefully washed with Et2O (3 X 15 mL). The filtrate was concentrated in
vacuo and the crude material purified by flash column chromatography (SiO2, pentane/Et2O, 5:1)
to give lactone 2.3 (0.78 g, 43 mmol, 61% yield, 93% ee) as a colorless oil. TLC: Rf=0.41
(Hexane/EtOAc, 3:1, Vanillin). 1H NMR (400 MHz,CDCl3): δ= δ 5.55-5.22 (m, 2H4.60- 4.43
(m, 1H), 3.51 (dd, J=16.3Hz, 5.8 Hz, 1H), 3.08 (dd, J=16.3Hz, 5.8 Hz, 1H), 2.19 q, J=7.3 Hz,
2H), 2.11- 1.89 (m, 3H), 1.40-1.23 (m, 6H), 0.88 (t, J= 6.9Hz, 3H).

13

C NMR (100 MHz,

CDCl3): δ= δ 168.33, 132.17, 127.10,70.89, 43.06, 34.84,31.64, 29.38, 27.34, 20.23, 14.19,
HRMS (ESI) calcd for C12H20O2 [M+H]+: 196.1463, found: 196.1460.

O

O

OH

C5H11

O
2.4

Compound 2.4 To a solution of diisopropylamine (2 mL, 14 mmol, 3.90eq.) in THF (10 mL)
was added at -78 oC n-bythyllithium (1.6M in hexane, 9 mL, 13.8 mmol, 3.77 eq) and the
mixture stirred for 15 min at -78 oC. Then at -78 oC a solution of methyl acetate (1 mL, 13.7
mmol 3.77 eq) in THF (5 mL) was added dropwise and the mixture stirred for another 20 min at
that temperature. A solution of lactone 2.3 (0.7g, 3.6 mmol, 1.00 eq) in THF (5 mL) was added
and the mixture kept stirring at -78 oC for 15 h. after consumption of the starting material the
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reaction was quenched with a saturated aqueous solution of NH4Cl (7 mL). The layers were
separated and the aqueous extracted with EtOAc (3 X 10 mL). The combined organic layers
were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. Purification by
flash column chromatography (SiO2, hexane/EtOAc, 10:1 to 3:1 gradient) gave the ketoester 2.4
(0.7g, 28.0 mmol, 74% yield) as a 14:1 mixture together with its tautomer as a pale yellow oil.
TLC: Rf=0.34 (hexane/EtOAc, 4:1, Vanillin). 1H NMR (400 MHz,CDCl3): δ= δ 12.15 (s, 1H),
5.46-5.26 (m, 2H), 4.09 (m, 1H), 4.02-3.93 (m, 2H), 3.74 (s, 3H), 3.70 (s, 2H), 3.64 (s, 1H), 3.49
(s, 2H), 2.75 (d, J=3.3Hz, 3H) 2.72- 2.64 (m, 2H), 2.63 (d, J=8.5Hz, 3H), 2.20- 2.08 (m, 2H),
2.03 (q, J=6.7 Hz, 2H), 1.66-1.51 (m, 1H), 1.40-1.23 (m, 7H), 0.88 (t, J= 6.9Hz, 3H). 13C NMR
(100 MHz, CDCl3): δ= δ 203.58, 175.75, 167.46, 131.20, 128.65, 90.99, 69.15, 52.60,51.39,
49.80, 43.01, 36.45, 31.64, 29.38, 27.34, 23.40, 22.72, 14.19, HRMS (ESI) calcd for C15H26O4
[M+Na]+: 293.1723, found: 293.1727
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Compound 2.5 To a solution of ketoester 2.4 (6.98 g, 25.8 mmol, 1.00 eq.) in MeCN (200
mL.) at 0 oC was added sequentially 4-acetamidobenzenesulfonyl azide (8.31g 33.6 mmol, 1.30
eq) and Et3N (7.26 mL, 5.16 mmol, 2.00 eq). The mixture was allowed to warm to room
temperature and stirred for 5.5 h. The reaction mixture became turbid druing that time and was
filtered through a plug of celite before it was concentrated in cacuo. The residue was taken up in
DCM (80 mL) and filtered again through a plug of celite. The solvent was removed in vacuo and
the residue purified by flash column chromatography (SiO2, hexane/ EtOAc, 7:1) to yield the
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diazo compound (7.39g, 24.8 mmol, 96%) as yellow oil. TLC: Rf=0.53 (hexane/EtOAc, 4:1,
Vanillin, UV). 1H NMR (400 MHz,CDCl3): δ= δ 5.41-5.26 (m, 2H), 4.11- 4.01 (m, 1H), 3.81 (s,
3H), 3.08- 2.97 (m, 2H), 2.90 (dd, J = 17.2Hz, 1H), 2.20- 2.08 (m, 2H), 2.00 (q, J=6.7 Hz, 2H),
1.64-1.41 (m, 2H), 1.36-1.18 (m, 6H), 0.85 (t, J= 6.9Hz, 3H). 13C NMR (100 MHz, CDCl3): δ= δ
192.87, 161.72, 130.88, 128.65, 67.71, 52.60, 46.90, 46.86, 36.45, 31.64, 29.38, 27.34, 23.40,
22.72, 14.19, HRMS (ESI) calcd for C15H24N2O4 [M+Na]+: 319.1634, found: 319.1628.
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Compound 2.6 To a solution of the diazo compound 2.5 (3.39g 11.4 mmol, 1.00 eq.) at 0 oC
was added imidazole (1.55g, 22.8 mmol, 2.00 eq.) and triethylchlorosilane (2.9 mL, 17.3 mmol,
1.51 eq.) The mixture was allowed to warm to room temperature and stirred for 3h. Then the
reaction mixture was diluted with Et2O (150 mL) and washed with water (400 mL). The organic
layer was dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash column
chromatography (SiO2, Hexane/EtOAc, 10:1) gave the TES-protected diazo compound 2.5 (4.0g,
11.18 mmol, 88%) as yellow oil. TLC: Rf=0.65 (hexane/EtOAc, 5:1, Vanillin, UV). 1H NMR
(400 MHz,CDCl3): δ= δ 5.401-5.30 (m, 2H), 4.31-4.20 (m, 1H), 3.83 (s, 3H), 3.15 (dd, J = 15.5,
7.2 Hz, 1H), 2.92 (dd, J =15.5Hz, 1H), 2.18- 1.97 (m, 4H), 1.61-1.48 (m, 2H), 1.39-1.18 (m, 6H),
0.99- 0.81 (m, 12H), 0.58 (q, J = 7.9 Hz, 6H).
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C NMR (100 MHz, CDCl3): δ= δ 191.03,

161.78, 130.56, 129.13, 68.88, 52.30, 47.42, 38.15, 31.69, 29.53, 27.34, 23.40, 22.72, 14.19,
6.99, 5.10 HRMS (ESI) calcd for C21H38N2O4 Si [M+Na]+: 433.2493, found: 433.2498.
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Compound 2.7 To a solution of Rh2(S-PTAD)4 (170 mg, 0.109 mmol, 0.01 eq) in DCM (200
mL) at reflux was added a solution of TES-protected diazo compound 2.6 (4.48g 10.9 mmol,
1.00 eq.) in DCM (30 mL.). The mixture was stirred at reflux for 20 min and then allowed to
cool to room temperature. The reaction mixture was concentrated in vacuo and purified by flash
column chromatography (SiO2, Hexane/Et2O, 10:1) to yield cyclic ketoester 2.7 (2.5g, 7.75
mmol, 59%) in a 9:1 mixture of diastereomers as yellow oil. TLC: Rf=0.29 (hexane/Et2O, 4:1,
Vanillin, UV). 1H NMR (400 MHz,CDCl3): δ= δ 12.24 (s, 1H), 5.58-5.25 (m, 2H), 4.45 (t, J=
3.8Hz, 1H), 3.71 (s, 3H), 3.64 (s, 3H), 3.15 (dd, J = 11.6Hz, 1H), 2.81-2.67 (m, 2H), 2.65-2.53
(m, 1H), 2.50 (dd, J= 18.0, 4.2 Hz, 1H), 2.44- 2.33 (m, 2H), 2.31- 2.18 (m, 1H), 2.01 (q, J= 7.0
Hz, 2H), 1.39-1.18 (m, 6H), 0.93 (t J = 7.9 Hz, 9H), 0.87 (t, J = 7.0 Hz, 3H), 0.59 (q, J = 7.8 Hz,
6H).

13

C NMR (100 MHz, CDCl3): δ= δ 210.20, 170.18, 132.28, , 126.17, 69.90, 57.71, 52.30,

49.46, 47.93, 31.69, 29.53, 27.34, 26.99, 22.72, 14.19, 6.99, 4.97. HRMS (ESI) calcd for
C21H38O4 Si [M+Na]+: 405.2432, found: 405.2438.
O
Si O

2-8

C5H11

Compound 2.8 A solution of cyclic β-ketoester 2.7 (2.69 g, 7.05 mmol, 1.00 equiv.) and
sodium chloride (12.36 g, 211 mmol, 30 equiv.) in degassed DMSO (100 mL) was immersed
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into an oil bath pre-heated to 140 oC and stirred for 30 min. Then the mixture was allowed to
cool to room temperature and diluted with water (900 mL). It was extracted with EtOAc (3 x 250
mL) and the combined organic layers were dried over MgSO4, filter and concentrated in vacuo.
Purification by flash column chromatography (SiO2, Hexane/EtOAc, 98:2) allowed the
separation of the cis-substituted cyclopentenone (1.49 g, 4.59 mmol, 65% yield). TLC: Rf= 0.71
(Hexane/EtOAc, 5:1, Vanillin). 1H NMR (400 MHz, CDCl3): δ= 5.51-5.28 (m, 2H), 4.49-4.35
(m, 1H), 2.43-1.92 (m, 9H), 1.43-1.18 (m, 6H), 0.95 (t J = 7.9 Hz, 9H), 0.89 (t, J = 7.0 Hz, 3H),
0.59 (q, J = 7.8 Hz, 6H).

13

C NMR (100 MHz, CDCl3): δ= δ 217.76, 132.28, , 126.17, 71.66,

49.46, 43.69, 41.17, 31.69, 29.53, 27.51, 27.49, 22.72, 14.19, 6.99, 4.97. HRMS (ESI) calcd for
C19H36O2 Si [M]+: 324.2485, found: 324.2483.

O

C5H11

2.9

Compound 2.9 To a solution of the cis-substituted cyclopentenone (1.21 g, 3.73 mmol, 1.00
equiv.) in CH2Cl2 (35 mL) at 0 oC was added 1,8-Diazabicyclo[5.4.0]undec-7-ene (5.60 mL, 37.2
mmol, 9.97 equiv.) and the mixture allowed to warm to room temperature. The layer was
separated and the aqueous was extracted with DCM (3 x 50 mL). The combined organic layers
were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. In order to
remove the residue silanol the mixture was azeotroped with toluene (5 x 15 mL). Purification by
flash column chromatography (SiO2, hexane/EtOAc, 7:1) gave cyclopentenone 2-8 (667 mg,
3.47 mmol, 93% yield) as a pale yellow oil. TLC: Rf= 0.52 (Hexane/EtOAc, 5:1, Vanillin, UV).
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1

H NMR (400 MHz,CDCl3): δ= 7.62 (dd, J=5.6, 2.5 Hz, 1H), 6.16 (dd, J=5.6, 2.0 Hz, 1H), 5.60-

5.26 (m, 1H), 3.04-2.96 (m, 1H), 2.51 (dd, J=18, 6.4 Hz, 1H), 2.39-2.11(m, 2H), 1.43-1.18 (m,
6H), 0.87 (t, J = 7.9 Hz, 3H. 13C NMR (100 MHz, CDCl3): δ= δ 209.98, 168.13, 134.19, 133.01,
125.17, 41.57, 40.65, 32.08, 31.62, 29.36, 27.51, 22.72, 14.19, HRMS (ESI) calcd for C13H20O
[M]+: 192.1509, found: 192.1508.

O

O
H

O
2.10

Compound 2.10 A solution of cyclopentene (10.34 mL, 113 mmol, 1.00 equiv.) and NaHCO3
(3.00 g, 35.7 mmol, 0.32 equiv.) in MeOH (46 mL) and DCM (225 mL) at -78 oC was ozonized
until a blue color persisted for 5 min. Then the solution was bubbled with N2 until the blue color
disappeared and allowed to warm to room temperature. Then the mixture was diluted with
benzene (150 mL) and concentrated to 65 mL. It was treated at 0 oC with Et3N (31.4 mL, 225
mmol, 2.00 equiv.) and Ac2O (21.28 mL, 225 mmol, 2.00 equiv.) for 1.5 h. The mixture was
washed with NaHCO3 and dried over Na2SO4, filtered and concentrated in vacuo to yield crude
aldehyde as colorless oil (11.64 g, 89.3 mmol, 79%). (7.09 g, 54.5 mmol, 1.00 equiv.) of the
crude product was added to a solution of 2-(triphenylphosphoranylidene) acetaldehyde (34.82 g,
114 mmol, 2.10 equiv.) in toluene (150 mL) and the mixture stirred at 70 oC for 12 h. Then it
was cooled to room temperature, poured onto petrol ether (300 mL) and stirred until a clear
yellow solution formed. It was filtered and the filtrate concentrated in vacuo. Purification by
flash column chromatography (SiO2, hexane/EtOAc, 3:1) gave the enal (4.67 g, 29.9 mmol, 55%
yield) as a pale yellow oil in a 5:1 E/Z mixture. TLC: Rf= 0.38 (Hexane/EtOAc, 3:1, Vanillin,
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UV). 1H NMR (400 MHz,CDCl3): δ= 9.50 (d, J = 7.8 Hz, 1H), 6.81 (dt, J = 15.3, 6.7 Hz, 1H),
6.12 (dd, J = 15.7, 7.8 Hz, 1H), 3.67 (s, 3H), 2.38 (dt, J = 14.0, 7.2 Hz, 4H), 1.85 (p, J = 7.4 Hz,
2H).13C NMR (100 MHz, CDCl3): δ= δ 193.94, 173.45,157.13, 133.63, 51.80, 33.26, 32.01,
23.12. HRMS (ESI) calcd for C8H12O3 [M+Na]+: 179.0679, found: 179.0685.
O

O

O

H

O
2.11

Compound 2.11 To a solution of enal 2.10 (1.9 g, 12.17 mmol, 1.00 equiv.) and (s)-2(diphenyl((trimethylsilyl)oy)methyl)-pyrrolidine (0.396 g, 1.217 mmol, 0.10 equiv.) in CH2Cl2 at
0 oC was added H2O2 (30% aqueous solution, 1.615 mL, 15.82 mmol, 1.30 equiv.) and the
mixture stirred at RT for 5 h. To the reaction mixture were added saturated aqueous solutions of
NaHCO3 and Na2S2O3 (1/1 (v/v), 30 mL) and the mixture stirred for 30 min. Then the layers
were separated and the aqueous extracted with CH2Cl2 (3 x 50 mL). The combined organic
layers were dried over MgSO4, filtered and concentrated in vacuo. Purification by flash column
chromatography (SiO2, CH2Cl2/MeOH 98:2) gave epoxy aldehyde 2.11 (1.07 g, 12.17 mmol, d.r.:
10:1, E/Z, 51% yield, 92% ee) as a colorless oil. TLC: Rf= 0.23 (Hexane/EtOAc, 5:1, Vanillin).
1

H NMR (400 MHz, CDCl3): δ= 9.00 (d, J = 6.2 Hz, 1H), 3.67 (s, 3H), 3.24 (ddd, J = 6.2, 4.3,

2.0 Hz), 3.14 (dd, J = 6.2, 2.0 Hz, 1H), 2.38 (dt, J = 14.0, 7.2 Hz, 2H), 1.88- 1.73 (m, 3H), 1.711.59 (m, 1H).

13

C NMR (100 MHz, CDCl3): δ= δ 198.25, 173.45, 58.96, 56.36, 51.80, 33.26,

30.67, 21.27. HRMS (ESI) calcd for C8H12O4 [M+Na]+: 195.0628, found: 195.0638.
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Compound 2.12 To a solution of LHMDS (503 mg, 3.01mmol, 1.20 equiv.) in THF (10 mL)
at -78 oC was added a solution of cyclopentenone 2.9 (482 mg, 2.50 mmol, 1.00 equiv.) in THF
(2 x 3 mL) and the mixture stirred for 30 min. Then a solution of epoxy aldehyde 2-10 (863 mg,
5.01 mmol, 2.00 equiv.) in THF (2 x 4 mL) was added and the mixture stirred at -78 oC for 1.5 h.
The reaction was quenched at -78 oC with a saturated, aqueous solution of NH4Cl (25 mL) and
the layers were separated. The aqueous layer was extracted with ether (3 x 40 mL) and the
combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated
in vacuo. The crude product and the co-spotting aldehyde X. without further purification the
mixture was dissolved in CH2Cl2 (20 mL) and treated at -78 oC with Et3N (2.1 mL, 15.05 mmol,
6.00 equiv.) and methanesulfonyl chloride (0.59 mL, 7.52 mmol, 10.00 equiv.). The mixture was
vigorously stirred at room temperature for 18 h and then filtered through a plug of celite. Then
the mixture was concentrated in vacuo and purified by flash column chromatography (SiO2,
hexane/EtOAc, 4:1 to 3:1 gradient) to give the dienone 2.12 (445 mg, 1.29 mmol, 64% yiled) as
a yellow oil. TLC: Rf= 0.58 (Hexane/EtOAc, 2:1, Vanillin, UV). 1H NMR (400 MHz,CDCl3): δ=
7.54 (ddd, J=6.0, 2.6, 0.9 Hz, 1H), 6.35 (dd, J=6.0, 1.8 Hz, 1H), 6.19 (dt, J = 8.2, 1.1 Hz, 1H),
5.60-5.45 (m, 1H), 5.41-5.26 (m, 1H), 3.65 (s, 3H,), 3.39 (dd, J = 8.2, 2.1 Hz, 1H), 2.99 (ddd, J =
6.4, 4.0, 2.1 Hz, 1H), 2.64-2.47 (m, 1H), 2.44-2.25 (m, 3H), 2.05-1.92 (m, 2H), 1.90-1.71 (m,
3H), 1.68- 1.49 (m, 2H), 1.43-1.18 (m, 6H), 0.87 (t, J = 7.9 Hz, 3H.

13

C NMR (100 MHz,

CDCl3): δ= δ 195.87, 173.59, 162.05, 141.24, 134.59, 133.52, 131.06, 124.53, 60.03, 55.05,
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51.78, 43.45, 33.59, 32.02, 31.67, 31.37, 29.34, 27.48, 22.69, 21.49, 14.20. HRMS (ESI) calcd
for C21H30O4 [M+Na]+: 369.2036, found: 369.2030.

O

O

O

OH
C5H11
EC

EC. To a solution of methyl ester 2.12 (80 mg, 0.231 mmol, 1.00 equiv.) in THF (1 mL) and
aqueous phosphate buffer pH 7 (4 mL) at room temperature was added Novozyme (30 mg) and
the mixture stirred for 1h. The mixture was filtered through a plug of cotton and the filtrate
treated with EtOAc (10 mL). The layers were separated and the pH of the aqueous layer was
carefully adjusted to pH 5 using 0.1 M HCl. Then the aqueous layer was extracted with EtOAc
(3 x 10 mL) and the combined organic layers were dried over Na2SO4, filtered and concentrated
in vacuo. Purification by flash column chromatography (SiO2, hexane/EtOAc/MeOH, 4:1:1) gave
EC (54 mg, 0.162 mmol, 70% yield) as a pale yellow oil. TLC: Rf= 0.4(Hexane/EtOAc/MeOH,
4:1:1, Vanillin, UV). 1H NMR (400 MHz,CDCl3): δ= 7.54 (ddd, J=6.0, 2.6, 0.9 Hz, 1H), 6.35
(dd, J=6.0, 1.8 Hz, 1H), 6.19 (dt, J = 8.2, 1.1 Hz, 1H), 5.60-5.45 (m, 1H), 5.41-5.26 (m, 1H),
3.69-3.64 (m, 1H), 3.39 (dd, J = 8.2, 2.1 Hz, 1H), 3.01- 2.98 (m, 1H), 2.64-2.47 (m, 1H), 2.45 (t,
J = 6.0 Hz, 2H), 2.32 (dt, J = 15.2, 8.3 Hz, 1H), 1.98 (q, J = 7.2 Hz, 2H), 1.90-1.71 (m, 3H),
1.68- 1.49 (m, 1H), 1.43-1.18 (m, 6H), 0.87 (t, J = 7.9 Hz, 3H. 13C NMR (100 MHz, CDCl3): δ=
δ 195.87, 177.41, 162.05, 141.24, 134.59, 133.52, 131.06, 124.53, 60.03, 55.05, 43.45, 33.59,
32.02, 31.67, 31.37, 29.34, 27.48, 22.69, 21.49, 14.20. HRMS (ESI) calcd for C20H28O4 [M-H]-:
331.1910, found: 331.1910.
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PECPC To a solution of EC (17.9 mg, 0.052 mmol, 1.00 equiv.) in CHCl3 (2.5 mL) at room
temperature was added 2,4,6-trichlorobenzoyl chloride (84 μL, 0.538 mmol, 10.0 equiv.), N,Ndimethyl-4-aminopydridine (66 mg, 0.54 mmol, 10.0 equiv.) and lyso-PC (80 mg, 0.162 mmol,
3.00 equiv.) and the mixture stirred at room temperature for 3 h. The reaction mixture was
concentrated in vacuo and purified by flash column chromatography (SiO2, DCM/MeOH/H2O,
80:20:0 to 80:18:2 gradient) to give PECPC (30 mg, 0.037 mmol, 69% yield) as a pale yellow oil.
TLC: Rf=0.16(MeOH, Vanillin, UV). 1H NMR (400 MHz,CDCl3): δ= 7.54 (dd, J=6.0, 2.6, 0.9
Hz, 1H), 6.35 (dd, J=6.0, 1.8 Hz, 1H), 6.14 (dt, J = 8.2, 1.1 Hz, 1H), 5.60-5.45 (m, 1H), 5.415.26 (m, 1H), 5,24 – 5.15 (m, 1H), 4.44 -4.26 (m, 3H), 4.12 (dd, J = 12.0, 7.0 Hz, 1H), 3.99- 3.91
(m, 2H), 3.80 (s, 3H), 3.69-3.64 (m, 1H), 3.35 (d, J = 10.1 Hz, 10H), 3.01- 2.98 (m, 1H), 2.51
(dd, J = 13.4, 6.5 Hz, 1H), 2.42- 2.21 (m, 6H), 2.00- 1.90 (m, 2H), 1.79 (s, 2H), 1.68- 1.49 (m,
3H), 1.23 (s, 30H), 0.87 (t, J = 7.9 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ= δ 195.87, 173.64,
172.48, 162.05, 141.24, 134.59, 133.52, 131.06, 128.22, 124.53, 71.15, 71.07, 66.60, 63.00,
55.05, 54.62, 43.45, 34.04, 33.81, 32.02, 31.67, 31.37, 29.34, 29.78, 29.66, 29.63, 29.48, 29.45,
29.42, 29.30, 27.48, 25.00,22.81, 22.69, 21.49, 14.20, 14.18. HRMS (ESI) calcd for
C44H76NO10P [M+Na]+: 832.5099, found: 832.5111.
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O
C5H11
Cl
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Compound 2.14 To a solution of 2.9 (1.92g, 10 mmol) in dry DMF (20 mL), m-CPBA (2.0g,
12 mmol) was added at 0 oC. The mixture was allowed to stir for 30 min at the same temperature.
6.6 M HCl/DMF solution (20 mL) was added slowly and the mixture was allowed to stir for
another 1 hour. After the temperature reached to room temperature, Na2SO3 solution was used to
quench the reaction. 40 mL of EtOAc was added and the mixture was transferred to a separated
funnel. The aqueous phase was extracted with EtOAc 20 mL × 3 and the combined organic
layers were dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash column
chromatography (SiO2, hexane/EtOAc, 6:1) gave 2.14 (1.4 g, 6.3 mmol, 63%) as a pale yellow
oil. 1H NMR (400 MHz,CDCl3): δ= 7.62 (dd, J=5.6, 2.5 Hz, 1H), 5.60-5.26 (m, 1H), 3.04-2.96
(m, 1H), 2.51 (dd, J=18, 6.4 Hz, 1H), 2.39-2.11(m, 2H), 1.43-1.18 (m, 6H), 0.87 (t, J = 7.9 Hz,
3H.

13

C NMR (100 MHz, CDCl3): δ= δ 193.25, 142.33, 134.19, 132.11, 125.17, 41.57, 40.65,

32.08, 31.62, 29.36, 27.51, 22.72, 14.19, HRMS (ESI) calcd for C13H19ClO [M]+: 227.1124,
found: 227.1532.
O
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Compound 2.15 To a solution of LHMDS (503 mg, 3.01mmol, 1.20 equiv.) in THF (10 mL)
at -78 oC was added a solution of cyclopentenone 2.14 (565 mg, 2.50 mmol, 1.00 equiv.) in THF
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(2 x 3 mL) and the mixture stirred for 30 min. Then a solution of epoxy aldehyde 2.10 (863 mg,
5.01 mmol, 2.00 equiv.) in THF (2 x 4 mL) was added and the mixture stirred at -78 oC for 1.5 h.
The reaction was quenched at -78 oC with a saturated, aqueous solution of NH4Cl (25 mL) and
the layers were separated. The aqueous layer was extracted with ether (3 x 40 mL) and the
combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated
in vacuo. The crude product and the co-spotting aldehyde X. without further purification the
mixture was dissolved in CH2Cl2 (20 mL) and treated at -78 oC with Et3N (2.1 mL, 15.05 mmol,
6.00 equiv.) and methanesulfonyl chloride (0.59 mL, 7.52 mmol, 10.00 equiv.). The mixture was
vigorously stirred at room temperature for 18 h and then filtered through a plug of celite. Then
the mixture was concentrated in vacuo and purified by flash column chromatography (SiO2,
hexane/EtOAc, 3:1) to give the dienone 2.15 (566 mg, 1.52 mmol, 61% yield) as a yellow oil.
TLC: Rf= 0.51 (Hexane/EtOAc, 2:1, Vanillin, UV). 1H NMR (400 MHz,CDCl3): δ= 7.54 (dd,
J=6.0, 2.6, 0.9 Hz, 1H), 6.19 (dt, J = 8.2, 1.1 Hz, 1H), 5.60-5.45 (m, 1H), 5.41-5.26 (m, 1H), 3.65
(s, 3H,), 3.39 (dd, J = 8.2, 2.1 Hz, 1H), 2.99 (ddd, J = 6.4, 4.0, 2.1 Hz, 1H), 2.64-2.47 (m, 1H),
2.44-2.25 (m, 3H), 2.05-1.92 (m, 2H), 1.90-1.71 (m, 3H), 1.68- 1.49 (m, 2H), 1.43-1.18 (m, 6H),
0.87 (t, J = 7.9 Hz, 3H).

13

C NMR (100 MHz, CDCl3): δ= δ 185.27, 173.59, 162.05, 145.34,

134.59, 133.52, 131.06, 124.53, 60.03, 55.05, 51.78, 43.45, 33.59, 32.02, 31.67, 31.37, 29.34,
27.48, 22.69, 21.49, 14.20. HRMS (ESI) calcd for C21H29ClO4 [M+Na]+: 403.1754, found:
403.2030.
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Compound 2.13 To a solution of methyl ester 2.15 (88 mg, 0.231 mmol, 1.00 equiv.) in THF
(1 mL) and aqueous phosphate buffer pH 7 (4 mL) at room temperature was added Novozyme
(30 mg) and the mixture stirred for 1h. The mixture was filtered through a plug of cotton and the
filtrate treated with EtOAc (10 mL). The layers were separated and the pH of the aqueous layer
was carefully adjusted to pH 5 using 0.1 M HCl. Then the aqueous layer was extracted with
EtOAc (3 x 10 mL) and the combined organic layers were dried over Na2SO4, filtered and
concentrated in vacuo. Purification by flash column chromatography(SiO2, hexane/EtOAc/MeOH,
4:1:1) gave Chloro-EC (40 mg, 0.162 mmol, 68% yield) as a pale yellow oil. TLC: Rf= 0.38
(Hexane/EtOAc/MeOH, 4:1:1, Vanillin, UV). 1H NMR (400 MHz,CDCl3): δ= 7.54 (dd, J=6.0,
2.6, 0.9 Hz, 1H), 6.19 (dt, J = 8.2, 1.1 Hz, 1H), 5.60-5.45 (m, 1H), 5.41-5.26 (m, 1H), 3.69-3.64
(m, 1H), 3.39 (dd, J = 8.2, 2.1 Hz, 1H), 3.01- 2.98 (m, 1H), 2.64-2.47 (m, 1H), 2.45 (t, J = 6.0
Hz, 2H), 2.32 (dt, J = 15.2, 8.3 Hz, 1H), 1.98 (q, J = 7.2 Hz, 2H), 1.90-1.71 (m, 3H), 1.68- 1.49
(m, 1H), 1.43-1.18 (m, 6H), 0.87 (t, J = 7.9 Hz, 3H. 13C NMR (100 MHz, CDCl3): δ= δ 187.27,
177.41, 162.05, 141.24, 134.59, 133.52, 131.06, 124.53, 60.03, 55.05, 43.45, 33.59, 32.02, 31.67,
31.37, 29.34, 27.48, 22.69, 21.49, 14.20. HRMS (ESI) calcd for C20H27O4Cl [M-H]-: 365.1598,
found: 365.1621.
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Compound 2.16 To a solution of Compound 1.12 (2.62 g, 10 mmol, 1.0 eq) in 50 mL of DCM,
Biotin.OSu.X (4.5g, 10 mmol, 1.0 eq) and TEA (1.5g, 15 mmol, 1.5 eq). The mixture was
allowed to stir for 2 hours at room temperature. 40 mL of DI water was added to quench the
reaction and the mixture was transferred to a separate funnel. The aqueous phase was extracted
with DCM (30 mL × 3). The combined organic layer was dried over Na2SO4 and concentrated in
vacuo. Purification by flash column chromatogra-phy gave compound 2.16 (5.4g, 9 mmol, 90%
yield). 1H NMR (400 MHz, CDCl3): δ= 4.4-4.8 (m, 4H), 3.2-3.7 (m, 19H), 2.8-3.2 (m, 2H), 2.24
(m, 4H), 1.3-1.7 (m, 12H) 1.2 (m, 2H). 13C NMR (100 MHz, CDCl3): δ= δ 174.5, 173.4, 164.3,
71.2, 70.8, 70.2, 63.8, 62.6, 55.6, 48.4, 41.3, 41.0, 38.9, 37.1, 36.5, 29.3, 28.4, 25.7, 25.2, 25.1,
24.4. HRMS (ESI) calcd for C26H47N7O7S [M+H]+: 602.3258, found: 602.3803.
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Compound 2.17 To a solution of Compound 2.16 (5.4 g, 9 mmol, 1.0 eq) in 50 mL of THF
and MeOH (v/v=1:1), 5 mL of AcOH and 5g of Zn were added respectively. The mixture was
sonicated at room temperature for 1 hour. The organic solvent was removed in high vacuo and
50 mL of saturated NaHCO3 was added to the residue. The aqueous phase was extracted with
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DCM (50 mL × 3) and the combined organic layer was dried over Na2SO4 and concentrated in
high vacuum. Purification by flash column chromatography gave compound 2.17 (4.5g, 7.8
mmol, 88% yield) as a white solid. 1H NMR (400 MHz, CDCl3): δ= 4.4-4.8 (m, 4H), 3.2-3.7 (m,
19H), 2.8-3.2 (m, 4H), 2.24 (m, 4H), 1.3-1.7 (m, 10H) 1.2 (m, 2H).

13

C NMR (100 MHz,

CDCl3): δ= δ 174.5, 173.4, 164.3, 71.2, 70.8, 70.2, 63.8, 62.6, 55.6, 41.8, 41.3, 41.0, 38.9, 37.1,
36.5, 29.3, 28.4, 25.7, 25.2, 25.1, 24.4. HRMS (ESI) calcd for C26H49N5O7S [M+H]+: 576.3353,
found: 576.3521.
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Compound EC-Biotin.X To a solution of EC (0.32 g, 1 mmol, 1.0 eq) in 10 mL of DCM,
EDC (0.23g, 1.2 mmol, 1.2 eq) and HOBt (0.22g, 1.2 mmol, 1.2 eq) were added. The mixture
was allowed to stir for 1 hour at room temperature. The amine 2.17 (0.57g, 1.0 mmol, 1.0 eq)
was added in 5 mL of DCM. The reaction was stirred overnight at room temperature. 15 mL of
DI water was added and the aqueous layer was extracted with DCM (10 mL × 3). The combined
organic layer was wash with 20 mL of brine, dried over Na2SO4 and concentrated in high
vacuum. Purification by flash column chromatography gave EC-Biotin.X (0.79g, 92% yield) as a
white solid. 1H NMR (400 MHz,CDCl3): δ= 7.54 (ddd, J=6.0, 2.6, 0.9 Hz, 1H), 6.35 (dd, J=6.0,
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1.8 Hz, 1H), 6.19 (dt, J = 8.2, 1.1 Hz, 1H), 5.60-5.45 (m, 1H), 5.41-5.26 (m, 1H), 4.4-4.8 (m,
4H), 3.2-3.7 (m, 20H), 3.39 (dd, J = 8.2, 2.1 Hz, 1H), 2.8-3.2 (m, 6H), 2.45 (t, J = 6.0 Hz, 2H),
2.32 (dt, J = 15.2, 8.3 Hz, 1H), 2.24 (m, 4H), 1.98 (q, J = 7.2 Hz, 2H), 1.90-1.71 (m, 3H), 1.3-1.7
(m, 17H) 1.2 (m, 2H), 0.87 (t, J = 7.9 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ= δ 195.87, 174.5,
173.4, 172.41, 164.3, 162.05, 141.24, 134.59, 133.52, 131.06, 124.53, 71.2, 70.8, 70.2, 63.8,
62.6, 60.03, 55.6, 55.05, 43.45, 41.8, 41.3, 41.0, 38.9, 37.1, 36.5, 33.59, 32.02, 31.67, 31.37,
29.34, 29.3, 28.4, 27.48, 25.7, 25.2, 25.1, 24.4, 22.69, 21.49, 14.20. HRMS (ESI) calcd for
C46H75N5O10S [M+H]+: 890.5235, found: 890.5632.
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Chapter 3
Modification and Synthesis of Derivatives of Ribityllumazines: Potential Antigens
for Activation of MAIT Cells
3.1 Introduction
3.1.1 Mucosal-Associated Invariant T (MAIT) Cells
Mucosal-Associated Invariant T (MAIT) Cells, a subset of homogenous T cell, were first
found in 1999 by Tilloy et al.1 They are unique innate-like T cells, that are surprisingly abundant
in human beings, up to 10% of the total circulating T cells, and are distributed throughout blood,
mesenteric lymph nodes, and gastrointestinal mucosa.2 In humans, MAIT cells consist of a semivariant T cell receptor (TCR) α-chain, Vα7.2 (TRAV1-2), joined to Jα33 (TRAJ33), paired with
a limited array of TCR β-chains (predominantly Vβ2 or Vβ13, i.e. TRBV6 or TRBV20) and are
activated by means of their αβ T-cell antigen receptors.1 MAIT cells express the semi-invariant
T cell receptor and are restricted by the evolutionarily conserved major histocompatibility
complex (MHC) related protein 1, MR1, which is ubiquitously expressed in human cells and a
necessity for in vivo development.1-6 Interestingly, MR1 alone can’t activate MAIT cells; it
needs the cooperation of a critical ligand--vitamin B metabolites--to achieve the activation,
which will be discussed in detail in the following section.7-11
Different from conventional T cells, MAIT cells have the innate ability to detect and respond
to infections.11, 12The roles of MAIT cells in human health and disease are not clear, but they
have been shown to have unique antibacterial function and phenotype. MAIT cells play a key
role in host defense against bacterial and fungal infection as well as in human autoimmune
diseases such as inflammatory bowel disease (IBD), multiple sclerosis (MS), systemic lupus
erythematosus, and also cancer.

3,4,13-21

For example, Sugimoto et al. demonstrated that
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populations of MAIT cells from fibromyalgia patients were lower than that of healthy donors,
which implies analysis of MAIT cells may provide a more objective standard for the diagnosis of
fibromyalgia syndrome and other related diseases, including rheumatoid arthritis and
spondyloarthritis.20 Serriari et al. illustrated that MAIT cells are activated in patients with
inflammatory bowel diseases (IBD) and accumulated in the inflamed mucosa, which suggests
MAIT cells are immune players in IBD and helpful to the understanding of IBD
pathophysiology.15 Miyazaki et al. explored the character of MAIT cells in multiple sclerosis
(MS) patients and suggested MAIT cells may have a disease-suppressive role and regulate the
immune system to prevent MS.14 Meierovics et al. utilized a murine model of pulmonary
infection to investigate the kinetics and function of murine MAIT cell responses in the lungs in
vivo and found MAIT cells can initiate mucosal immunity in early phases but also contribute to
pulmonary immune responses in the later phases of infection.22
3.1.2 Activation of MAIT Cells
Previous studies have demonstrated that there are two pathways for the activation of MAIT
cells, as shown in Figure 3.1. One is TCR-dependent activation, and the other is TCRindependent cytokine activation.

3, 23-26

In the TCR-independent situation, MAIT cells are

triggered by cytokines produced by infected cells, including interleukin-12 (IL-12), IL-15, IL-18
and IL-7, as well as release of anti-bacterial effector molecules, including cytokines and cytolytic
products.24 In the TCR-dependent situation, the MAIT cells are activated through T-cell receptor
αβ chain (TCR-αβ) binding with the MR1-ligand, which is vitamin B metabolites presented on
MR1. The MAIT/T Cell then may produce cytokines and cytolytic products that are related to
the regulation of inflammation or result in local proliferation and apoptosis which may result in
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shaping the TCR repertoire.25The primary challenge is the identification of the MR1-restricted
antigens and recent research points to the characterization of these special kinds of antigens.

Figure 3.1 Mucosal-associated invariant T (MAIT) cell activation pathways with infected cells surroundings. (1)
TCR-dependent MAIT cell activation (2) TCR-independent MAIT cell activation (Adapted from reference [26])

Godfrey et al. elucidated that MAIT cells are activated by a wide range of microorganisms,
including diverse strains of bacteria and some yeast species, which all contain the riboflavin
(vitamin B2) synthetic pathway. Conversely, MAIT cells are not activated by S. pyogenes or E.
faecalis, which lack the riboflavin synthetic pathway.29 Kjer-Nielsen et al. identified the ligands
that bind MR1 and confirmed these ligands are responsible for the response of MAIT cells to a
wide range of bacteria.8 They observed 6-formyl pterin (6-FP), a vitamin B9 metabolite, bound
to MR1 and stabilized this molecule, but were unable to stimulate the MAIT cells. Considering
the culture supernatant S. typhimurium could activate MAIT cells, the ligand herein should have
the ability to activate MAIT cells. They analyzed and confirmed this kind of ligand should be
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reduced to 6-hydroxymethyl-8-D-ribityllumazine (rRL-6-CH2OH), a metabolic by-product of
riboflavin (vitamin B2) metabolism. Furthermore, they synthesized compounds derived from
riboflavin metabolism, 7-hydroxy-6-methyl-8-d-ribityllumazine (RL-6-Me-7-OH) and 6, 7dimethyl-8-d-ribityllumazine (RL-6,7-diMe) and found these compounds could also stimulate
primary MAIT cells in MRI-dependent manners. These findings are consistent with the results
illustrated in previous studies3, 4 -the riboflavin synthesis pathway is a key point in the activation
of MAIT cells.8
Sakala et al. further utilized MR1/ribityllumazine (RL, bacterial vitamin B2 metabolites)
tetramers to stimulate mouse MAIT cells and investigated the importance of the subsets of MAIT
cells in antimycobacterial immunity and the mechanisms of how MAIT cells provided early
protection against mycobacterial infection.27
Corbett et al. illustrated the early unstable intermediates in bacterial riboflavin synthesis, 5-(2oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU) and 5-(2-oxopropylideneamino)-6-Dribitylaminouracil (5-OP-RU), and gave identical results in the activation of MAIT cells as rRL6-CH2OH. These unstable intermediates can undergo dehydration upon ring closure to convert to
stable, isolatable lumazines, including RL-6,7-diMe, which have been verified to activate MAIT
cells.28
3.1.3 MR1–Antigen Structures
Which kinds of small molecules can work as ligands for MR1? Among these ligands, what is
the real MR1-restricted antigen in living organisms? To explore these questions, let us begin
with some deep insight into MR1 and its ligands.
The overall structure of human MR1 adopts a standard binary MHC-I fold, shown in Figure
3.2, and comprises of a α1-α2 cleft and a α3 sheet, both non-covalently associated with the
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β2microglobulin (β2m) subunit. The α1-α2 cleft in fact contains two long α-helices at the top of
the β2m (structurally similar to the HLA-A2 and CD1d) and is proven to be the MR1 antigenbinding center. The MR1 still has its unique characteristics, and its central cleft is not suited to
accept the peptide- or lipid-based antigens like HLA-A2 or CD1d. There are some morphological
features of MR1 that may be explanations for this particular pheromone, shown in Figure 3.3.
Firstly, the α1-α2 central cavity of MR1 is about 760Å3-much smaller than that of classical
MHC-I molecules. This suggests bigger lipid-like ligands are not fit for the MR1 cavity.
Secondly, different from that of HLA-A2 or CD1d, MR1 contains both basic (arginine and lysine)
and hydrophobic (aromatic residues in tryptophan, tyrosine and phenylalanine) residues, and is
mostly solvent exposed, while the HLA-A2 is mostly polar and solvent exposed, which is the
primary reason that it is suited for binding peptides. Furthermore, the CD1d cleft is hydrophobic
and shielded from solvent. Thirdly, the end of the MR1 cavity doesn’t have a small opening
portal and is mostly closed because of a large number of bulky side chains occupied in/by the
cleft.
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Figure 3.2 Overview of the crystal structure of MR1–antigen complex. a, Structure of MR1. b, Overlay of the α1
and α2 helices using the residues within the antigen-binding cleft of MR1 with HFE (left), MHC-I (middle, HLA-A2)
and CD1d (right). MR1 is in cyan; HFE is in yellow; MHC-I is in red; CD1d is in magenta. Adapted from
reference[8].

Figure 3.3 Comparison of MR1, MHC-I and MHC-I-like binding clefts. Adapted from reference[8]. a, Electrostatic
surface of MR1, HLA-A2 and CD1d antigen-binding clefts. Peptide, green; lipid, cyan. A’ and F’ are binding
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pockets within CD1d. b, Side (left) and top (right) views of MR1–6-FP and CD1d–α-galactosylceramide. c, Left,
peptide interaction with HLA-A2 residues; right, corresponding MR1 residues. Six pockets (A–F) of MHC-I,
colored in orange, red, cyan, green, magenta and brown, respectively; peptide is in green. The surface in b and c is
transparent to show 6-FP binding. d, Top (left) and side (right) views of MR1–6-FP. MR1 residues that contact 6-FP
are in yellow. H-bond and van der Waals interactions are shown in black- and red-dashed lines, respectively. MR1 is
in cyan; 6-FP is in magenta.

Considering the aromatic and basic residues, the MR1-antigen cavity should have one overall
basic charge. Considering its smaller size, the ligands fit for this special cavity should be small
molecules with polar residues and potentially negative charge. As mentioned in the previous
papers, 6-FP, RL-6,7-diMe, RL-6-Me-7-OH, rRL-6-CH2OH all meet these requirements and
present a structural scaffold for binding of MR1, shown in Figure 3.4.
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Figure 3.4 Structures of 6-FP, RL-6,7-diMe, RL-6-Me-7-OH, rRL-6-CH2OH

3.1.4 Synthesis of Ligands of MR1
To better understand the functions of MAIT cells in human beings, organic synthesis of
antigens that align with MR1 to stimulate MAIT cells is an essential assistance to facilitate
further research.
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The antigens for MR1 have been proved to be related to the riboflavin-based metabolites and
are ribityllumazine derivatives. The synthesis of these potential antigens has been carried out in
some previous papers. Plaut, E. et al. focused on the synthesis of substituted lumazines and
demonstrated how to use 4-chlorouracil to easily prepare lumazines.30-32
3.2 Synthesis of Ligands of MR1
To better understand the functions of MAIT cells in human beings, organic synthesis of
antigens that aligned with MR1 to stimulate MAIT cells is an essential assistance to facilitate the
further research.
The antigens for the MR1 have been proved to being related with the riboflavin-based
metabolites and are the ribityllumazine derivatives. The synthesis of these potential antigens has
been carried out in some previous papers. Plaut, G. W. E. et al. focused on the synthesis of
substituted lumazines and demonstrated how to use 4-chlorouracil to easily prepare lumazines.3032

In our study, synthesis of derivatives of ribityllumazine was first to investigate. We selected
RL-6,7-DiMe (Structure shown in Figure 3.4) as our synthetic target product and proposed one
synthetic route for RL-6,7-DiMe and ribityllumazine (See Scheme3.1 ).
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Scheme 3.1 Proposed synthetic pathway for RL-6,7-DiMe and ribityllumazines

Reagents: a) Hydroxylamine hydrochloride, NaOMe. 64.4% yield. b) PtO2, AcOH, MeOH,
H2/ 50 PSI. 59.5% yield. c) 4-chloropyrimidine-2,4(1H,3H)-dione, H2O, Refluxing. 56% yield. d)
Sodium nitrite, 50 oC. 65% yield. e) KOH, Sodium hydrosulfite, H2O. 61% yield. f). pyruvic acid
sodium slat, HCl, H2O. 22.6% yield. g) Sodium hydrosulfite, PBS. 31.6% yield.

D-(-) Ribose was used as starting material, treated with hydroxylamine in presence of NaOMe
to afford compound 3-1. Catalytic hydrogenation reduction of compound 3-1 using PtO2 gave
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the corresponding amine 3-2, which coupled with 4-chloropyrimidine-2,4(1H,3H)-dione in
presence of boiling water to provide compound 3-3. Oxidation by Sodium nitrite in presence of
acidic solution gave compound 3-4, which underwent a reduction by Sodium hydrosulfite under
basic condition to form the amine 3-5. The key step in the whole synthetic strategy was
conducted through coupling compound 3-5 with pyruvic acid to provide the important the
compound 3-6. Rearrangement of 3-6 using Sodium hydrosulfite in the PBS solution gave the
target compound 3-7.
3.3 Results
Two target compounds 3.7 and 3.6 (RL-6,7-DiMe) were sent for investigation of their
bioactivities.
3.4 Collusions
Since we successfully synthesized two compounds using our proposed pattern, further
synthesis of ribityllumazine derivatives can be accessed. Once we have results of bioactivities of
compound 3.7 and 3.6, further synthesis and modification will be employed.
3.5 Experiment Section
General: Reagents were purchased from Aldrich Chemical Co. unless otherwise noted.
Methylene chloride, THF, DMF, pyridine, and DMSO were dried by passage through a Glass
Contour solvent drying system containing a cylinder of activated alumina. Silica gel was used for
chromatography unless otherwise noted.
Instrumentation: 1H and 13C NMR spectra were recorded on a Varian Gemini 500 (500 MHz)
spectrometer. Proton chemical shift were referenced to tretramethylsilane (TMS). Carbon
chemical shifts were referenced to carbon resonance of solvents (CDCl3, CD3OD). High
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resolution electron impact mass spectra (HR-MS) were obtained on a JOEL SX 102A
spectrometer.

OH
HO

OH

HO
N

OH

3-1

Compound 3.1 Hydroxylamine hydrochloride (5.90 g, 84.9 mmol, 2.34 equiv.) was dissolved in
MeOH (dry, 40 mL) and stirred at room temperature. 2 drops of phenolphthalein (1%, solution in
EtOH) was added to mixture. Then a solution of NaOMe (4.75 g, 88 mmol, 2.45 equiv.) in
MeOH (40 mL) was added slowly to the suspension, upon with a white precipitate formed.
When the reaction stayed pink for 1 min, addition of base (NaOMe) was halted. The mixture was
stirred for several mins and filtered to remove slats. The filtrate was transferred to a round
bottom flask (250 mL) and warmed to 70 oC. Then D-(-) Ribose (5.45g, 36.3 mmol, 1.00 equiv.)
was added to reaction in small portions. The mixture was allowed to stir at 70 oC until the sugar
had completely dissolved (5-10 min) and cooled down to room temperature. The product 3-1
(3.86 g, 23.4 mmol, 64.4%) was precipitated from solution after keeping the mixture at fridge
overnight. TLC: Rf=0.38 (CHCl3/MeOH/NH4.OH 12:9:4, CAM). 1H NMR (400 MHz, D2O): δ=
7.45 (m, 1H), 6.86 (m, 1H), 5.08 (m, 1H), 4.42 (m, 1H), 3.81-3.65 (m, 6H), 3.64-3.61 (m, 2H)
13

C NMR (100 MHz, CDCl3): δ= δ 153.2, 152.8, 74.6, 74.3, 73.1, 72.7, 71.1, 67.3, 64.4, 64.1.

HRMS (ESI) calcd for C5H11NO5 [M+Na]+: 188.0637, found: 188.0548.
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Comound 3.2 The compound 3-1 (2.86g, 17.3 mmol, 1.00 equiv.) was diluted with glacial
AcOH (10 mL) and MeOH (10 mL), and PtO2 (100mg) was added. The mixture was
hydrogenated with shaking on a parr apparatus at 50 PSI for 36h at room temperature. The
mixture was then filtered to remove the catalyst. The filtrate was concentrated in vacuo and
purified by flash column chromatography (SiO2, CHCl3/MeOH/NH4.OH 12:9:4) to give the
white sold compound 3-2 (1.56g, 10.3 mmol, 59.5%).TLC: Rf=0.18 (CHCl3/MeOH/NH4.OH
12:9:4, CAM). 1H NMR (400 MHz, D2O): δ= 3.70-3.65 (m, 2H), 3.58 (m, 1H), 3.45 (m, 1H),
3.41 (m, 1H), 2.72 (m, 1H), 2.64 (m, 1H)

13

C NMR (100 MHz, CDCl3): δ= δ 73.2, 72.4, 72.0,

63.1, 42.1. HRMS (ESI) calcd for C5H13NO4 [M+H]+: 152.0845, found: 152.0923.
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Compound 3.3 6-D-Ribitylaminopyrimidine-2,4(1H,3H)-dione compound 3-3 was prepared by
a modification of the method of Maley and Plaut as follows. To a solution of D-ribitylamine
(1.56g, 10.3 mmol, 1.00 equiv.) in 25 mL DI water,4-chloropyrimidine -2,4(1H,3H)-dione (1.5g,
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5.6 mmol, 0.5 equiv) was added. The reaction was allowed to reflux for 12 h with stirring. Then
the mixture was cooled to room temperature and poured into 150 mL MeOH with stirring. After
being allowed to stand in fridge overnight, the precipitate was collected, dried, and recystallised
from acetic acid-ethnaol (4:1) to give the target compound 3-3 as colourless crystals (810mg, 3.1
mmol, 56%). TLC: Rf=0.32 (CHCl3/MeOH/NH4.OH 12:9:4, CAM, UV). 1H NMR (400 MHz,
D2O): δ= 5.52 (s, 1H), 3.70-3.65 (m, 2H), 3.58 (m, 1H), 3.45 (m, 1H), 3.41 (m, 1H), 2.72 (m,
1H), 2.64 (m, 1H) 13C NMR (100 MHz, CDCl3): δ= δ 175.2, 170.2, 162.3, 98.1, 73.2, 72.4, 72.0,
63.1, 42.3. HRMS (ESI) calcd for C9H15N3O6 [M+H]+: 262.0961, found: 262.1011.
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Compound 3.4 To a solution of compound 3-3 (458 mg, 1.75 mmol, 1.00 equiv.) in 5 mL DI
water, sodium nitrite (360 mg, 5.26 mmol, 3.00 equiv) was added. The mixture was adjusted to
pH 4.3 with several drops of Acetic acid slowly, and was allowed to warm at 50 oC for 30 min.
The reaction was allowed to cool down to room temperature and dry off the solvent in high
vacuum. Purification by flash column chromatography (SiO2, CHCl3/MeOH/NH4.OH 12:9:4) to
give the target product 3-4 (189 mg, 65% yield) as a red sold. TLC: Rf=0.28
(CHCl3/MeOH/NH4.OH 12:9:4, CAM, UV). 1H NMR (400 MHz, D2O): δ= 3.70-3.65 (m, 2H),
3.58 (m, 1H), 3.45 (m, 1H), 3.41 (m, 1H), 2.72 (m, 1H), 2.64 (m, 1H)
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13

C NMR (100 MHz,

CDCl3): δ= δ 165.6, 140.8, 140.3, 78.5, 73.2, 72.4, 72.0, 63.1, 42.1. HRMS (ESI) calcd for
C9H14N4O7 [M+H]+: 291.0862, found: 292.0921.
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Compound 3.5 To a solution of compound 3-4 (100 mg, 0.344 mmol, 1.0 equiv.) in 4 mL DI
water with stirring, was adjusted to pH 5.8 by the addition a few drops of 2N KOH solution and
heated on a boiling oil bath. To the hot reaction, sodium hydrosulfite (200 mg, 1.2 mmol, 3.5
equiv) was added. The clear red solution turned pale yellow within 5 min. The mixture was
allowed to cool down to room temperature and dry off water by high vacuum. Purification by
flash column chromatography (SiO2, CHCl3/MeOH/NH4.OH 12:9:4) to give the target product 35 (58 mg, 0.21 mmol, 61.1%) as a yellow sold. TLC: Rf=0.12 (CHCl3/MeOH/NH4.OH 12:9:4,
CAM, UV). 1H NMR (400 MHz,D2O): δ= 3.70-3.65 (m, 2H), 3.58 (m, 1H), 3.45 (m, 1H), 3.41
(m, 1H), 2.72 (m, 1H), 2.64 (m, 1H)

13

C NMR (100 MHz, CDCl3): δ= δ 165.6, 140.8, 140.3,

94.5, 73.2, 72.4, 72.0, 63.1, 42.4. HRMS (ESI) calcd for C9H16N4O6 [M+H]+: 277.1070, found:
277.1321.
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Compound 3.6 To a solution of compound 3-5 (250 mg, 0.9 mmol, 1.0 equiv.) in 4 mL DI water
with stirring, pyruvic acid sodium slat (1.8g, 16.3 mmol, 18.0 equiv.) was added. The mixture
was adjusted to pH 4.5 by addition a few drops of 2N HCl solution carefully. Then the reaction
was allowed to heat up to 80 oC in an oil bath for 20 min. After cool down to room temperature,
the solvent was dried off by high vacuum. Purification by flash column chromatography (SiO2,
CHCl3/MeOH/NH4.OH 12:9:4) to give the target product 3-6 (67 mg, 0.21mmol, 22.6%) as a
yellow sold. TLC: Rf=0.24 (CHCl3/MeOH/NH4.OH 12:9:4, CAM, UV).

1

H NMR (400

MHz,D2O): δ= 3.70-3.65 (m, 2H), 3.58 (m, 1H), 3.45 (m, 1H), 3.41 (m, 1H), 2.96 (s, 3H), 2.72
(m, 1H), 2.64 (m, 1H)

13

C NMR (100 MHz, CDCl3): δ= δ 181.4, 162.3, 161.2, 156.3, 131.2,

85.3, 73.2, 72.4, 72.0, 63.1, 42.1. HRMS (ESI) calcd for C12H16N4O7 [M+Na]+: 351.0917,
found: 351.1044.

OH
HO
HO
HO

OH

N

H
N

NH

N
3-7
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Compound 3.7 To a solution of compound 3-6 (180 mg, 0.55 mmol, 1.0 equiv.) in 5 mL PBS
buffer solution (pH = 7.4), sodium hydrosulfite (400 mg, 2.74 mmol, 5.0 equiv.) was added with
stirring. The mixture was allowed to stir at room temperature for 1 h. After the solvent was dried
off by high vacuum, purification by flash column chromatography (SiO2, CHCl3/MeOH/NH4.OH
12:9:4) to give the target product 3-7 (55 mg, 0.17, 31.1%) as a yellow sold. TLC: Rf=0.25
(CHCl3/MeOH/NH4.OH 12:9:4, CAM, UV). 1H NMR (400 MHz,D2O): δ= 4.81 (m, 1H), 3.703.65 (m, 2H), 3.58 (m, 1H), 3.45 (m, 1H), 3.41 (m, 1H), 2.72 (m, 1H), 2.64 (m, 1H) ,1.95 (s,
3H). 13C NMR (100 MHz, CDCl3): δ= δ 164.4, 162.3, 157.2, 156.3, 86.7, 85.3, 73.2, 72.4, 72.0,
63.1, 45.9. HRMS (ESI) calcd for C12H18N4O7 [M+H]+: 331.1175, found: 331.1182.
OH
HO

OH

HO
N

OH

3-8

Compound 3.8 Hydroxylamine hydrochloride (3.0 g, 43 mmol, 2.34 equiv.) was dissolved in
MeOH (dry, 40 mL) and stirred at room temperature. 2 drops of phenolphthalein (1%, solution in
EtOH) was added to mixture. Then a solution of NaOMe (2.4 g, 44 mmol, 2.45 equiv.) in MeOH
(40 mL) was added slowly to the suspension, upon with a white precipitate formed. When the
reaction stayed pink for 1 min, addition of base (NaOMe) was halted. The mixture was stirred for
several mins and filtered to remove slats. The filtrate was transferred to a round bottom flask
(250 mL) and warmed to 70 oC. Then D-(-) Xylose (2.8 g, 18 mmol, 1.00 equiv.) was added to
reaction in small portions. The mixture was allowed to stir at 70 oC until the sugar had
completely dissolved (5-10 min) and cooled down to room temperature. The product 3-8 (2.8 g,
16.9 mmol, 94.2%) was precipitated from solution after keeping the mixture at fridge overnight.
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TLC: Rf=0.38 (CHCl3/MeOH/NH4.OH 12:9:4, CAM). 1H NMR (400 MHz, D2O): δ= 7.51 (m,
1H), 6.88 (m, 1H), 4.96 (m, 1H), 4.36 (m, 1H), 3.79-3.69 (m, 6H), 3.63 (m, 2H) 13C NMR (100
MHz, CDCl3): δ= δ 153.8, 153.2, 73.5, 73.3, 73.0, 72.5, 71.3, 67.0, 64.4, 64.1. HRMS (ESI)
calcd for C5H11NO5 [M+Na]+: 188.0637, found: 188.0589.
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Appendix A:
List of abbreviation
9-BBN
AcOH
Ac2O
Boc
Boc2O
CH3CN
DCM
DMF
DMAP
DMSO
DLS
EDCI
EtOAc
Fmoc
FT-IR
HPC
HOBt
ICP-OES
KHMDS
OM
PEC
Ph3P
LPS
MAIT Cells
MsCl
MRI
MIC
MBC
MeOH
NOTA
Tr
THF
p-TsOH
TEM
TCR
SPECT
SNPs
COMU

9-Borabicyclo[3.3.1]nonane solution
Acetic acid
Acetic anhydride
tert-Butoxycarbonyl
Di-tert-butyl dicarbonate
Acetonitrile
Dichloromethane
Dimethylformamide
Dimethylaminopropylamine
Dimethyl sulfoxide
Dynamic light scattering
1-Ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride
Ethyl acetate
9-Fluorenylmethoxycarbonyl
Fourier-transform Infrared Spectroscopy
Hydroxypropyl Cellulose
Hydroxybenztriazole
Inductively Coupled Plasma - optical emission spectrometry
Potassium bis(trimethylsilyl)amide
Outer Membrane LPS Lipopolysaccharide
Positron Emission Tomography
Triphenylphosphine
Lipopolysaccharide
Mucosal-Associated Invariant T Cells
Methanesulfonyl chloride
Magnetic Resonance Imaging
Minimum Inhibitory Concentration
Minimum Bactericidal Concentration
Methanol
1, 4, 7-Triazacyclononane-1,4-bis-tert-butyl acetate-7-acetic acid
Trityl
Tetrahydrofuran
p-Toluenesulfonic acid
Transmission Electron Microscopy
T cell Receptor
Single Photon Emission Computed Tomography
SmartSilverAS Silver Nanoparticles
(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylaminomorpholino-carbenium hexafluorophosphate
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Appendix B:
NMR Spectra
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